IDEAS home Printed from https://ideas.repec.org/f/c/pde347.html
   My authors  Follow this author

Nancy Devlin

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Blog mentions

As found by EconAcademics.org, the blog aggregator for Economics research:
  1. Karl Claxton & Steve Martin & Marta Soares & Nigel Rice & Eldon Spackman & Sebastian Hinde & Nancy Devlin & Peter C Smith & Mark Sculpher, 2013. "Methods for the estimation of the NICE cost effectiveness threshold," Working Papers 081cherp, Centre for Health Economics, University of York.

    Mentioned in:

    1. Sofosbuvir: a fork in the road for NICE?
      by Chris Sampson in The Academic Health Economists' Blog on 2015-01-20 17:21:00
    2. Chris Sampson’s journal round-up for 22nd May 2017
      by Chris Sampson in The Academic Health Economists' Blog on 2017-05-22 16:00:45
    3. Rita Faria’s journal round-up for 18th June 2018
      by Rita Faria in The Academic Health Economists' Blog on 2018-06-18 11:00:47
  2. Juan M. Ramos-Goñi & Mark Oppe & Elly Stolk & Koonal Shah & Simone Kreimeier & Oliver Rivero-Arias & Nancy Devlin, 2020. "International Valuation Protocol for the EQ-5D-Y-3L," PharmacoEconomics, Springer, vol. 38(7), pages 653-663, July.

    Mentioned in:

    1. Chris Sampson’s journal round-up for 29th June 2020
      by Chris Sampson in The Academic Health Economists' Blog on 2020-06-29 11:00:06
  3. Koonal K. Shah & Juan Manuel Ramos-Goñi & Simone Kreimeier & Nancy J. Devlin, 2020. "An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(7), pages 1091-1103, September.

    Mentioned in:

    1. Chris Sampson’s journal round-up for 7th September 2020
      by Chris Sampson in The Academic Health Economists' Blog on 2020-09-07 11:00:07
  4. Appleby, John & Devlin, Nancy & Parkin, David & Buxton, Martin & Chalkidou, Kalipso, 2009. "Searching for cost effectiveness thresholds in the NHS," Health Policy, Elsevier, vol. 91(3), pages 239-245, August.

    Mentioned in:

    1. Sofosbuvir: a fork in the road for NICE?
      by Chris Sampson in The Academic Health Economists' Blog on 2015-01-20 17:21:00

    Mentioned in:

    1. Simon McNamara’s journal round-up for 6th August 2018
      by sjmcnamara1 in The Academic Health Economists' Blog on 2018-08-06 11:00:29
  5. Nancy J. Devlin & Koonal K. Shah & Yan Feng & Brendan Mulhern & Ben van Hout, 2018. "Valuing health‐related quality of life: An EQ‐5D‐5L value set for England," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 7-22, January.

    Mentioned in:

    1. Rita Faria’s journal round-up for 10th December 2018
      by Rita Faria in The Academic Health Economists' Blog on 2018-12-10 12:00:31
    2. My quality-adjusted life year
      by Bren Collins in The Academic Health Economists' Blog on 2019-03-07 07:00:07

Working papers

  1. Karl Claxton & Steve Martin & Marta Soares & Nigel Rice & Eldon Spackman & Sebastian Hinde & Nancy Devlin & Peter C Smith & Mark Sculpher, 2013. "Methods for the estimation of the NICE cost effectiveness threshold," Working Papers 081cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Miqdad Asaria & Susan Griffin & Richard Cookson, 2016. "Distributional Cost-Effectiveness Analysis," Medical Decision Making, , vol. 36(1), pages 8-19, January.
    2. J. Raftery, 2014. "NICE’s Cost-Effectiveness Range: Should it be Lowered?," PharmacoEconomics, Springer, vol. 32(7), pages 613-615, July.
    3. Stephen Martin & James Lomas & Karl Claxton & Francesco Longo, 2021. "How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13," Applied Health Economics and Health Policy, Springer, vol. 19(6), pages 885-903, November.
    4. John Brazier & Aki Tsuchiya, 2015. "Improving Cross-Sector Comparisons: Going Beyond the Health-Related QALY," Applied Health Economics and Health Policy, Springer, vol. 13(6), pages 557-565, December.
    5. Donna Rowen & John Brazier & Clara Mukuria & Anju Keetharuth & Arne Risa Hole & Aki Tsuchiya & Sophie Whyte & Phil Shackley, 2016. "Eliciting Societal Preferences for Weighting QALYs for Burden of Illness and End of Life," Medical Decision Making, , vol. 36(2), pages 210-222, February.
    6. Hareth Al-Janabi & Job van Exel & Werner Brouwer & Joanna Coast, 2016. "A Framework for Including Family Health Spillovers in Economic Evaluation," Medical Decision Making, , vol. 36(2), pages 176-186, February.
    7. Linda Ryen & Mikael Svensson, 2015. "The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature," Health Economics, John Wiley & Sons, Ltd., vol. 24(10), pages 1289-1301, October.
    8. Paul Revill & Simon Walker & Jason Madan & Andrea Ciaranello & Takondwa Mwase & Diana M Gibb & Karl Claxton & Mark J Sculpher, 2014. "Using cost-effectiveness thresholds to determine value for money in low- and middle-income country healthcare systems: Are current international norms fit for purpose?," Working Papers 098cherp, Centre for Health Economics, University of York.
    9. Mike Paulden & Christopher McCabe & Jonathan Karnon, 2014. "Achieving Allocative Efficiency in Healthcare: Nice in Theory, not so NICE in Practice?," PharmacoEconomics, Springer, vol. 32(4), pages 315-318, April.
    10. B. Rodríguez-Sánchez & L. M. Peña-Longobardo & A. J. Sinclair, 2020. "Cost-effectiveness analysis of the Neuropad device as a screening tool for early diabetic peripheral neuropathy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(3), pages 335-349, April.
    11. J. Jaime Caro & John E. Brazier & Jonathan Karnon & Peter Kolominsky-Rabas & Alistair J. McGuire & Erik Nord & Michael Schlander, 2019. "Determining Value in Health Technology Assessment: Stay the Course or Tack Away?," PharmacoEconomics, Springer, vol. 37(3), pages 293-299, March.
    12. Andrew J. Mirelman & Miqdad Asaria & Bryony Dawkins & Susan Griffin & Richard Cookson & Peter Berman, 2020. "Fairer Decisions, Better Health for All: Health Equity and Cost-Effectiveness Analysis," World Scientific Book Chapters, in: Paul Revill & Marc Suhrcke & Rodrigo Moreno-Serra & Mark Sculpher (ed.), Global Health Economics Shaping Health Policy in Low- and Middle-Income Countries, chapter 4, pages 99-132, World Scientific Publishing Co. Pte. Ltd..
    13. Simon Eckermann & Brita Pekarsky, 2014. "Can the Real Opportunity Cost Stand Up: Displaced Services, the Straw Man Outside the Room," PharmacoEconomics, Springer, vol. 32(4), pages 319-325, April.
    14. Torbjørn Wisløff & Gunhild Hagen & Vida Hamidi & Espen Movik & Marianne Klemp & Jan Olsen, 2014. "Estimating QALY Gains in Applied Studies: A Review of Cost-Utility Analyses Published in 2010," PharmacoEconomics, Springer, vol. 32(4), pages 367-375, April.
    15. Eldon Spackman & Stewart Richmond & Mark Sculpher & Martin Bland & Stephen Brealey & Rhian Gabe & Ann Hopton & Ada Keding & Harriet Lansdown & Sara Perren & David Torgerson & Ian Watt & Hugh MacPherso, 2014. "Cost-Effectiveness Analysis of Acupuncture, Counselling and Usual Care in Treating Patients with Depression: The Results of the ACUDep Trial," PLOS ONE, Public Library of Science, vol. 9(11), pages 1-12, November.
    16. Alec Morton & Amanda I. Adler & David Bell & Andrew Briggs & Werner Brouwer & Karl Claxton & Neil Craig & Alastair Fischer & Peter McGregor & Pieter van Baal, 2016. "Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal," Health Economics, John Wiley & Sons, Ltd., vol. 25(8), pages 933-938, August.
    17. Ryen, Linda & Svensson, Mikael, 2014. "The Willingness to Pay for a QALY: a Review of the Empirical Literature," Karlstad University Working Papers in Economics 12, Karlstad University, Department of Economics.
    18. Mike Paulden & Tania Stafinski & Devidas Menon & Christopher McCabe, 2015. "Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework," PharmacoEconomics, Springer, vol. 33(3), pages 255-269, March.
    19. Jessica Ochalek & Haiyin Wang & Yuanyuan Gu & James Lomas & Henry Cutler & Chunlin Jin, 2020. "Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach," PharmacoEconomics, Springer, vol. 38(12), pages 1319-1331, December.
    20. Wildman, John & McMeekin, Peter & Grieve, Eleanor & Briggs, Andrew, 2016. "Economic evaluation of integrated new technologies for health and social care: Suggestions for policy makers, users and evaluators," Social Science & Medicine, Elsevier, vol. 169(C), pages 141-148.
    21. Doug Coyle & Matthew C. Cheung & Gerald A. Evans, 2014. "Opportunity Cost of Funding Drugs for Rare Diseases," Medical Decision Making, , vol. 34(8), pages 1016-1029, November.
    22. Adrian Towse;Paul Barnsley;Sarah Karlsberg-Schaffer;Jon Sussex, 2013. "Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold," Occasional Paper 000106, Office of Health Economics.
    23. Sebastian Hinde & Eldon Spackman, 2015. "Bidirectional Citation Searching to Completion: An Exploration of Literature Searching Methods," PharmacoEconomics, Springer, vol. 33(1), pages 5-11, January.
    24. Ulrikke J. V. Hernæs & Kjell A. Johansson & Trygve Ottersen & Ole F. Norheim, 2017. "Distribution-Weighted Cost-Effectiveness Analysis Using Lifetime Health Loss," PharmacoEconomics, Springer, vol. 35(9), pages 965-974, September.
    25. Iftekhar Khan & Mandy Maredza & Melina Dritsaki & Dipesh Mistry & Ranjit Lall & Sarah E. Lamb & Keith Couper & Simon Gates & Gavin D. Perkins & Stavros Petrou, 2020. "Is Protocolised Weaning that Includes Early Extubation Onto Non-Invasive Ventilation More Cost Effective Than Protocolised Weaning Without Non-Invasive Ventilation? Findings from the Breathe Study," PharmacoEconomics - Open, Springer, vol. 4(4), pages 697-710, December.
    26. Alan Haycox, 2016. "Why Cancer?," PharmacoEconomics, Springer, vol. 34(7), pages 625-627, July.
    27. Mark Sculpher & Stephen Palmer, 2020. "After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?," PharmacoEconomics, Springer, vol. 38(3), pages 247-257, March.
    28. Drew Carter & Arlene Vogan & Hossein Haji Ali Afzali, 2016. "Governments Need Better Guidance to Maximise Value for Money: The Case of Australia’s Pharmaceutical Benefits Advisory Committee," Applied Health Economics and Health Policy, Springer, vol. 14(4), pages 401-407, August.
    29. A. Newall & M. Jit & R. Hutubessy, 2014. "Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines," PharmacoEconomics, Springer, vol. 32(6), pages 525-531, June.
    30. Miqdad Asaria & Susan Griffin & Richard Cookson, 2013. "Distributional cost-effectiveness analysis: a tutorial," Working Papers 092cherp, Centre for Health Economics, University of York.
    31. Ken Willis & Bob Crabtree & Liesl M. Osman & Kirsty Cathrine, 2016. "Green space and health benefits: a QALY and CEA of a mental health programme," Journal of Environmental Economics and Policy, Taylor & Francis Journals, vol. 5(2), pages 163-180, July.
    32. James F. O’Mahony & Mike Paulden & Chris McCabe, 2021. "NICE’s Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests," PharmacoEconomics, Springer, vol. 39(2), pages 139-146, February.
    33. Emma Cowles & Grace Marsden & Amanda Cole & Nancy Devlin, 2017. "A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?," Applied Health Economics and Health Policy, Springer, vol. 15(4), pages 469-477, August.
    34. Mike Paulden & Christopher McCabe, 2021. "Modifying NICE’s Approach to Equity Weighting," PharmacoEconomics, Springer, vol. 39(2), pages 147-160, February.
    35. Simon Eckermann, 2015. "Kinky Thresholds Revisited: Opportunity Costs Differ in the NE and SW Quadrants," Applied Health Economics and Health Policy, Springer, vol. 13(1), pages 7-13, February.
    36. Pieter van Baal & Meg Perry‐Duxbury & Pieter Bakx & Matthijs Versteegh & Eddy van Doorslaer & Werner Brouwer, 2019. "A cost‐effectiveness threshold based on the marginal returns of cardiovascular hospital spending," Health Economics, John Wiley & Sons, Ltd., vol. 28(1), pages 87-100, January.
    37. Kinghorn, Philip & Afentou, Nafsika, 2021. "Eliciting a monetary threshold for a year of sufficient capability to inform resource allocation decisions in public health and social care," Social Science & Medicine, Elsevier, vol. 279(C).
    38. Helen Weatherly & Rita Faria & Bernard Van den Berg & Mark Sculpher & Peter O’Neill & Kay Nolan & Julie Glanville & Jaana Isojarvi & Erin Baragula & Mary Edwards, 2017. "Scoping review on social care economic evaluation methods," Working Papers 150cherp, Centre for Health Economics, University of York.
    39. Pieter van Baal & David Meltzer & Werner Brouwer, 2016. "Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost‐Effectiveness Analysis," Health Economics, John Wiley & Sons, Ltd., vol. 25(2), pages 237-248, February.
    40. Charles E Phelps & Chris Cinatl, 2021. "Estimating optimal willingness to pay thresholds for cost‐effectiveness analysis: A generalized method," Health Economics, John Wiley & Sons, Ltd., vol. 30(7), pages 1697-1702, July.
    41. Karlsberg Schaffer, Sarah & Sussex, Jon & Devlin, Nancy & Walker, Andrew, 2015. "Local health care expenditure plans and their opportunity costs," Health Policy, Elsevier, vol. 119(9), pages 1237-1244.
    42. Brick, Aoife & Gorecki, Paul K. & Nolan, Anne, 2013. "Ireland: Pharmaceutical Prices, Prescribing Practices and Usage of Generics in a Comparative Context," Research Series, Economic and Social Research Institute (ESRI), number RS32.
    43. Mark Sculpher, 2013. "Methods Development for Health Technology Assessment," Medical Decision Making, , vol. 33(3), pages 313-315, April.
    44. Luigi Siciliani & James Gaughan & Nils Gutacker & Hugh Gravelle & Martin Chalkley, 2021. "Paying for health gains," Working Papers 183cherp, Centre for Health Economics, University of York.
    45. Peter J. Neumann & David D. Kim & Thomas A. Trikalinos & Mark J. Sculpher & Joshua A. Salomon & Lisa A. Prosser & Douglas K. Owens & David O. Meltzer & Karen M. Kuntz & Murray Krahn & David Feeny & An, 2018. "Future Directions for Cost-effectiveness Analyses in Health and Medicine," Medical Decision Making, , vol. 38(7), pages 767-777, October.
    46. Bevan, Gwyn & Brown, Lawrence D., 2014. "The political economy of rationing health care in England and the US: the ‘accidental logics’ of political settlements," LSE Research Online Documents on Economics 57129, London School of Economics and Political Science, LSE Library.
    47. Paul Revill & Simon Walker & Valentina Cambiano & Andrew Phillips & Mark J Sculpher, 2018. "Reflecting the real value of health care resources in modelling and cost-effectiveness studies—The example of viral load informed differentiated care," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-13, January.
    48. Beth Woods & Paul Revill & Mark Sculpher & Karl Claxton, 2015. "Country-level cost-effectiveness thresholds: initial estimates and the need for further research," Working Papers 109cherp, Centre for Health Economics, University of York.
    49. Mike Paulden & James O’Mahony & Anthony Culyer & Christopher McCabe, 2014. "Some Inconsistencies in NICE’s Consideration of Social Values," PharmacoEconomics, Springer, vol. 32(11), pages 1043-1053, November.

  2. Helen Dakin & Nancy Devlin & Yan Feng & Nigel Rice & Phill O’Neill & David Parkin, 2013. "The influence of cost-effectiveness and other factors on NICE decisions," Working Papers 093cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Wettstein, Dominik J. & Boes, Stefan, 2022. "How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence," Health Policy, Elsevier, vol. 126(2), pages 112-121.
    2. J. Raftery, 2014. "NICE’s Cost-Effectiveness Range: Should it be Lowered?," PharmacoEconomics, Springer, vol. 32(7), pages 613-615, July.
    3. Anna Hobbins & Luke Barry & Dan Kelleher & Koonal Shah & Nancy Devlin & Juan Manuel Ramos Goni & Ciaran O’Neill, 2018. "Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L," PharmacoEconomics, Springer, vol. 36(11), pages 1345-1353, November.
    4. Fischer, Katharina Elisabeth & Heisser, Thomas & Stargardt, Tom, 2016. "Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia," Health Policy, Elsevier, vol. 120(10), pages 1115-1122.
    5. Mikael Svensson & Fredrik Nilsson & Karl Arnberg, 2015. "Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness," PharmacoEconomics, Springer, vol. 33(11), pages 1229-1236, November.
    6. Carlos K. H. Wong & Brian H. H. Lang & Vivian Y. W. Guo & Cindy L. K. Lam, 2016. "Possible Impact of Incremental Cost-Effectiveness Ratio (ICER) on Decision Making for Cancer Screening in Hong Kong: A Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 14(6), pages 647-657, December.
    7. Olina Efthymiadou, 2023. "Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(7), pages 1023-1031, September.
    8. M. J. Walton & J. O’Connor & C. Carroll & L. Claxton & R. Hodgson, 2019. "A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process," PharmacoEconomics - Open, Springer, vol. 3(3), pages 403-410, September.
    9. Maynou, Laia & Cairns, John, 2019. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," Health Policy, Elsevier, vol. 123(2), pages 130-139.
    10. Maynou, Laia & Cairns, John, 2018. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," LSE Research Online Documents on Economics 90877, London School of Economics and Political Science, LSE Library.
    11. Carlos King Ho Wong & Olivia Wu & Bernard M. Y. Cheung, 2018. "Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions," Applied Health Economics and Health Policy, Springer, vol. 16(1), pages 5-14, February.
    12. Lisa Masucci & Jaclyn Beca & Mona Sabharwal & Jeffrey S. Hoch, 2017. "Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)," PharmacoEconomics - Open, Springer, vol. 1(4), pages 255-263, December.
    13. Cynthia P. Iglesias & Alexander Thompson & Wolf H. Rogowski & Katherine Payne, 2016. "Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations," PharmacoEconomics, Springer, vol. 34(11), pages 1161-1172, November.
    14. Benedikt Schoser & Andreas Hahn & Emma James & Digant Gupta & Matthew Gitlin & Suyash Prasad, 2019. "A Systematic Review of the Health Economics of Pompe Disease," PharmacoEconomics - Open, Springer, vol. 3(4), pages 479-493, December.
    15. Sebastian Jobjornsson & Martin Forster & Paolo Pertile & Carl-Fredrik Burman, 2015. "Late-Stage Pharmaceutical R & D and Pricing Policies under Two-Stage Regulation," Discussion Papers 15/16, Department of Economics, University of York.
    16. Shafrin, Jason & Skornicki, Michelle & Brauer, Michelle & Villeneuve, Julie & Lees, Michael & Hertel, Nadine & Penrod, John R. & Jansen, Jeroen, 2018. "An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?," Health Policy, Elsevier, vol. 122(6), pages 607-613.
    17. Peter Ghijben & Yuanyuan Gu & Emily Lancsar & Silva Zavarsek, 2018. "Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review," PharmacoEconomics, Springer, vol. 36(3), pages 323-340, March.
    18. Pieter Baal & Alec Morton & David Meltzer & Werner Brouwer, 2019. "Future unrelated medical costs need to be considered in cost effectiveness analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 1-5, February.
    19. Shiroiwa, Takeru & Fukuda, Takashi & Ikeda, Shunya & Takura, Tomoyuki, 2017. "New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations," Health Policy, Elsevier, vol. 121(8), pages 836-841.
    20. Angela Rocchi & Elizabeth Miller & Robert Hopkins & Ron Goeree, 2012. "Common Drug Review Recommendations," PharmacoEconomics, Springer, vol. 30(3), pages 229-246, March.
    21. Kerr, Anne & Hill, Rosemary L. & Till, Christopher, 2018. "The limits of responsible innovation: Exploring care, vulnerability and precision medicine," Technology in Society, Elsevier, vol. 52(C), pages 24-31.
    22. Francesco Paolucci & Ken Redekop & Ayman Fouda & Gianluca Fiorentini, 2017. "Decision Making and Priority Setting: The Evolving Path Towards Universal Health Coverage," Applied Health Economics and Health Policy, Springer, vol. 15(6), pages 697-706, December.

  3. Nils Gutacker & Chris Bojke & Silvio Daidone & Nancy Devlin & Andrew Street, 2012. "Analysing Hospital Variation in Health Outcome at the Level of EQ-5D Dimensions," Working Papers 074cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Giulia Cavrini & J. Zamberletti & M. Zoli, 2016. "Could the EQ-5D be Used to Predict Mortality and Hospitalization Over a Long Term Period?," Social Indicators Research: An International and Interdisciplinary Journal for Quality-of-Life Measurement, Springer, vol. 128(2), pages 813-834, September.

  4. Versteegh, MM & Attema, AE & Oppe, M & Devlin, NJ & Stolk, EA, 2012. "Time to tweak the TTO. But how?," MPRA Paper 37989, University Library of Munich, Germany.

    Cited by:

    1. Attema, AE & Versteegh, MM, 2012. "Would you rather be ill now, or later?," MPRA Paper 37990, University Library of Munich, Germany.

  5. Nils Gutacker & Chris Bojke & Silvio Daidone & Nancy Devlin & David Parkin & Andrew Street, 2011. "Truly inefficient or providing better quality of care? Analysing the relationship between riskadjusted hospital costs and patients’ health outcomes," Working Papers 068cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Valerie Moran & Rowena Jacobs, 2018. "Investigating the relationship between costs and outcomes for English mental health providers: a bi-variate multi-level regression analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(5), pages 709-718, June.
    2. Laura Di Giorgio & Massimo Filippini & Giuliano Masiero, 2014. "The relationship between costs and quality in nonprofit nursing homes," IdEP Economic Papers 1402, USI Università della Svizzera italiana.
    3. Steenhuis, Sander & Groeneweg, Niels & Koolman, Xander & Portrait, France, 2017. "Good, better, best? A comprehensive comparison of healthcare providers’ performance: An application to physiotherapy practices in primary care," Health Policy, Elsevier, vol. 121(12), pages 1225-1232.
    4. Adrian Gheorghe & Tracy Roberts & Karla Hemming & Melanie Calvert, 2015. "Evaluating the Generalisability of Trial Results: Introducing a Centre- and Trial-Level Generalisability Index," PharmacoEconomics, Springer, vol. 33(11), pages 1195-1214, November.
    5. J. Buckell & A. Smith & R. Longo & D. Holland, 2015. "Efficiency, heterogeneity and cost function analysis: empirical evidence from pathology services in the National Health Service in England," Applied Economics, Taylor & Francis Journals, vol. 47(31), pages 3311-3331, July.
    6. Edwin Lau & Zsuzsanna Lonti & Rebecca Schultz, 2017. "Challenges in the Measurement of Public Sector Productivity in OECD 180 Countries," International Productivity Monitor, Centre for the Study of Living Standards, vol. 32, pages 180-195, Spring.
    7. Smith, Andrew S.J. & Ojeda Cabral, Manuel, 2022. "Is higher quality always costly? Marginal costs of quality: Theory and application to railway punctuality," Transportation Research Part A: Policy and Practice, Elsevier, vol. 157(C), pages 258-273.
    8. France R. M. Portrait & Onno van der Galiën & Bernard Van den Berg, 2016. "Measuring Healthcare Providers' Performances Within Managed Competition Using Multidimensional Quality and Cost Indicators," Health Economics, John Wiley & Sons, Ltd., vol. 25(4), pages 408-423, April.
    9. Francette Koechlin & Paul Konijn & Luca Lorenzoni & Paul Schreyer, 2017. "Comparing Hospitals and Health Prices and Volumes Across Countries: A New Approach," Social Indicators Research: An International and Interdisciplinary Journal for Quality-of-Life Measurement, Springer, vol. 131(1), pages 43-64, March.
    10. Malgorzata Cyganska & Piotr Cyganski & Chris Pyke, 2019. "Development of clinical value unit method for calculating patient costs," Health Economics, John Wiley & Sons, Ltd., vol. 28(8), pages 971-983, August.
    11. Sverre A. C. Kittelsen & Kjartan S. Anthun & Fanny Goude & Ingrid M. S. Huitfeldt & Unto Häkkinen & Marie Kruse & Emma Medin & Clas Rehnberg & Hanna Rättö & on behalf of the EuroHOPE study group, 2015. "Costs and Quality at the Hospital Level in the Nordic Countries," Health Economics, John Wiley & Sons, Ltd., vol. 24(S2), pages 140-163, December.
    12. Francesco Longo & Luigi Siciliani & Hugh Gravelle & Rita Santos, 2017. "Do hospitals respond to rivals' quality and efficiency? A spatial panel econometric analysis," Health Economics, John Wiley & Sons, Ltd., vol. 26(S2), pages 38-62, September.
    13. Häkkinen, Unto & Rosenqvist, Gunnar & Peltola, Mikko & Kapiainen, Satu & Rättö, Hanna & Cots, Francesc & Geissler, Alexander & Or, Zeynep & Serdén, Lisbeth & Sund, Reijo, 2014. "Quality, cost, and their trade-off in treating AMI and stroke patients in European hospitals," Health Policy, Elsevier, vol. 117(1), pages 15-27.
    14. Enrique Jiménez-Rodríguez & José Manuel Feria-Domínguez & Alonso Sebastián-Lacave, 2018. "Assessing the Health-Care Risk: The Clinical-VaR, a Key Indicator for Sound Management," IJERPH, MDPI, vol. 15(4), pages 1-17, March.
    15. Francesco Longo & Luigi Siciliani & Andrew Street, 2015. "Are costs differences between specialist and general hospitals compensated by the prospective payment system?," Discussion Papers 15/30, Department of Economics, University of York.
    16. L. Di Giorgio & M. Filippini & G. Masiero, 2016. "Is higher nursing home quality more costly?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 1011-1026, November.
    17. Sara Jamalabadi & Vera Winter & Jonas Schreyögg, 2020. "A Systematic Review of the Association Between Hospital Cost/price and the Quality of Care," Applied Health Economics and Health Policy, Springer, vol. 18(5), pages 625-639, October.
    18. Unto Häkkinen & Gunnar Rosenqvist & Tor Iversen & Clas Rehnberg & Timo T. Seppälä & on behalf of the EuroHOPE study group, 2015. "Outcome, Use of Resources and Their Relationship in the Treatment of AMI, Stroke and Hip Fracture at European Hospitals," Health Economics, John Wiley & Sons, Ltd., vol. 24(S2), pages 116-139, December.
    19. Seghieri, Chiara & Berta, Paolo & Nuti, Sabina, 2019. "Geographic variation in inpatient costs for Acute Myocardial Infarction care: Insights from Italy," Health Policy, Elsevier, vol. 123(5), pages 449-456.
    20. Tor Iversen & Eline Aas & Gunnar Rosenqvist & Unto Häkkinen & on behalf of the EuroHOPE study group, 2015. "Comparative Analysis of Treatment Costs in EUROHOPE," Health Economics, John Wiley & Sons, Ltd., vol. 24(S2), pages 5-22, December.

  6. N J Devlin & P Hansen & P Kind & A H Williams, 2000. "The health state preferences and logistical inconsistencies of New Zealanders: a tale of two tariffs," Working Papers 180chedp, Centre for Health Economics, University of York.

    Cited by:

    1. Shnece Duncan & Andrea Menclova & Maggie-Lee Huckabee & Dominique Cadilhac & Anna Ranta, 2023. "How Much Does Dysphagia Cost? An Estimation of the Additional Annual Cost of Dysphagia in Patients Hospitalised with Stroke," Working Papers in Economics 23/16, University of Canterbury, Department of Economics and Finance.
    2. David Parkin & Nancy Devlin, 2006. "Is there a case for using visual analogue scale valuations in cost‐utility analysis?," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 653-664, July.
    3. Richard Milne & Kathy Heaton-Brown & Paul Hansen & David Thomas & Vernon Harvey & Alison Cubitt, 2006. "Quality-of-Life Valuations of Advanced Breast Cancer by New Zealand Women," PharmacoEconomics, Springer, vol. 24(3), pages 281-292, March.
    4. Henry Bailey & Mathieu F Janssen & Althea La Foucade & Paul Kind, 2019. "EQ-5D-5L population norms and health inequalities for Trinidad and Tobago," PLOS ONE, Public Library of Science, vol. 14(4), pages 1-14, April.
    5. Jacqueline Cumming, 2015. "Health Economics and Health Policy: Experiences from New Zealand," Applied Health Economics and Health Policy, Springer, vol. 13(3), pages 281-289, June.
    6. M. F. Janssen & A. Szende & J. Cabases & J. M. Ramos-Goñi & G. Vilagut & H. H. König, 2019. "Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(2), pages 205-216, March.

Articles

  1. Chris Sampson & Bernarda Zamora & Sam Watson & John Cairns & Kalipso Chalkidou & Patricia Cubi-Molla & Nancy Devlin & Borja García-Lorenzo & Dyfrig A. Hughes & Ashley A. Leech & Adrian Towse, 2022. "Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy," Applied Health Economics and Health Policy, Springer, vol. 20(5), pages 651-667, September.

    Cited by:

    1. Sampson, Chris & Cookson, Graham, 2024. "Marginal cost per QALY estimates: What are they good for?," Health Policy, Elsevier, vol. 142(C).

  2. Tianxin Pan & Brendan Mulhern & Rosalie Viney & Richard Norman & Janel Hanmer & Nancy Devlin, 2022. "A Comparison of PROPr and EQ-5D-5L Value Sets," PharmacoEconomics, Springer, vol. 40(3), pages 297-307, March.

    Cited by:

    1. Finch, Aureliano Paolo & Mulhern, Brendan, 2022. "Where do measures of health, social care and wellbeing fit within a wider measurement framework? Implications for the measurement of quality of life and the identification of bolt-ons," Social Science & Medicine, Elsevier, vol. 313(C).

  3. Joseph Kwon & Louise Freijser & Elisabeth Huynh & Martin Howell & Gang Chen & Kamran Khan & Shahd Daher & Nia Roberts & Conrad Harrison & Sarah Smith & Nancy Devlin & Kirsten Howard & Emily Lancsar & , 2022. "Correction to: Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures," PharmacoEconomics, Springer, vol. 40(4), pages 477-478, April.

    Cited by:

    1. Victoria Gale & Jill Carlton, 2023. "Including Young Children in the Development and Testing of Patient Reported Outcome (PRO) Instruments: A Scoping Review of Children’s Involvement and Qualitative Methods," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 16(5), pages 425-456, September.

  4. Joseph Kwon & Louise Freijser & Elisabeth Huynh & Martin Howell & Gang Chen & Kamran Khan & Shahd Daher & Nia Roberts & Conrad Harrison & Sarah Smith & Nancy Devlin & Kirsten Howard & Emily Lancsar & , 2022. "Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures," PharmacoEconomics, Springer, vol. 40(4), pages 379-431, April.

    Cited by:

    1. Victoria Gale & Jill Carlton, 2023. "Including Young Children in the Development and Testing of Patient Reported Outcome (PRO) Instruments: A Scoping Review of Children’s Involvement and Qualitative Methods," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 16(5), pages 425-456, September.

  5. Tessa Peasgood & Clara Mukuria & Jill Carlton & Janice Connell & Nancy Devlin & Karen Jones & Rosemary Lovett & Bhash Naidoo & Stacey Rand & Juan Carlos Rejon-Parrilla & Donna Rowen & Aki Tsuchiya & J, 2021. "What is the best approach to adopt for identifying the domains for a new measure of health, social care and carer-related quality of life to measure quality-adjusted life years? Application to the dev," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(7), pages 1067-1081, September.

    Cited by:

    1. Spencer, Anne & Rivero-Arias, Oliver & Wong, Ruth & Tsuchiya, Aki & Bleichrodt, Han & Edwards, Rhiannon Tudor & Norman, Richard & Lloyd, Andrew & Clarke, Philip, 2022. "The QALY at 50: One story many voices," Social Science & Medicine, Elsevier, vol. 296(C).
    2. Finch, Aureliano Paolo & Mulhern, Brendan, 2022. "Where do measures of health, social care and wellbeing fit within a wider measurement framework? Implications for the measurement of quality of life and the identification of bolt-ons," Social Science & Medicine, Elsevier, vol. 313(C).

  6. Patricia Cubi-Molla & Martin Buxton & Nancy Devlin, 2021. "Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?," Applied Health Economics and Health Policy, Springer, vol. 19(5), pages 635-644, September.

    Cited by:

    1. Francis Shupo & Keith R. Abrams & Zanfina Ademi & Grace Wayi-Wayi & Natasa Zibelnik & Matt Kirchmann & Carolyn Rutherford & Kelly Makarounas-Kirchmann, 2023. "Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease," PharmacoEconomics - Open, Springer, vol. 7(5), pages 777-792, September.
    2. James Lomas & Jessica Ochalek & Rita Faria, 2022. "Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment," Applied Health Economics and Health Policy, Springer, vol. 20(1), pages 13-18, January.

  7. Andrew J. Palmer & Julie A. Campbell & Barbara de Graaff & Nancy Devlin & Hasnat Ahmad & Philip M Clarke & Mingsheng Chen & Lei Si, 2021. "Population norms for quality adjusted life years for the United States of America, China, the United Kingdom and Australia," Health Economics, John Wiley & Sons, Ltd., vol. 30(8), pages 1950-1977, August.

    Cited by:

    1. Xiao, Kun & Yu, Bolin & Cheng, Lei & Li, Fei & Fang, Debin, 2022. "The effects of CCUS combined with renewable energy penetration under the carbon peak by an SD-CGE model: Evidence from China," Applied Energy, Elsevier, vol. 321(C).

  8. Cristina Gutierrez-Delgado & Rosa-María Galindo-Suárez & Cesar Cruz-Santiago & Koonal Shah & Manny Papadimitropoulos & Yan Feng & Bernarda Zamora & Nancy Devlin, 2021. "EQ-5D-5L Health-State Values for the Mexican Population," Applied Health Economics and Health Policy, Springer, vol. 19(6), pages 905-914, November.

    Cited by:

    1. Fan Yang & Kenneth R. Katumba & Bram Roudijk & Zhihao Yang & Paul Revill & Susan Griffin & Perez N. Ochanda & Mohammed Lamorde & Giulia Greco & Janet Seeley & Mark Sculpher, 2022. "Developing the EQ-5D-5L Value Set for Uganda Using the ‘Lite’ Protocol," PharmacoEconomics, Springer, vol. 40(3), pages 309-321, March.

  9. Koonal K. Shah & Juan Manuel Ramos-Goñi & Simone Kreimeier & Nancy J. Devlin, 2020. "An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(7), pages 1091-1103, September.

    Cited by:

    1. Stefan A. Lipman & Liying Zhang & Koonal K. Shah & Arthur E. Attema, 2023. "Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(2), pages 293-305, March.
    2. Cristina Gutierrez-Delgado & Rosa-María Galindo-Suárez & Cesar Cruz-Santiago & Koonal Shah & Manny Papadimitropoulos & Yan Feng & Bernarda Zamora & Nancy Devlin, 2021. "EQ-5D-5L Health-State Values for the Mexican Population," Applied Health Economics and Health Policy, Springer, vol. 19(6), pages 905-914, November.
    3. S. A. Lipman & V. T. Reckers-Droog & M. Karimi & M. Jakubczyk & A. E. Attema, 2021. "Self vs. other, child vs. adult. An experimental comparison of valuation perspectives for valuation of EQ-5D-Y-3L health states," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1507-1518, December.
    4. Finch, Aureliano Paolo & Meregaglia, Michela & Ciani, Oriana & Roudijk, Bram & Jommi, Claudio, 2022. "An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration," Social Science & Medicine, Elsevier, vol. 292(C).

  10. Juan M. Ramos-Goñi & Mark Oppe & Elly Stolk & Koonal Shah & Simone Kreimeier & Oliver Rivero-Arias & Nancy Devlin, 2020. "International Valuation Protocol for the EQ-5D-Y-3L," PharmacoEconomics, Springer, vol. 38(7), pages 653-663, July.

    Cited by:

    1. Saskia Schawo & Renske Hoefman & Vivian Reckers-Droog & Liesbet Lawerman-van de Wetering & Yifrah Kaminer & Werner Brouwer & Leona Hakkaart-van Roijen, 2024. "Obtaining preference scores for an abbreviated self-completion version of the Teen-Addiction Severity Index (ASC T-ASI) to value therapy outcomes of systemic family interventions: a discrete choice ex," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(5), pages 903-913, July.
    2. Stefan A. Lipman & Liying Zhang & Koonal K. Shah & Arthur E. Attema, 2023. "Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(2), pages 293-305, March.
    3. S. A. Lipman & V. T. Reckers-Droog & M. Karimi & M. Jakubczyk & A. E. Attema, 2021. "Self vs. other, child vs. adult. An experimental comparison of valuation perspectives for valuation of EQ-5D-Y-3L health states," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1507-1518, December.
    4. Powell, Philip A. & Rowen, Donna & Keetharuth, Anju & Mukuria, Clara, 2024. "Understanding UK public views on normative decisions made to value health-related quality of life in children: A qualitative study," Social Science & Medicine, Elsevier, vol. 340(C).

  11. Zhang, Angela & Prang, Khic-Houy & Devlin, Nancy & Scott, Anthony & Kelaher, Margaret, 2020. "The impact of price transparency on consumers and providers: A scoping review," Health Policy, Elsevier, vol. 124(8), pages 819-825.

    Cited by:

    1. Amir Hossein Sepehrian & Zahra Sadat Mirzazadeh & Malihe Sadat Aghaei Shahri, 2023. "Effect of price transparency on the perception of fair price and satisfaction with the purchase of sports products," Journal of Revenue and Pricing Management, Palgrave Macmillan, vol. 22(5), pages 327-337, October.
    2. Christopher T. Robertson & Wendy Netter Epstein & Hansoo Ko, 2023. "The effects of price transparency and debt collection policies on intentions to consume recommended health care: A randomized vignette experiment," Journal of Empirical Legal Studies, John Wiley & Sons, vol. 20(4), pages 941-960, December.
    3. Kjellberg, Hans & Sjögren, Ebba & Krafve, Linus Johansson, 2023. "The functions of known to be inaccurate prices in markets: A cross-country comparison of pharmaceutical list pricing," Journal of Business Research, Elsevier, vol. 167(C).
    4. Dariusz Dudek & Marcin Lipowski & Ilona Bondos, 2021. "Changing Energy Supplier on the Market with a Strong Position of Incumbent Suppliers—Polish Example," Energies, MDPI, vol. 14(13), pages 1-16, June.
    5. Sabanovic, Hana & La Brooy, Camille & Méndez, Susan J. & Yong, Jongsay & Scott, Anthony & Elshaug, Adam G. & Prang, Khic-Houy, 2023. "“It's not a one operation fits all”: A qualitative study exploring fee setting and participation in price transparency initiatives amongst medical specialists in the Australian private healthcare sect," Social Science & Medicine, Elsevier, vol. 339(C).
    6. Alex Hoagland & David M. Anderson & Ed Zhu, 2022. "Medical Bill Shock and Imperfect Moral Hazard," Papers 2211.01116, arXiv.org, revised Mar 2024.

  12. Sullivan, Trudy & Hansen, Paul & Ombler, Franz & Derrett, Sarah & Devlin, Nancy, 2020. "A new tool for creating personal and social EQ-5D-5L value sets, including valuing ‘dead’," Social Science & Medicine, Elsevier, vol. 246(C).

    Cited by:

    1. Babashahi, Saeideh & Hansen, Paul & Sullivan, Trudy, 2021. "Creating a priority list of non-communicable diseases to support health research funding decision-making," Health Policy, Elsevier, vol. 125(2), pages 221-228.
    2. Haghani, Milad & Bliemer, Michiel C.J. & Hensher, David A., 2021. "The landscape of econometric discrete choice modelling research," Journal of choice modelling, Elsevier, vol. 40(C).
    3. María Carmen Carnero, 2020. "Waste Segregation FMEA Model Integrating Intuitionistic Fuzzy Set and the PAPRIKA Method," Mathematics, MDPI, vol. 8(8), pages 1-29, August.
    4. Mark McGillivray & Simon Feeny & Paul Hansen & Stephen Knowles & Franz Ombler, 2023. "What are Valid Weights for the Human Development Index? A Discrete Choice Experiment for the United Kingdom," Social Indicators Research: An International and Interdisciplinary Journal for Quality-of-Life Measurement, Springer, vol. 165(2), pages 679-694, January.
    5. Yiu, Hei Hang Edmund & Buckell, John & Petrou, Stavros & Stewart-Brown, Sarah & Madan, Jason, 2023. "Derivation of a UK preference-based value set for the Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS) to allow estimation of Mental Well-being Adjusted Life Years (MWALYs)," Social Science & Medicine, Elsevier, vol. 327(C).

  13. Donna Rowen & Oliver Rivero-Arias & Nancy Devlin & Julie Ratcliffe, 2020. "Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in Child and Adolescent Populations: Where are We Now and Where are We Going?," PharmacoEconomics, Springer, vol. 38(4), pages 325-340, April.

    Cited by:

    1. Jiaer Lin & Carlos King Ho Wong & Jason Pui Yin Cheung & Prudence Wing Hang Cheung & Nan Luo, 2022. "Psychometric performance of proxy-reported EQ-5D youth version 5-level (EQ-5D-Y-5L) in comparison with three-level (EQ-5D-Y-3L) in children and adolescents with scoliosis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(8), pages 1383-1395, November.
    2. Paul Mark Mitchell & Samantha Husbands & Sarah Byford & Philip Kinghorn & Cara Bailey & Tim J. Peters & Joanna Coast, 2021. "Challenges in developing capability measures for children and young people for use in the economic evaluation of health and care interventions," Health Economics, John Wiley & Sons, Ltd., vol. 30(9), pages 1990-2003, September.
    3. Husbands, Samantha & Mitchell, Paul Mark & Kinghorn, Philip & Byford, Sarah & Bailey, Cara & Anand, Paul & Peters, Tim J. & Floredin, Isabella & Coast, Joanna, 2024. "Is well-becoming important for children and young people? Evidence from in-depth interviews with children and young people and their parents," LSE Research Online Documents on Economics 122060, London School of Economics and Political Science, LSE Library.
    4. Ruvini M. Hettiarachchi & Peter Arrow & Sameera Senanayake & Hannah Carter & David Brain & Richard Norman & Utsana Tonmukayawul & Lisa Jamieson & Sanjeewa Kularatna, 2023. "Developing an Australian utility value set for the Early Childhood Oral Health Impact Scale-4D (ECOHIS-4D) using a discrete choice experiment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(8), pages 1285-1296, November.
    5. Titi Sahidah Fitriana & Bram Roudijk & Fredrick Dermawan Purba & Jan J. V. Busschbach & Elly Stolk, 2022. "Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values," PharmacoEconomics, Springer, vol. 40(2), pages 157-167, December.
    6. Huang, Li & Devlin, Nancy & Chen, Gang & Dalziel, Kim, 2024. "A happiness approach to valuing health states for children," Social Science & Medicine, Elsevier, vol. 348(C).
    7. S. A. Lipman & V. T. Reckers-Droog & M. Karimi & M. Jakubczyk & A. E. Attema, 2021. "Self vs. other, child vs. adult. An experimental comparison of valuation perspectives for valuation of EQ-5D-Y-3L health states," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1507-1518, December.
    8. Powell, Philip A. & Rowen, Donna & Keetharuth, Anju & Mukuria, Clara, 2024. "Understanding UK public views on normative decisions made to value health-related quality of life in children: A qualitative study," Social Science & Medicine, Elsevier, vol. 340(C).
    9. Kim Dalziel & Max Catchpool & Borja García-Lorenzo & Inigo Gorostiza & Richard Norman & Oliver Rivero-Arias, 2020. "Feasibility, Validity and Differences in Adolescent and Adult EQ-5D-Y Health State Valuation in Australia and Spain: An Application of Best–Worst Scaling," PharmacoEconomics, Springer, vol. 38(5), pages 499-513, May.

  14. Hobbins, Anna P. & Barry, Luke & Kelleher, Dan & Shah, Koonal & Devlin, Nancy & Ramos Goni, Juan Manuel & O’Neill, Ciaran, 2020. "Do people with private health insurance attach a higher value to health than those without insurance? Results from an EQ-5D-5 L valuation study in Ireland," Health Policy, Elsevier, vol. 124(6), pages 639-646.

    Cited by:

    1. Dan Kelleher & Samer Kharroubi & Edel Doherty & Gianluca Baio & Ciaran O’Neill, 2022. "Examining the Association between Polish Migrant Status and Health Preferences Using a Novel Application of a Smaller Design EQ-5D-5L Valuation Study," PharmacoEconomics - Open, Springer, vol. 6(3), pages 425-435, May.

  15. Nancy J. Devlin & Koonal K. Shah & Brendan J. Mulhern & Krystallia Pantiri & Ben van Hout, 2019. "A new method for valuing health: directly eliciting personal utility functions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(2), pages 257-270, March.

    Cited by:

    1. Schneider, Paul, 2019. "Social tariffs and democratic choice – do population-based health state values reflect the will of the people?," SocArXiv 2qvjb, Center for Open Science.
    2. Koonal K. Shah & Juan Manuel Ramos-Goñi & Simone Kreimeier & Nancy J. Devlin, 2020. "An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(7), pages 1091-1103, September.
    3. Michał Jakubczyk & Dominik Golicki, 2020. "Elicitation and modelling of imprecise utility of health states," Theory and Decision, Springer, vol. 88(1), pages 51-71, February.
    4. Sullivan, Trudy & Hansen, Paul & Ombler, Franz & Derrett, Sarah & Devlin, Nancy, 2020. "A new tool for creating personal and social EQ-5D-5L value sets, including valuing ‘dead’," Social Science & Medicine, Elsevier, vol. 246(C).
    5. S. A. Lipman & V. T. Reckers-Droog & M. Karimi & M. Jakubczyk & A. E. Attema, 2021. "Self vs. other, child vs. adult. An experimental comparison of valuation perspectives for valuation of EQ-5D-Y-3L health states," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1507-1518, December.
    6. Paul Schneider & Nancy Devlin & Ben van Hout & John Brazier, 2024. "Exploring health preference heterogeneity in the UK: Using the online elicitation of personal utility functions approach to construct EQ‐5D‐5L value functions on societal, group and individual level," Health Economics, John Wiley & Sons, Ltd., vol. 33(5), pages 894-910, May.
    7. Yiu, Hei Hang Edmund & Buckell, John & Petrou, Stavros & Stewart-Brown, Sarah & Madan, Jason, 2023. "Derivation of a UK preference-based value set for the Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS) to allow estimation of Mental Well-being Adjusted Life Years (MWALYs)," Social Science & Medicine, Elsevier, vol. 327(C).
    8. Paul Peter Schneider, 2021. "Social tariffs and democratic choice—Do population‐based health state values reflect the will of the people?," Health Economics, John Wiley & Sons, Ltd., vol. 30(1), pages 104-112, January.

  16. Fan Yang & Nancy Devlin & Nan Luo, 2019. "Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 99-105, February.

    Cited by:

    1. Mona Aghdaee & Bonny Parkinson & Kompal Sinha & Yuanyuan Gu & Rajan Sharma & Emma Olin & Henry Cutler, 2022. "An examination of machine learning to map non‐preference based patient reported outcome measures to health state utility values," Health Economics, John Wiley & Sons, Ltd., vol. 31(8), pages 1525-1557, August.

  17. Nancy Devlin & John Brazier & A. Simon Pickard & Elly Stolk, 2018. "3L, 5L, What the L? A NICE Conundrum," PharmacoEconomics, Springer, vol. 36(6), pages 637-640, June.

    Cited by:

    1. Paul F M Krabbe & Ruslan Jabrayilov & Patrick Detzel & Livia Dainelli & Karin M Vermeulen & Antoinette D I van Asselt, 2020. "A two-step procedure to generate utilities for the Infant health-related Quality of life Instrument (IQI)," PLOS ONE, Public Library of Science, vol. 15(4), pages 1-14, April.
    2. Finch, Aureliano Paolo & Meregaglia, Michela & Ciani, Oriana & Roudijk, Bram & Jommi, Claudio, 2022. "An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration," Social Science & Medicine, Elsevier, vol. 292(C).

  18. Brendan Mulhern & Yan Feng & Koonal Shah & Mathieu F. Janssen & Michael Herdman & Ben Hout & Nancy Devlin, 2018. "Correction to: Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets," PharmacoEconomics, Springer, vol. 36(6), pages 727-727, June.

    Cited by:

    1. Becky Pennington & Monica Hernandez-Alava & Stephen Pudney & Allan Wailoo, 2019. "The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals," PharmacoEconomics, Springer, vol. 37(1), pages 75-84, January.

  19. Yan Feng & Nancy J. Devlin & Koonal K. Shah & Brendan Mulhern & Ben van Hout, 2018. "New methods for modelling EQ‐5D‐5L value sets: An application to English data," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 23-38, January.

    Cited by:

    1. Brendan Mulhern & Yan Feng & Koonal Shah & Mathieu F. Janssen & Michael Herdman & Ben Hout & Nancy Devlin, 2018. "Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets," PharmacoEconomics, Springer, vol. 36(6), pages 699-713, June.
    2. Nancy Devlin & John Brazier & A. Simon Pickard & Elly Stolk, 2018. "3L, 5L, What the L? A NICE Conundrum," PharmacoEconomics, Springer, vol. 36(6), pages 637-640, June.
    3. Mike Herdman & Jameel Nazir & Zalmai Hakimi & Emad Siddiqui & Moses Huang & Marco Pavesi & Scott MacDiarmid & Marcus J. Drake & Nancy Devlin, 2017. "Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 10(6), pages 677-686, December.
    4. Spencer, Anne & Rivero-Arias, Oliver & Wong, Ruth & Tsuchiya, Aki & Bleichrodt, Han & Edwards, Rhiannon Tudor & Norman, Richard & Lloyd, Andrew & Clarke, Philip, 2022. "The QALY at 50: One story many voices," Social Science & Medicine, Elsevier, vol. 296(C).
    5. Eliza L. Y. Wong & Juan Manuel Ramos-Goñi & Annie W. L. Cheung & Amy Y. K. Wong & Oliver Rivero-Arias, 2018. "Assessing the Use of a Feedback Module to Model EQ-5D-5L Health States Values in Hong Kong," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 11(2), pages 235-247, April.
    6. Anna Selivanova & Erik Buskens & Paul F. M. Krabbe, 2018. "Head-to-Head Comparison of EQ‐5D‐3L and EQ‐5D‐5L Health Values," PharmacoEconomics, Springer, vol. 36(6), pages 715-725, June.
    7. Micah Rose & Stephen Rice & Dawn Craig, 2018. "Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals," PharmacoEconomics - Open, Springer, vol. 2(2), pages 97-107, June.
    8. Kristina Ludwig & J.-Matthias Graf von der Schulenburg & Wolfgang Greiner, 2018. "German Value Set for the EQ-5D-5L," PharmacoEconomics, Springer, vol. 36(6), pages 663-674, June.
    9. Sullivan, Trudy & Hansen, Paul & Ombler, Franz & Derrett, Sarah & Devlin, Nancy, 2020. "A new tool for creating personal and social EQ-5D-5L value sets, including valuing ‘dead’," Social Science & Medicine, Elsevier, vol. 246(C).
    10. Brendan Mulhern & Richard Norman & Deborah J. Street & Rosalie Viney, 2019. "One Method, Many Methodological Choices: A Structured Review of Discrete-Choice Experiments for Health State Valuation," PharmacoEconomics, Springer, vol. 37(1), pages 29-43, January.
    11. Yiu, Hei Hang Edmund & Buckell, John & Petrou, Stavros & Stewart-Brown, Sarah & Madan, Jason, 2023. "Derivation of a UK preference-based value set for the Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS) to allow estimation of Mental Well-being Adjusted Life Years (MWALYs)," Social Science & Medicine, Elsevier, vol. 327(C).
    12. Teresa C. O. Tsui & Kelvin K. W. Chan & Feng Xie & Eleanor M. Pullenayegum, 2024. "Creating a Multiply Imputed Value Set for the EQ-5D-5L in Canada: State-Level Misspecification Terms Are Needed to Characterize Parameter Uncertainty Correctly," Medical Decision Making, , vol. 44(4), pages 405-414, May.

  20. Martina Garau & Grace Hampson & Nancy Devlin & Nicola Amedeo Mazzanti & Antonio Profico, 2018. "Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)," PharmacoEconomics - Open, Springer, vol. 2(2), pages 153-163, June.

    Cited by:

    1. Ahumada-Canale, Antonio & Jeet, Varinder & Bilgrami, Anam & Seil, Elizabeth & Gu, Yuanyuan & Cutler, Henry, 2023. "Barriers and facilitators to implementing priority setting and resource allocation tools in hospital decisions: A systematic review," Social Science & Medicine, Elsevier, vol. 322(C).

  21. Brendan Mulhern & Yan Feng & Koonal Shah & Mathieu F. Janssen & Michael Herdman & Ben Hout & Nancy Devlin, 2018. "Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets," PharmacoEconomics, Springer, vol. 36(6), pages 699-713, June.

    Cited by:

    1. Nancy Devlin & John Brazier & A. Simon Pickard & Elly Stolk, 2018. "3L, 5L, What the L? A NICE Conundrum," PharmacoEconomics, Springer, vol. 36(6), pages 637-640, June.
    2. Eliza Kruger & Daniel Aggio & Hayley Freitas & Andrew Lloyd, 2023. "Estimation of Health Utility Scores for Glycogen Storage Disease Type Ia," PharmacoEconomics - Open, Springer, vol. 7(4), pages 627-638, July.
    3. Merili Tamson & Rainer Reile & Diana Sokurova & Kaire Innos & Eha Nurk & Kaia Laidra & Sigrid Vorobjov, 2022. "Health-Related Quality of Life and Its Socio-Demographic and Behavioural Correlates during the COVID-19 Pandemic in Estonia," IJERPH, MDPI, vol. 19(15), pages 1-12, July.
    4. Becky Pennington & Monica Hernandez-Alava & Stephen Pudney & Allan Wailoo, 2019. "The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals," PharmacoEconomics, Springer, vol. 37(1), pages 75-84, January.
    5. Mihir Gandhi & Marcus Ang & Kelvin Teo & Chee Wai Wong & Yvonne Chung-Hsi Wei & Rachel Lee-Yin Tan & Mathieu F. Janssen & Nan Luo, 2019. "EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 12(4), pages 383-392, August.
    6. Anna Selivanova & Erik Buskens & Paul F. M. Krabbe, 2018. "Head-to-Head Comparison of EQ‐5D‐3L and EQ‐5D‐5L Health Values," PharmacoEconomics, Springer, vol. 36(6), pages 715-725, June.
    7. Ângela Jornada Ben & Johanna M. Dongen & Aureliano Paolo Finch & Mohamed El Alili & Judith E. Bosmans, 2023. "To what extent does the use of crosswalks instead of EQ-5D value sets impact reimbursement decisions?: a simulation study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(8), pages 1253-1270, November.

  22. Nancy Devlin & John Brazier & A. Simon Pickard & Elly Stolk, 2018. "Correction to: 3L, 5L, What the L? A NICE Conundrum," PharmacoEconomics, Springer, vol. 36(6), pages 729-729, June.

    Cited by:

    1. Paul F M Krabbe & Ruslan Jabrayilov & Patrick Detzel & Livia Dainelli & Karin M Vermeulen & Antoinette D I van Asselt, 2020. "A two-step procedure to generate utilities for the Infant health-related Quality of life Instrument (IQI)," PLOS ONE, Public Library of Science, vol. 15(4), pages 1-14, April.
    2. Finch, Aureliano Paolo & Meregaglia, Michela & Ciani, Oriana & Roudijk, Bram & Jommi, Claudio, 2022. "An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration," Social Science & Medicine, Elsevier, vol. 292(C).

  23. Nancy J. Devlin & Koonal K. Shah & Yan Feng & Brendan Mulhern & Ben van Hout, 2018. "Valuing health‐related quality of life: An EQ‐5D‐5L value set for England," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 7-22, January.

    Cited by:

    1. Webb, Edward J.D. & Hess, Stephane, 2021. "Joint modelling of choice and rating data: Theory and examples," Journal of choice modelling, Elsevier, vol. 40(C).
    2. Spencer, Anne & Rivero-Arias, Oliver & Wong, Ruth & Tsuchiya, Aki & Bleichrodt, Han & Edwards, Rhiannon Tudor & Norman, Richard & Lloyd, Andrew & Clarke, Philip, 2022. "The QALY at 50: One story many voices," Social Science & Medicine, Elsevier, vol. 296(C).
    3. Olsen, Jan Abel & Lindberg, Marie Hella & Lamu, Admassu Nadew, 2020. "Health and wellbeing in Norway: Population norms and the social gradient," Social Science & Medicine, Elsevier, vol. 259(C).
    4. Wen Wan & M. Reza Skandari & Alexa Minc & Aviva G. Nathan & Parmida Zarei & Aaron N. Winn & Michael O’Grady & Elbert S. Huang, 2018. "Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial," Medical Decision Making, , vol. 38(8), pages 942-953, November.
    5. John Mullahy, 2018. "Treatment Effects with Multiple Outcomes," NBER Working Papers 25307, National Bureau of Economic Research, Inc.
    6. Admassu N. Lamu, 2020. "Does linear equating improve prediction in mapping? Crosswalking MacNew onto EQ-5D-5L value sets," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(6), pages 903-915, August.
    7. Himmler, Sebastian & Jonker, Marcel & van Krugten, Frédérique & Hackert, Mariska & van Exel, Job & Brouwer, Werner, 2022. "Estimating an anchored utility tariff for the well-being of older people measure (WOOP) for the Netherlands," Social Science & Medicine, Elsevier, vol. 301(C).
    8. Sebastian Himmler & Job Exel & Werner Brouwer, 2022. "Did the COVID-19 pandemic change the willingness to pay for an early warning system for infectious diseases in Europe?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(1), pages 81-94, February.
    9. Héctor Pifarré i Arolas & Christian Dudel, 2017. "An ordinal measure of population health," MPIDR Working Papers WP-2017-010, Max Planck Institute for Demographic Research, Rostock, Germany.
    10. Tianxin Pan & Brendan Mulhern & Rosalie Viney & Richard Norman & Janel Hanmer & Nancy Devlin, 2022. "A Comparison of PROPr and EQ-5D-5L Value Sets," PharmacoEconomics, Springer, vol. 40(3), pages 297-307, March.
    11. Ernest H. Law & A. Simon Pickard & Feng Xie & Surrey M. Walton & Todd A. Lee & Alan Schwartz, 2018. "Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets," Medical Decision Making, , vol. 38(8), pages 968-982, November.
    12. Marcel F. Jonker & Richard Norman, 2022. "Not all respondents use a multiplicative utility function in choice experiments for health state valuations, which should be reflected in the elicitation format (or statistical analysis)," Health Economics, John Wiley & Sons, Ltd., vol. 31(2), pages 431-439, February.
    13. Jing Shen & Sarah Hill & David Mott & Matthew Breckons & Luke Vale & Rob Pickard, 2019. "Conducting a Time Trade-Off Study Alongside a Clinical Trial: A Case Study and Recommendations," PharmacoEconomics - Open, Springer, vol. 3(1), pages 5-20, March.
    14. Kelleher, Dan & Barry, Luke & Hobbins, Anna & O'Neill, Stephen & Doherty, Edel & O'Neill, Ciaran, 2020. "Examining the transnational health preferences of a group of Eastern European migrants relative to a European host population using the EQ-5D-5L," Social Science & Medicine, Elsevier, vol. 246(C).
    15. Guillem López-Casasnovas & José Luis Pinto Prades, 2022. "QALY Maximization and the Social Optimum," Hacienda Pública Española / Review of Public Economics, IEF, vol. 242(3), pages 111-127, September.
    16. Donna Rowen & Clara Mukuria & Emily McDool, 2022. "A Systematic Review of the Methodologies and Modelling Approaches Used to Generate International EQ-5D-5L Value Sets," PharmacoEconomics, Springer, vol. 40(9), pages 863-882, September.
    17. Mihir Gandhi & Marcus Ang & Kelvin Teo & Chee Wai Wong & Yvonne Chung-Hsi Wei & Rachel Lee-Yin Tan & Mathieu F. Janssen & Nan Luo, 2019. "EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 12(4), pages 383-392, August.
    18. Brendan Mulhern & Richard Norman & John Brazier, 2021. "Valuing SF-6Dv2 in Australia Using an International Protocol," PharmacoEconomics, Springer, vol. 39(10), pages 1151-1162, October.
    19. Rachael Maree Hunter & Rob Anderson & Tim Kirkpatrick & Charlotte Lennox & Fiona Warren & Rod S. Taylor & Jenny Shaw & Mark Haddad & Alex Stirzaker & Mike Maguire & Richard Byng, 2022. "Economic evaluation of a complex intervention (Engager) for prisoners with common mental health problems, near to and after release: a cost-utility and cost-consequences analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(2), pages 193-210, March.
    20. Mónica Hernández‐Alava & Stephen Pudney, 2022. "Mapping between EQ‐5D‐3L and EQ‐5D‐5L: A survey experiment on the validity of multi‐instrument data," Health Economics, John Wiley & Sons, Ltd., vol. 31(6), pages 923-939, June.
    21. Lipman, Stefan A. & Brouwer, Werner B.F. & Attema, Arthur E., 2020. "Living up to expectations: Experimental tests of subjective life expectancy as reference point in time trade-off and standard gamble," Journal of Health Economics, Elsevier, vol. 71(C).
    22. Elliott, Jack & Tsuchiya, Aki, 2022. "Do they just know more, or do they also have different preferences? An exploratory analysis of the effects of self-reporting serious health problems on health state valuation," Social Science & Medicine, Elsevier, vol. 315(C).
    23. Sullivan, Trudy & Hansen, Paul & Ombler, Franz & Derrett, Sarah & Devlin, Nancy, 2020. "A new tool for creating personal and social EQ-5D-5L value sets, including valuing ‘dead’," Social Science & Medicine, Elsevier, vol. 246(C).
    24. S. A. Lipman & V. T. Reckers-Droog & M. Karimi & M. Jakubczyk & A. E. Attema, 2021. "Self vs. other, child vs. adult. An experimental comparison of valuation perspectives for valuation of EQ-5D-Y-3L health states," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1507-1518, December.
    25. Rowen, Donna & Mukuria, Clara & Bray, Nathan & Carlton, Jill & Longworth, Louise & Meads, David & O'Neill, Ciaran & Shah, Koonal & Yang, Yaling, 2022. "Assessing the comparative feasibility, acceptability and equivalence of videoconference interviews and face-to-face interviews using the time trade-off technique," Social Science & Medicine, Elsevier, vol. 309(C).
    26. Dhfer Alshayban & Royes Joseph, 2020. "Health-related quality of life among patients with type 2 diabetes mellitus in Eastern Province, Saudi Arabia: A cross-sectional study," PLOS ONE, Public Library of Science, vol. 15(1), pages 1-12, January.
    27. Taylor, Kevin & Ratcliffe, Julie & Bessarab, Dawn & Smith, Kate, 2023. "Valuing indigenous quality of life: A review of preference-based quality of life instruments and elicitation techniques with global older indigenous populations," Social Science & Medicine, Elsevier, vol. 336(C).
    28. Chen, Gang & Ratcliffe, Julie & Milte, Rachel & Khadka, Jyoti & Kaambwa, Billingsley, 2021. "Quality of care experience in aged care: An Australia-Wide discrete choice experiment to elicit preference weights," Social Science & Medicine, Elsevier, vol. 289(C).
    29. Sahar Al Shabasy & Bram Roudijk & Maggie Abbassi & Aureliano Finch & Elly Stolk & Samar Farid, 2023. "The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned," PharmacoEconomics, Springer, vol. 41(3), pages 329-338, March.
    30. Mihir Gandhi & Marcus Ang & Kelvin Teo & Chee Wai Wong & Yvonne Chung-Hsi Wei & Rachel Lee-Yin Tan & Mathieu F. Janssen & Nan Luo, 2020. "A vision ‘bolt-on’ increases the responsiveness of EQ-5D: preliminary evidence from a study of cataract surgery," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(4), pages 501-511, June.
    31. Teresa C. O. Tsui & Kelvin K. W. Chan & Feng Xie & Eleanor M. Pullenayegum, 2024. "Creating a Multiply Imputed Value Set for the EQ-5D-5L in Canada: State-Level Misspecification Terms Are Needed to Characterize Parameter Uncertainty Correctly," Medical Decision Making, , vol. 44(4), pages 405-414, May.
    32. Gamze Bayin Donar & Mehmet Top, 2020. "A conceptual framework of quality of life in chronic kidney disease in Turkey: A patient‐focused approach," International Journal of Health Planning and Management, Wiley Blackwell, vol. 35(6), pages 1335-1350, November.
    33. Ole Marten & Brendan Mulhern & Nick Bansback & Aki Tsuchiya, 2020. "Implausible States: Prevalence of EQ-5D-5L States in the General Population and Its Effect on Health State Valuation," Medical Decision Making, , vol. 40(6), pages 735-745, August.

  24. Amanda Cole & Koonal Shah & Brendan Mulhern & Yan Feng & Nancy Devlin, 2018. "Valuing EQ-5D-5L health states ‘in context’ using a discrete choice experiment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 595-605, May.

    Cited by:

    1. Nancy J. Devlin & Koonal K. Shah & Brendan J. Mulhern & Krystallia Pantiri & Ben van Hout, 2019. "A new method for valuing health: directly eliciting personal utility functions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(2), pages 257-270, March.
    2. Brendan Mulhern & Richard Norman & Koonal Shah & Nick Bansback & Louise Longworth & Rosalie Viney, 2018. "How Should Discrete Choice Experiments with Duration Choice Sets Be Presented for the Valuation of Health States?," Medical Decision Making, , vol. 38(3), pages 306-318, April.
    3. Brendan Mulhern & Richard Norman & Deborah J. Street & Rosalie Viney, 2019. "One Method, Many Methodological Choices: A Structured Review of Discrete-Choice Experiments for Health State Valuation," PharmacoEconomics, Springer, vol. 37(1), pages 29-43, January.

  25. Anna Hobbins & Luke Barry & Dan Kelleher & Koonal Shah & Nancy Devlin & Juan Manuel Ramos Goni & Ciaran O’Neill, 2018. "Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L," PharmacoEconomics, Springer, vol. 36(11), pages 1345-1353, November.

    Cited by:

    1. Ernest H. Law & A. Simon Pickard & Feng Xie & Surrey M. Walton & Todd A. Lee & Alan Schwartz, 2018. "Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets," Medical Decision Making, , vol. 38(8), pages 968-982, November.
    2. Henry, Edward & Cullinan, John, 2021. "Mental health spillovers from serious family illness: Doubly robust estimation using EQ-5D-5L population normative data," Social Science & Medicine, Elsevier, vol. 279(C).
    3. Kelleher, Dan & Barry, Luke & Hobbins, Anna & O'Neill, Stephen & Doherty, Edel & O'Neill, Ciaran, 2020. "Examining the transnational health preferences of a group of Eastern European migrants relative to a European host population using the EQ-5D-5L," Social Science & Medicine, Elsevier, vol. 246(C).
    4. Sullivan, Trudy & Hansen, Paul & Ombler, Franz & Derrett, Sarah & Devlin, Nancy, 2020. "A new tool for creating personal and social EQ-5D-5L value sets, including valuing ‘dead’," Social Science & Medicine, Elsevier, vol. 246(C).
    5. Dan Kelleher & Samer Kharroubi & Edel Doherty & Gianluca Baio & Ciaran O’Neill, 2022. "Examining the Association between Polish Migrant Status and Health Preferences Using a Novel Application of a Smaller Design EQ-5D-5L Valuation Study," PharmacoEconomics - Open, Springer, vol. 6(3), pages 425-435, May.
    6. Hobbins, Anna P. & Barry, Luke & Kelleher, Dan & Shah, Koonal & Devlin, Nancy & Ramos Goni, Juan Manuel & O’Neill, Ciaran, 2020. "Do people with private health insurance attach a higher value to health than those without insurance? Results from an EQ-5D-5 L valuation study in Ireland," Health Policy, Elsevier, vol. 124(6), pages 639-646.

  26. Nancy J. Devlin & Richard Brooks, 2017. "EQ-5D and the EuroQol Group: Past, Present and Future," Applied Health Economics and Health Policy, Springer, vol. 15(2), pages 127-137, April.

    Cited by:

    1. Helena Janols & Carl Wadsten & Christoffer Forssell & Elena Raffeti & Christer Janson & Xingwu Zhou & Marta A Kisiel, 2024. "Enhancing EQ-5D-5L Sensitivity in Capturing the Most Common Symptoms in Post-COVID-19 Patients: An Exploratory Cross-Sectional Study with a Focus on Fatigue, Memory/Concentration Problems and Dyspnea ," IJERPH, MDPI, vol. 21(5), pages 1-14, May.
    2. Bischof, Anja & Salvi, Irene & Kuklinski, David & Vogel, Justus & Geissler, Alexander, 2023. "Design Principles of Clinical Dashboards Incorporating PROMs: Crafting and Elaborating the Potential of Clinical Dashboards Incorporating PROMs," Working Paper Series in Health Economics, Management and Policy 2023-05, University of St.Gallen, School of Medicine, Chair of Health Economics, Policy and Management.
    3. Ines Buchholz & Mathieu F. Janssen & Thomas Kohlmann & You-Shan Feng, 2018. "A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5D," PharmacoEconomics, Springer, vol. 36(6), pages 645-661, June.
    4. Angelis, A. & Montibeller, G. & Kanavos, P., 2023. "A structured methodology for essential medicines lists and health emergency stockpiles: Experience with the Emergency Medicines Buffer Stock in the United Kingdom," Social Science & Medicine, Elsevier, vol. 337(C).
    5. David G. T. Whitehurst & Nicholas R. Latimer & Aura Kagan & Rebecca Palmer & Nina Simmons-Mackie & J. Charles Victor & Jeffrey S. Hoch, 2018. "Developing Accessible, Pictorial Versions of Health-Related Quality-of-Life Instruments Suitable for Economic Evaluation: A Report of Preliminary Studies Conducted in Canada and the United Kingdom," PharmacoEconomics - Open, Springer, vol. 2(3), pages 225-231, September.
    6. Marta Encheva & Slaveyko Djambazov & Toni Vekov & Dominik Golicki, 2020. "EQ-5D-5L Bulgarian population norms," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(8), pages 1169-1178, November.
    7. Wenjing Zhou & Anle Shen & Zhihao Yang & Pei Wang & Bin Wu & Michael Herdman & Nan Luo, 2021. "Patient-caregiver agreement and test–retest reliability of the EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients with haematological malignancies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(7), pages 1103-1113, September.
    8. Pei Wang & Sheue-Lih Chong & Rachel Lee-Yin Tan & Nan Luo, 2023. "A hearing bolt-on item increased the measurement properties of the EQ-5D-5L in a community-based hearing loss screening program," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(3), pages 393-398, April.
    9. Charles F. Manski, 2023. "Using Limited Trial Evidence to Credibly Choose Treatment Dosage when Efficacy and Adverse Effects Weakly Increase with Dose," NBER Working Papers 31305, National Bureau of Economic Research, Inc.
    10. Héctor Pifarré i Arolas & Christian Dudel, 2017. "An ordinal measure of population health," MPIDR Working Papers WP-2017-010, Max Planck Institute for Demographic Research, Rostock, Germany.
    11. Hannah Christensen & Hareth Al-Janabi & Pierre Lévy & Maarten J. Postma & David E. Bloom & Paolo Landa & David M. Salisbury & Javier Diez-Domingo & Adrian K. Towse & Paula K. Lorgelly & Koonal K. Shah, 2020. "Economic evaluation of meningococcal vaccines: considerations for the future," Post-Print hal-03120553, HAL.
    12. Márta Péntek & Ottó Hajdu & Fanni Rencz & Zsuzsanna Beretzky & Valentin Brodszky & Petra Baji & Zsombor Zrubka & Klára Major & László Gulácsi, 2019. "Subjective expectations regarding ageing: a cross-sectional online population survey in Hungary," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 17-30, June.
    13. Saidatulakmal Mohd & Abdul Rais Abdul Latiff & Abdelhak Senadjki, 2019. "Travel Behavior of Elderly in George Town and Malacca, Malaysia," Sustainability, MDPI, vol. 11(19), pages 1-20, September.
    14. Stefan A. Lipman & Liying Zhang & Koonal K. Shah & Arthur E. Attema, 2023. "Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(2), pages 293-305, March.
    15. Asrul Akmal Shafie & Annushiah Vasan Thakumar, 2020. "Multiplicative modelling of EQ-5D-3L TTO and VAS values," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(9), pages 1411-1420, December.
    16. Menyfah Q. Alanazi & Waleed Abdelgawwad & Thamer A. Almangour & Fatma Mostafa & Mona Almuheed, 2023. "Impact of COVID-19 on the Health-Related Quality of Life of Patients during Infection and after Recovery in Saudi Arabia," IJERPH, MDPI, vol. 20(6), pages 1-14, March.
    17. Matthew Kennedy-Martin & Bernhard Slaap & Michael Herdman & Mandy Reenen & Tessa Kennedy-Martin & Wolfgang Greiner & Jan Busschbach & Kristina S. Boye, 2020. "Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(8), pages 1245-1257, November.
    18. Nancy J. Devlin & Koonal K. Shah & Brendan J. Mulhern & Krystallia Pantiri & Ben van Hout, 2019. "A new method for valuing health: directly eliciting personal utility functions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(2), pages 257-270, March.
    19. Tessa Peasgood & Julia M. Caruana & Clara Mukuria, 2023. "Systematic Review of the Effect of a One-Day Versus Seven-Day Recall Duration on Patient Reported Outcome Measures (PROMs)," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 16(3), pages 201-221, May.
    20. Yea-Chan Lee & Da-Hye Son & Yu-Jin Kwon, 2020. "U-Shaped Association between Sleep Duration, C-Reactive Protein, and Uric Acid in Korean Women," IJERPH, MDPI, vol. 17(8), pages 1-11, April.
    21. Suzi Claflin & Julie A. Campbell & Richard Norman & Deborah F. Mason & Tomas Kalincik & Steve Simpson-Yap & Helmut Butzkueven & William M. Carroll & Andrew J. Palmer & C. Leigh Blizzard & Ingrid van d, 2023. "Using the EQ-5D-5L to investigate quality-of-life impacts of disease-modifying therapy policies for people with multiple sclerosis (MS) in New Zealand," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(6), pages 939-950, August.
    22. Hernández-Alava, Mónica & Pudney, Stephen, 2017. "Econometric modelling of multiple self-reports of health states: The switch from EQ-5D-3L to EQ-5D-5L in evaluating drug therapies for rheumatoid arthritis," Journal of Health Economics, Elsevier, vol. 55(C), pages 139-152.
    23. Runhua Liu & Zhuxin Mao & Zhihao Yang, 2022. "Validating the Well-Being of Older People (WOOP) Instrument in China," IJERPH, MDPI, vol. 20(1), pages 1-12, December.
    24. Chen-Wei Pan & Jun-Yi He & Yan-Bo Zhu & Chun-Hua Zhao & Nan Luo & Pei Wang, 2023. "Comparison of EQ-5D-5L and EORTC QLU-C10D utilities in gastric cancer patients," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(6), pages 885-893, August.
    25. Jasmin Barman-Aksözen & Anna-Elisabeth Minder & Francesca Granata & Mårten Pettersson & Cornelia Dechant & Mehmet Hakan Aksözen & Rocco Falchetto, 2023. "Quality-Adjusted Life Years in Erythropoietic Protoporphyria and Other Rare Diseases: A Patient-Initiated EQ-5D Feasibility Study," IJERPH, MDPI, vol. 20(7), pages 1-15, March.
    26. Ji Hye Shin & Ji Hyun Kim, 2022. "Family Caregivers of People with Dementia Associate with Poor Health-Related Quality of Life: A Nationwide Population-Based Study," IJERPH, MDPI, vol. 19(23), pages 1-14, December.
    27. Luis Eduardo Genaro & José Victor Marconato & Elaine Pereira da Silva Tagliaferro & Felipe Eduardo Pinotti & Aylton Valsecki Júnior & Tânia Adas Saliba & Fernanda Lopez Rosell, 2024. "Home Care for the Elderly: An Integrated Approach to Perception, Quality of Life, and Cognition," IJERPH, MDPI, vol. 21(5), pages 1-14, April.
    28. Eva-Carin Lindgren & Jeanette Källstrand & Åsa Alftberg & Pia Johansson & Lars Kristén & Linn Håman & Andreas Ivarsson & Ing-Marie Carlsson, 2022. "Empowerment-Based Physical Activity Intervention for People with Advanced Dry Age-Related Macular Degeneration: Mixed-Methods Protocol," IJERPH, MDPI, vol. 20(1), pages 1-12, December.
    29. Cassandra Mah & Vanessa K. Noonan & Stirling Bryan & David G. T. Whitehurst, 2021. "Empirical Validity of a Generic, Preference-Based Capability Wellbeing Instrument (ICECAP-A) in the Context of Spinal Cord Injury," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 14(2), pages 223-240, March.
    30. Aimin Wang & Kim Rand & Zhihao Yang & Richard Brooks & Jan Busschbach, 2022. "The remarkably frequent use of EQ-5D in non-economic research," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(6), pages 1007-1014, August.
    31. Pickles, Kristen & Lancsar, Emily & Seymour, Janelle & Parkin, David & Donaldson, Cam & Carter, Stacy M., 2019. "Accounts from developers of generic health state utility instruments explain why they produce different QALYs: A qualitative study," Social Science & Medicine, Elsevier, vol. 240(C).
    32. McDaid, David & Park, A-La, 2023. "Making an economic argument for investment in global mental health: the case of conflict-affected refugees and displaced people," LSE Research Online Documents on Economics 118149, London School of Economics and Political Science, LSE Library.
    33. Klara Greffin & Holger Muehlan & Neeltje van den Berg & Wolfgang Hoffmann & Oliver Ritter & Michael Oeff & Georg Schomerus & Silke Schmidt, 2021. "Setting-Sensitive Conceptualization and Assessment of Quality of Life in Telemedical Care—Study Protocol of the Tele-QoL Project," IJERPH, MDPI, vol. 18(19), pages 1-13, October.
    34. Al Ozonoff & Naresh Doni Jayavelu & Shanshan Liu & Esther Melamed & Carly E. Milliren & Jingjing Qi & Linda N. Geng & Grace A. McComsey & Charles B. Cairns & Lindsey R. Baden & Joanna Schaenman & Albe, 2024. "Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study," Nature Communications, Nature, vol. 15(1), pages 1-17, December.
    35. Daniele Fineschi & Sofia Acciai & Margherita Napolitani & Giovanni Scarafuggi & Gabriele Messina & Giovanni Guarducci & Nicola Nante, 2022. "Game of Mirrors: Health Profiles in Patient and Physician Perceptions," IJERPH, MDPI, vol. 19(3), pages 1-8, January.
    36. Guizhi Weng & Yanming Hong & Nan Luo & Clara Mukuria & Jie Jiang & Zhihao Yang & Sha Li, 2023. "Comparing EQ-5D-3L and EQ-5D-5L in measuring the HRQoL burden of 4 health conditions in China," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(2), pages 197-207, March.
    37. Stephen Poteet & Benjamin M. Craig, 2021. "QALYs for COVID-19: A Comparison of US EQ-5D-5L Value Sets," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 14(3), pages 339-345, May.
    38. Marian Sorin Paveliu & Elena Olariu & Raluca Caplescu & Yemi Oluboyede & Ileana-Gabriela Niculescu-Aron & Simona Ernu & Luke Vale, 2021. "Estimating an EQ-5D-3L Value Set for Romania Using Time Trade-Off," IJERPH, MDPI, vol. 18(14), pages 1-16, July.
    39. Jiyune Yi & Seul Gee Kim & Taegyu Khil & Minja Shin & Jin-Hee You & Sookja Jeon & Gue Hong Park & Ah Young Jeong & Youngsuwn Lim & Kahye Kim & Jingun Kim & Byunghoon Kang & Jueun Lee & Jeong Hwan Park, 2021. "Psycho-Electrophysiological Benefits of Forest Therapies Focused on Qigong and Walking with Elderly Individuals," IJERPH, MDPI, vol. 18(6), pages 1-16, March.
    40. Anja Niemann & Vivienne Hillerich & Jürgen Wasem & Jan Dieris-Hirche & Laura Bottel & Magdalena Pape & Stephan Herpertz & Nina Timmesfeld & Jale Basten & Bert Theodor te Wildt & Klaus Wölfling & Raine, 2023. "Health Economic Evaluation of an Online-Based Motivational Program to Reduce Problematic Media Use and Promote Treatment Motivation for Internet Use Disorder—Results of the OMPRIS Study," IJERPH, MDPI, vol. 20(24), pages 1-14, December.
    41. David Flecks Howell & Agneta Malmgren Fänge & Cecilia Rogmark & Eva Ekvall Hansson, 2023. "Rehabilitation Outcomes Following Hip Fracture of Home-Based Exercise Interventions Using a Wearable Device—A Randomized Controlled Pilot and Feasibility Study," IJERPH, MDPI, vol. 20(4), pages 1-13, February.
    42. Lei Si & Liudan Tu & Ya Xie & Gang Chen & Mickaël Hiligsmann & Mingcan Yang & Yanli Zhang & Xi Zhang & Yutong Jiang & Qiujing Wei & Jieruo Gu & Andrew J. Palmer, 2022. "Evaluating Health Related Quality of Life in Older People at Risk of Osteoporotic Fracture: A Head-to-Head Comparison of the EQ-5D-5L and AQoL-6D," Social Indicators Research: An International and Interdisciplinary Journal for Quality-of-Life Measurement, Springer, vol. 160(2), pages 809-824, April.

  27. Paul F. M. Krabbe & Elly A. Stolk & Nancy J. Devlin & Feng Xie & Elise H. Quik & A. Simon Pickard, 2017. "Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(8), pages 967-977, November.

    Cited by:

    1. Irvine, Alastair & van der Pol, Marjon & Phimister, Euan, 2019. "A comparison of professional and private time preferences of General Practitioners," Social Science & Medicine, Elsevier, vol. 222(C), pages 256-264.
    2. Mina Bahrampour & Joshua Byrnes & Richard Norman & Paul A. Scuffham & Martin Downes, 2020. "Discrete choice experiments to generate utility values for multi-attribute utility instruments: a systematic review of methods," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(7), pages 983-992, September.

  28. Emma Cowles & Grace Marsden & Amanda Cole & Nancy Devlin, 2017. "A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?," Applied Health Economics and Health Policy, Springer, vol. 15(4), pages 469-477, August.

    Cited by:

    1. Dale, Elina & Evans, David B. & Gopinathan, Unni & Kurowski, Christoph & Norheim, Ole F. & Ottersen, Trygve & Voorhoeve, Alex, 2023. "Open and inclusive: fair processes for financing universal health coverage," LSE Research Online Documents on Economics 119795, London School of Economics and Political Science, LSE Library.
    2. Francisca Crispi & Huseyin Naci & Eva Barkauskaite & Leeza Osipenko & Elias Mossialos, 2019. "Assessment of Devices, Diagnostics and Digital Technologies: A Review of NICE Medical Technologies Guidance," Applied Health Economics and Health Policy, Springer, vol. 17(2), pages 189-211, April.
    3. James Love-Koh & Alison Peel & Juan Carlos Rejon-Parrilla & Kate Ennis & Rosemary Lovett & Andrea Manca & Anastasia Chalkidou & Hannah Wood & Matthew Taylor, 2018. "The Future of Precision Medicine: Potential Impacts for Health Technology Assessment," PharmacoEconomics, Springer, vol. 36(12), pages 1439-1451, December.
    4. Eve Wittenberg & Lyndon P. James & Lisa A. Prosser, 2019. "Spillover Effects on Caregivers’ and Family Members’ Utility: A Systematic Review of the Literature," PharmacoEconomics, Springer, vol. 37(4), pages 475-499, April.

  29. David Parkin & Nancy Devlin & Yan Feng, 2016. "What Determines the Shape of an EQ-5D Index Distribution?," Medical Decision Making, , vol. 36(8), pages 941-951, November.

    Cited by:

    1. Sang-Dol Kim, 2020. "Impacts of Sociodemographic Characteristics and Cardinal Health Problems on Health-Related Quality of Life among Korean Older Adults," Sustainability, MDPI, vol. 12(18), pages 1-9, September.
    2. Guizhi Weng & Yanming Hong & Nan Luo & Clara Mukuria & Jie Jiang & Zhihao Yang & Sha Li, 2023. "Comparing EQ-5D-3L and EQ-5D-5L in measuring the HRQoL burden of 4 health conditions in China," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(2), pages 197-207, March.

  30. Helen Dakin & Nancy Devlin & Yan Feng & Nigel Rice & Phill O'Neill & David Parkin, 2015. "The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions," Health Economics, John Wiley & Sons, Ltd., vol. 24(10), pages 1256-1271, October.
    See citations under working paper version above.
  31. David Nuttall & David Parkin & Nancy Devlin, 2015. "Inter‐Provider Comparison Of Patient‐Reported Outcomes: Developing An Adjustment To Account For Differences In Patient Case Mix," Health Economics, John Wiley & Sons, Ltd., vol. 24(1), pages 41-54, January.

    Cited by:

    1. Manuel Gomes & Nils Gutacker & Chris Bojke & Andrew Street, 2014. "Addressing missing data in patient-reported outcome measures (PROMs): implications for comparing provider performance," Working Papers 101cherp, Centre for Health Economics, University of York.
    2. Milena Vainieri & Guido Noto & Francesca Ferre & Laura C. Rosella, 2020. "A Performance Management System in Healthcare for All Seasons?," IJERPH, MDPI, vol. 17(15), pages 1-10, August.

  32. Karlsberg Schaffer, Sarah & Sussex, Jon & Devlin, Nancy & Walker, Andrew, 2015. "Local health care expenditure plans and their opportunity costs," Health Policy, Elsevier, vol. 119(9), pages 1237-1244.

    Cited by:

    1. Patricia Cubi-Molla & Martin Buxton & Nancy Devlin, 2021. "Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?," Applied Health Economics and Health Policy, Springer, vol. 19(5), pages 635-644, September.
    2. Beata Gavurova & Kristina Kocisova, 2020. "The efficiency of hospitals: platform for sustainable health care system," Entrepreneurship and Sustainability Issues, VsI Entrepreneurship and Sustainability Center, vol. 8(2), pages 133-146, December.
    3. Laura Catherine Edney & Hossein Haji Ali Afzali & Terence Chai Cheng & Jonathan Karnon, 2018. "Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System," PharmacoEconomics, Springer, vol. 36(2), pages 239-252, February.
    4. Viera Ivanková & Rastislav Kotulič & Jaroslav Gonos & Martin Rigelský, 2019. "Health Care Financing Systems and Their Effectiveness: An Empirical Study of OECD Countries," IJERPH, MDPI, vol. 16(20), pages 1-22, October.
    5. Martina Garau & Grace Hampson & Nancy Devlin & Nicola Amedeo Mazzanti & Antonio Profico, 2018. "Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)," PharmacoEconomics - Open, Springer, vol. 2(2), pages 153-163, June.
    6. Jonathan Siverskog & Martin Henriksson, 2020. "Mutually Exclusive Interventions in the Cost-Effectiveness Bookshelf," Medical Decision Making, , vol. 40(3), pages 399-403, April.

  33. Feng Xie & A. Pickard & Paul Krabbe & Dennis Revicki & Rosalie Viney & Nancy Devlin & David Feeny, 2015. "A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE)," PharmacoEconomics, Springer, vol. 33(8), pages 867-877, August.

    Cited by:

    1. Peasgood, Tessa & Bourke, Mackenzie & Devlin, Nancy & Rowen, Donna & Yang, Yaling & Dalziel, Kim, 2023. "Randomised comparison of online interviews versus face-to-face interviews to value health states," Social Science & Medicine, Elsevier, vol. 323(C).
    2. Michael J. Zoratti & A. Simon Pickard & Peep F. M. Stalmeier & Daniel Ollendorf & Andrew Lloyd & Kelvin K W Chan & Don Husereau & John E. Brazier & Murray Krahn & Mitchell Levine & Lehana Thabane & Fe, 2021. "Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(5), pages 723-733, July.
    3. Nancy J. Devlin & Koonal K. Shah & Yan Feng & Brendan Mulhern & Ben van Hout, 2018. "Valuing health‐related quality of life: An EQ‐5D‐5L value set for England," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 7-22, January.
    4. Mina Bahrampour & Joshua Byrnes & Richard Norman & Paul A. Scuffham & Martin Downes, 2020. "Discrete choice experiments to generate utility values for multi-attribute utility instruments: a systematic review of methods," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(7), pages 983-992, September.
    5. Tonya Moen Hansen & Knut Stavem & Kim Rand, 2023. "Completing the time trade-off with respondents who are older, in poorer health or with an immigrant background in an EQ-5D-5L valuation study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(6), pages 877-884, August.
    6. Finch, Aureliano Paolo & Meregaglia, Michela & Ciani, Oriana & Roudijk, Bram & Jommi, Claudio, 2022. "An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration," Social Science & Medicine, Elsevier, vol. 292(C).

  34. Nils Gutacker & Chris Bojke & Silvio Daidone & Nancy J. Devlin & David Parkin & Andrew Street, 2013. "Truly Inefficient Or Providing Better Quality Of Care? Analysing The Relationship Between Risk‐Adjusted Hospital Costs And Patients' Health Outcomes," Health Economics, John Wiley & Sons, Ltd., vol. 22(8), pages 931-947, August.
    See citations under working paper version above.
  35. Federico Augustovski & Lucila Rey-Ares & Vilma Irazola & Mark Oppe & Nancy Devlin, 2013. "Lead versus lag-time trade-off variants: does it make any difference?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 25-31, July.

    Cited by:

    1. Stefan A. Lipman & Liying Zhang & Koonal K. Shah & Arthur E. Attema, 2023. "Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(2), pages 293-305, March.
    2. Koonal K. Shah & Juan Manuel Ramos-Goñi & Simone Kreimeier & Nancy J. Devlin, 2020. "An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(7), pages 1091-1103, September.

  36. Koonal Shah & Andrew Lloyd & Mark Oppe & Nancy Devlin, 2013. "One-to-one versus group setting for conducting computer-assisted TTO studies: findings from pilot studies in England and the Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 65-73, July.

    Cited by:

    1. Ogorevc, Marko & Murovec, Nika & Fernandez, Natacha Bolanos & Rupel, Valentina Prevolnik, 2019. "Questioning the differences between general public vs. patient based preferences towards EQ-5D-5L defined hypothetical health states," Health Policy, Elsevier, vol. 123(2), pages 166-172.
    2. Peasgood, Tessa & Bourke, Mackenzie & Devlin, Nancy & Rowen, Donna & Yang, Yaling & Dalziel, Kim, 2023. "Randomised comparison of online interviews versus face-to-face interviews to value health states," Social Science & Medicine, Elsevier, vol. 323(C).
    3. Nancy J. Devlin & Koonal K. Shah & Yan Feng & Brendan Mulhern & Ben van Hout, 2018. "Valuing health‐related quality of life: An EQ‐5D‐5L value set for England," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 7-22, January.
    4. Paul F. M. Krabbe & Elly A. Stolk & Nancy J. Devlin & Feng Xie & Elise H. Quik & A. Simon Pickard, 2017. "Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(8), pages 967-977, November.
    5. Finch, Aureliano Paolo & Meregaglia, Michela & Ciani, Oriana & Roudijk, Bram & Jommi, Claudio, 2022. "An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration," Social Science & Medicine, Elsevier, vol. 292(C).

  37. Matthijs Versteegh & Arthur Attema & Mark Oppe & Nancy Devlin & Elly Stolk, 2013. "Time to tweak the TTO: results from a comparison of alternative specifications of the TTO," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 43-51, July.

    Cited by:

    1. Stefan A. Lipman & Liying Zhang & Koonal K. Shah & Arthur E. Attema, 2023. "Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(2), pages 293-305, March.
    2. Ruixuan Jiang & Thomas Kohlmann & Todd A. Lee & Axel Mühlbacher & James Shaw & Surrey Walton & A. Simon Pickard, 2021. "Increasing respondent engagement in composite time trade-off tasks by imposing three minimum trade-offs to improve data quality," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(1), pages 17-33, February.
    3. Arthur Attema & Yvette Edelaar-Peeters & Matthijs Versteegh & Elly Stolk, 2013. "Time trade-off: one methodology, different methods," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 53-64, July.

  38. Nils Gutacker & Chris Bojke & Silvio Daidone & Nancy Devlin & Andrew Street, 2013. "Hospital Variation in Patient-Reported Outcomes at the Level of EQ-5D Dimensions," Medical Decision Making, , vol. 33(6), pages 804-818, August.

    Cited by:

    1. McCarthy, Ian M., 2016. "Eliminating composite bias in treatment effects estimates: Applications to quality of life assessment," Journal of Health Economics, Elsevier, vol. 50(C), pages 47-58.
    2. Gutacker, Nils & Bloor, Karen & Bojke, Chris & Walshe, Kieran, 2018. "Should interventions to reduce variation in care quality target doctors or hospitals?," Health Policy, Elsevier, vol. 122(6), pages 660-666.
    3. Nils Gutacker & Andrew Street, 2015. "Multidimensional performance assessment using dominance criteria," Working Papers 115cherp, Centre for Health Economics, University of York.
    4. Gutacker, Nils & Siciliani, Luigi & Moscelli, Giuseppe & Gravelle, Hugh, 2016. "Choice of hospital: Which type of quality matters?," Journal of Health Economics, Elsevier, vol. 50(C), pages 230-246.
    5. Matthew Skellern, 2017. "The hospital as a multi-product firm: the effect of hospital competition on value-added indicators of clinical quality," CEP Discussion Papers dp1484, Centre for Economic Performance, LSE.
    6. Henry Bailey & Mathieu F Janssen & Althea La Foucade & Paul Kind, 2019. "EQ-5D-5L population norms and health inequalities for Trinidad and Tobago," PLOS ONE, Public Library of Science, vol. 14(4), pages 1-14, April.
    7. Luigi Siciliani & James Gaughan & Nils Gutacker & Hugh Gravelle & Martin Chalkley, 2021. "Paying for health gains," Working Papers 183cherp, Centre for Health Economics, University of York.
    8. Nils Gutacker & Thomas Patton & Koonal Shah & David Parkin, 2020. "Using EQ-5D Data to Measure Hospital Performance: Are General Population Values Distorting Patients’ Choices?," Medical Decision Making, , vol. 40(4), pages 511-521, May.

  39. Nancy Devlin & Paul Krabbe, 2013. "The development of new research methods for the valuation of EQ-5D-5L," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 1-3, July.

    Cited by:

    1. Rachel J. Knott & Nicole Black & Bruce Hollingsworth & Paula K. Lorgelly, 2017. "Response‐Scale Heterogeneity in the EQ‐5D," Health Economics, John Wiley & Sons, Ltd., vol. 26(3), pages 387-394, March.
    2. Knott, R. & Lorgelly, P. & Black, N. & Hollingsworth, B., 2016. "Differential item functioning in the EQ-5D: An exploratory analysis using anchoring vignettes," Health, Econometrics and Data Group (HEDG) Working Papers 16/14, HEDG, c/o Department of Economics, University of York.
    3. Franz Ombler & Michael Albert & Paul Hansen, 2018. "How Significant Are “High†Correlations Between EQ-5D Value Sets?," Medical Decision Making, , vol. 38(6), pages 635-645, August.
    4. Lyttkens, Carl Hampus & Gerdtham, Ulf-G. & Tinghög, Gustav, 2018. "Do We Know What We Are Doing? An Exploratory Study on Swedish Health Economists and the EQ-5D," Working Papers 2018:40, Lund University, Department of Economics.
    5. Yan Feng & Nancy J. Devlin & Koonal K. Shah & Brendan Mulhern & Ben van Hout, 2018. "New methods for modelling EQ‐5D‐5L value sets: An application to English data," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 23-38, January.
    6. Anja Frei & Kaba Dalla Lana & Thomas Radtke & Emily Stone & Nevil Knöpfli & Milo A. Puhan, 2019. "A novel approach to increase physical activity in older adults in the community using citizen science: a mixed-methods study," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 64(5), pages 669-678, June.
    7. Karimi, M. & Brazier, J. & Paisley, S., 2017. "How do individuals value health states? A qualitative investigation," Social Science & Medicine, Elsevier, vol. 172(C), pages 80-88.
    8. Franz Ombler & Michael Albert & Paul Hansen, 2017. "The true significance of ‘high’ correlations between EQ-5D value sets," Working Papers 1704, University of Otago, Department of Economics, revised Mar 2017.
    9. Hobbins, Anna P. & Barry, Luke & Kelleher, Dan & Shah, Koonal & Devlin, Nancy & Ramos Goni, Juan Manuel & O’Neill, Ciaran, 2020. "Do people with private health insurance attach a higher value to health than those without insurance? Results from an EQ-5D-5 L valuation study in Ireland," Health Policy, Elsevier, vol. 124(6), pages 639-646.
    10. Guizhi Weng & Yanming Hong & Nan Luo & Clara Mukuria & Jie Jiang & Zhihao Yang & Sha Li, 2023. "Comparing EQ-5D-3L and EQ-5D-5L in measuring the HRQoL burden of 4 health conditions in China," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(2), pages 197-207, March.

  40. Nancy Devlin & Ken Buckingham & Koonal Shah & Aki Tsuchiya & Carl Tilling & Grahame Wilkinson & Ben van Hout, 2013. "A Comparison Of Alternative Variants Of The Lead And Lag Time Tto," Health Economics, John Wiley & Sons, Ltd., vol. 22(5), pages 517-532, May.

    Cited by:

    1. José Luis Pinto-Prades & Eva Rodríguez-Míguez, 2015. "The Lead Time Tradeoff," Medical Decision Making, , vol. 35(3), pages 305-315, April.
    2. Federico Augustovski & Lucila Rey-Ares & Vilma Irazola & Mark Oppe & Nancy Devlin, 2013. "Lead versus lag-time trade-off variants: does it make any difference?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 25-31, July.
    3. Eliza L. Y. Wong & Juan Manuel Ramos-Goñi & Annie W. L. Cheung & Amy Y. K. Wong & Oliver Rivero-Arias, 2018. "Assessing the Use of a Feedback Module to Model EQ-5D-5L Health States Values in Hong Kong," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 11(2), pages 235-247, April.
    4. Nan Luo & Minghui Li & Elly Stolk & Nancy Devlin, 2013. "The effects of lead time and visual aids in TTO valuation: a study of the EQ-VT framework," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 15-24, July.
    5. Yan Feng & Nancy J. Devlin & Koonal K. Shah & Brendan Mulhern & Ben van Hout, 2018. "New methods for modelling EQ‐5D‐5L value sets: An application to English data," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 23-38, January.
    6. Matthijs Versteegh & Arthur Attema & Mark Oppe & Nancy Devlin & Elly Stolk, 2013. "Time to tweak the TTO: results from a comparison of alternative specifications of the TTO," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 43-51, July.
    7. Mark Oppe & Kim Rand-Hendriksen & Koonal Shah & Juan M. Ramos‐Goñi & Nan Luo, 2016. "EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes," PharmacoEconomics, Springer, vol. 34(10), pages 993-1004, October.
    8. Stefan A. Lipman & Liying Zhang & Koonal K. Shah & Arthur E. Attema, 2023. "Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(2), pages 293-305, March.
    9. Nancy J. Devlin & Koonal K. Shah & Yan Feng & Brendan Mulhern & Ben van Hout, 2018. "Valuing health‐related quality of life: An EQ‐5D‐5L value set for England," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 7-22, January.
    10. Koonal K. Shah & Juan Manuel Ramos-Goñi & Simone Kreimeier & Nancy J. Devlin, 2020. "An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(7), pages 1091-1103, September.
    11. Bansback, Nick & Hole, Arne Risa & Mulhern, Brendan & Tsuchiya, Aki, 2014. "Testing a discrete choice experiment including duration to value health states for large descriptive systems: Addressing design and sampling issues," Social Science & Medicine, Elsevier, vol. 114(C), pages 38-48.
    12. Versteegh, MM & Attema, AE & Oppe, M & Devlin, NJ & Stolk, EA, 2012. "Time to tweak the TTO. But how?," MPRA Paper 37989, University Library of Munich, Germany.
    13. Yan Feng & Arne Risa Hole & Milad Karimi & Aki Tsuchiya & Ben van Hout, 2018. "An exploration of the non‐iterative time trade‐off method to value health states," Health Economics, John Wiley & Sons, Ltd., vol. 27(8), pages 1247-1263, August.
    14. Fernando Lera-Lopez & Andrea Ollo-López & Mirian Garrués-Irisarri & Juan M. Cabasés & Eduardo Sánchez, 2019. "How the relationship between physical activity and health changes with age," European Journal of Ageing, Springer, vol. 16(1), pages 3-15, March.
    15. Sullivan, Trudy & Hansen, Paul & Ombler, Franz & Derrett, Sarah & Devlin, Nancy, 2020. "A new tool for creating personal and social EQ-5D-5L value sets, including valuing ‘dead’," Social Science & Medicine, Elsevier, vol. 246(C).
    16. Juan Ramos-Goñi & Oliver Rivero-Arias & María Errea & Elly Stolk & Michael Herdman & Juan Cabasés, 2013. "Dealing with the health state ‘dead’ when using discrete choice experiments to obtain values for EQ-5D-5L heath states," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 33-42, July.
    17. Anja Schwalm & You-Shan Feng & Jörn Moock & Thomas Kohlmann, 2015. "Differences in EQ-5D-3L health state valuations among patients with musculoskeletal diseases, health care professionals and healthy volunteers," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(8), pages 865-877, November.
    18. Hobbins, Anna P. & Barry, Luke & Kelleher, Dan & Shah, Koonal & Devlin, Nancy & Ramos Goni, Juan Manuel & O’Neill, Ciaran, 2020. "Do people with private health insurance attach a higher value to health than those without insurance? Results from an EQ-5D-5 L valuation study in Ireland," Health Policy, Elsevier, vol. 124(6), pages 639-646.
    19. Koonal Shah & Andrew Lloyd & Mark Oppe & Nancy Devlin, 2013. "One-to-one versus group setting for conducting computer-assisted TTO studies: findings from pilot studies in England and the Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 65-73, July.
    20. Ruixuan Jiang & Thomas Kohlmann & Todd A. Lee & Axel Mühlbacher & James Shaw & Surrey Walton & A. Simon Pickard, 2021. "Increasing respondent engagement in composite time trade-off tasks by imposing three minimum trade-offs to improve data quality," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(1), pages 17-33, February.
    21. Finch, Aureliano Paolo & Meregaglia, Michela & Ciani, Oriana & Roudijk, Bram & Jommi, Claudio, 2022. "An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration," Social Science & Medicine, Elsevier, vol. 292(C).
    22. P. Wang & M. Li & G. Liu & J. Thumboo & N. Luo, 2015. "Do Chinese have similar health-state preferences? A comparison of mainland Chinese and Singaporean Chinese," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(8), pages 857-863, November.
    23. Arthur Attema & Yvette Edelaar-Peeters & Matthijs Versteegh & Elly Stolk, 2013. "Time trade-off: one methodology, different methods," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 53-64, July.

  41. Nan Luo & Minghui Li & Elly Stolk & Nancy Devlin, 2013. "The effects of lead time and visual aids in TTO valuation: a study of the EQ-VT framework," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 15-24, July.

    Cited by:

    1. Zhao, Jing & Zhang, Qin, 2021. "The effect of contract methods on the lead time of a two-level photovoltaic supply chain: revenue-sharing vs. cost-sharing," Energy, Elsevier, vol. 231(C).
    2. Ruixuan Jiang & Thomas Kohlmann & Todd A. Lee & Axel Mühlbacher & James Shaw & Surrey Walton & A. Simon Pickard, 2021. "Increasing respondent engagement in composite time trade-off tasks by imposing three minimum trade-offs to improve data quality," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(1), pages 17-33, February.
    3. P. Wang & M. Li & G. Liu & J. Thumboo & N. Luo, 2015. "Do Chinese have similar health-state preferences? A comparison of mainland Chinese and Singaporean Chinese," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(8), pages 857-863, November.

  42. Jon Sussex & Adrian Towse & Nancy Devlin, 2013. "Operationalizing Value-Based Pricing of Medicines," PharmacoEconomics, Springer, vol. 31(1), pages 1-10, January.

    Cited by:

    1. Wettstein, Dominik J. & Boes, Stefan, 2022. "How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence," Health Policy, Elsevier, vol. 126(2), pages 112-121.
    2. Axel C. Mühlbacher & Anika Kaczynski, 2016. "Making Good Decisions in Healthcare with Multi-Criteria Decision Analysis: The Use, Current Research and Future Development of MCDA," Applied Health Economics and Health Policy, Springer, vol. 14(1), pages 29-40, February.
    3. Aris Angelis & Ansgar Lange & Panos Kanavos, 2018. "Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(1), pages 123-152, January.
    4. Levaggi, Laura & Levaggi, Rosella, 2024. "Competition, value-based prices and incentives to research personalised drugs," Socio-Economic Planning Sciences, Elsevier, vol. 93(C).
    5. Martina Garau & Grace Hampson & Nancy Devlin & Nicola Amedeo Mazzanti & Antonio Profico, 2018. "Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)," PharmacoEconomics - Open, Springer, vol. 2(2), pages 153-163, June.
    6. Volman, Lucas, 2018. "The TRIPS Article 31 Tug of War Developing Country Compulsory Licensing of Pharmaceutical Patents and Developed Country Retaliation," LawArXiv 6cxaj, Center for Open Science.
    7. Casanova-Juanes, Julieta & Mestre-Ferrandiz, Jorge & Espín-Balbino, Jaime, 2018. "Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in Andalusia," Health Policy, Elsevier, vol. 122(12), pages 1310-1315.
    8. Mónica D. Oliveira & Inês Mataloto & Panos Kanavos, 2019. "Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(6), pages 891-918, August.
    9. Kevin Marsh & Tereza Lanitis & David Neasham & Panagiotis Orfanos & Jaime Caro, 2014. "Assessing the Value of Healthcare Interventions Using Multi-Criteria Decision Analysis: A Review of the Literature," PharmacoEconomics, Springer, vol. 32(4), pages 345-365, April.
    10. Dukhanin, Vadim & Searle, Alexandra & Zwerling, Alice & Dowdy, David W. & Taylor, Holly A. & Merritt, Maria W., 2018. "Integrating social justice concerns into economic evaluation for healthcare and public health: A systematic review," Social Science & Medicine, Elsevier, vol. 198(C), pages 27-35.
    11. Rutger P. Daems PhD & Edith L. Maes DBA, 2013. "Pharmaceutical Portfolio Management: Global Disease Burden and Corporate Performance Metrics," Working Papers 2013/07, Maastricht School of Management.
    12. Nancy J. Devlin & Richard Brooks, 2017. "EQ-5D and the EuroQol Group: Past, Present and Future," Applied Health Economics and Health Policy, Springer, vol. 15(2), pages 127-137, April.
    13. Victoria Brennan & Simon Dixon, 2013. "Incorporating Process Utility into Quality Adjusted Life Years: A Systematic Review of Empirical Studies," PharmacoEconomics, Springer, vol. 31(8), pages 677-691, August.
    14. Pereira, Miguel Alves & Marques, Rui Cunha, 2022. "Is sunshine regulation the new prescription to brighten up public hospitals in Portugal?," Socio-Economic Planning Sciences, Elsevier, vol. 84(C).

  43. Nancy J. Devlin & Aki Tsuchiya & Ken Buckingham & Carl Tilling, 2011. "A uniform time trade off method for states better and worse than dead: feasibility study of the ‘lead time’ approach," Health Economics, John Wiley & Sons, Ltd., vol. 20(3), pages 348-361, March.

    Cited by:

    1. Liv Ariane Augestad & Kim Rand-Hendriksen & Ivar Sønbø Kristiansen & Knut Stavem, 2012. "Impact of Transformation of Negative Values and Regression Models on Differences Between the UK and US EQ-5D Time Trade-Off Value Sets," PharmacoEconomics, Springer, vol. 30(12), pages 1203-1214, December.
    2. Feng Xie & Eleanor Pullenayegum & Kathryn Gaebel & Mark Oppe & Paul Krabbe, 2014. "Eliciting preferences to the EQ-5D-5L health states: discrete choice experiment or multiprofile case of best–worst scaling?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(3), pages 281-288, April.
    3. Spencer, Anne & Rivero-Arias, Oliver & Wong, Ruth & Tsuchiya, Aki & Bleichrodt, Han & Edwards, Rhiannon Tudor & Norman, Richard & Lloyd, Andrew & Clarke, Philip, 2022. "The QALY at 50: One story many voices," Social Science & Medicine, Elsevier, vol. 296(C).
    4. Arthur E. Attema & Werner B.F. Brouwer, 2014. "Deriving Time Discounting Correction Factors For Tto Tariffs," Health Economics, John Wiley & Sons, Ltd., vol. 23(4), pages 410-425, April.
    5. Federico Augustovski & Lucila Rey-Ares & Vilma Irazola & Mark Oppe & Nancy Devlin, 2013. "Lead versus lag-time trade-off variants: does it make any difference?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 25-31, July.
    6. José Luis Pinto-Prades & Eva Rodríguez-Míguez, 2011. "The Lead Time Trade-Off: The case of health states better than death," Working Papers 1101, Universidade de Vigo, Departamento de Economía Aplicada.
    7. John Brazier & Jennifer Roberts, 2006. "Methods for Developing Preference-based Measures of Health," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, chapter 35, Edward Elgar Publishing.
    8. Manuela Alcañiz & Aïda Solé-Auró, 2018. "“Ageing and health-related quality of life: evidence from Catalonia (Spain)”," IREA Working Papers 201802, University of Barcelona, Research Institute of Applied Economics, revised Mar 2018.
    9. Arthur E. Attema & Matthijs M. Versteegh & Mark Oppe & Werner B. F. Brouwer & Elly A. Stolk, 2013. "Lead Time Tto: Leading To Better Health State Valuations?," Health Economics, John Wiley & Sons, Ltd., vol. 22(4), pages 376-392, April.
    10. Nan Luo & Minghui Li & Elly Stolk & Nancy Devlin, 2013. "The effects of lead time and visual aids in TTO valuation: a study of the EQ-VT framework," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 15-24, July.
    11. Nancy Devlin & Paul Krabbe, 2013. "The development of new research methods for the valuation of EQ-5D-5L," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 1-3, July.
    12. Michał Jakubczyk, 2023. "What if 0 is not equal to 0? Inter-personal health utilities anchoring using the largest health gains," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(7), pages 1217-1233, September.
    13. Matthijs Versteegh & Arthur Attema & Mark Oppe & Nancy Devlin & Elly Stolk, 2013. "Time to tweak the TTO: results from a comparison of alternative specifications of the TTO," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 43-51, July.
    14. Bansback, Nick & Brazier, John & Tsuchiya, Aki & Anis, Aslam, 2010. "Using a discrete choice experiment to estimate societal health state utility values," MPRA Paper 29933, University Library of Munich, Germany.
    15. Jose-Maria Abellan-Perpiñan & Jorge-Eduardo Martinez-Perez & Jose-Luis Pinto-Prades & Fernando-Ignacio Sanchez-Martinez, 2024. "Testing Nonmonotonicity in Health Preferences," Medical Decision Making, , vol. 44(1), pages 42-52, January.
    16. John Brazier & Andrew Briggs & Stirling Bryan, 2018. "EQ‐5D‐5L: Smaller steps but a major step change?," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 4-6, January.
    17. Round, Jeff, 2012. "Is a QALY still a QALY at the end of life?," Journal of Health Economics, Elsevier, vol. 31(3), pages 521-527.
    18. Nancy J. Devlin & Koonal K. Shah & Yan Feng & Brendan Mulhern & Ben van Hout, 2018. "Valuing health‐related quality of life: An EQ‐5D‐5L value set for England," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 7-22, January.
    19. Johanna Vásquez & Sergio Botero, 2020. "Hybrid Methodology to Improve Health Status Utility Values Derivation Using EQ-5D-5L and Advanced Multi-Criteria Techniques," IJERPH, MDPI, vol. 17(4), pages 1-18, February.
    20. Floortje Nooten & Jan Busschbach & Michel Agthoven & Job Exel & Werner Brouwer, 2018. "What should we know about the person behind a TTO?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(9), pages 1207-1211, December.
    21. Stefan A. Lipman & Werner B. F. Brouwer & Arthur E. Attema, 2020. "What is it going to be, TTO or SG? A direct test of the validity of health state valuation," Health Economics, John Wiley & Sons, Ltd., vol. 29(11), pages 1475-1481, November.
    22. Attema, AE & Versteegh, MM, 2012. "Would you rather be ill now, or later?," MPRA Paper 37990, University Library of Munich, Germany.
    23. Michał Jakubczyk & Dominik Golicki, 2020. "Elicitation and modelling of imprecise utility of health states," Theory and Decision, Springer, vol. 88(1), pages 51-71, February.
    24. Bansback, Nick & Hole, Arne Risa & Mulhern, Brendan & Tsuchiya, Aki, 2014. "Testing a discrete choice experiment including duration to value health states for large descriptive systems: Addressing design and sampling issues," Social Science & Medicine, Elsevier, vol. 114(C), pages 38-48.
    25. Versteegh, MM & Attema, AE & Oppe, M & Devlin, NJ & Stolk, EA, 2012. "Time to tweak the TTO. But how?," MPRA Paper 37989, University Library of Munich, Germany.
    26. Yan Feng & Arne Risa Hole & Milad Karimi & Aki Tsuchiya & Ben van Hout, 2018. "An exploration of the non‐iterative time trade‐off method to value health states," Health Economics, John Wiley & Sons, Ltd., vol. 27(8), pages 1247-1263, August.
    27. Manuela Alcañiz & Aïda Solé-Auró, 2018. "Ageing and health-related quality of life: evidence from Catalonia (Spain)," Working Papers 2018-01, Universitat de Barcelona, UB Riskcenter.
    28. Bas Janssen & Mark Oppe & Matthijs Versteegh & Elly Stolk, 2013. "Introducing the composite time trade-off: a test of feasibility and face validity," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 5-13, July.
    29. Raymond Oppong & Billingsley Kaambwa & Jacqueline Nuttall & Kerenza Hood & Richard Smith & Joanna Coast, 2013. "The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(2), pages 197-209, April.
    30. Yuanyuan Gu & Richard Norman & Rosalie Viney, 2014. "Estimating Health State Utility Values From Discrete Choice Experiments—A Qaly Space Model Approach," Health Economics, John Wiley & Sons, Ltd., vol. 23(9), pages 1098-1114, September.
    31. S. A. Lipman & V. T. Reckers-Droog & M. Karimi & M. Jakubczyk & A. E. Attema, 2021. "Self vs. other, child vs. adult. An experimental comparison of valuation perspectives for valuation of EQ-5D-Y-3L health states," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1507-1518, December.
    32. Devlin, N. & Tsuchiya, A. & Buckingham, K. & Tilling, C., 2009. "Does the value of quality of life depend on duration?," Working Papers 09/07, Department of Economics, City University London.
    33. Koonal Shah & Andrew Lloyd & Mark Oppe & Nancy Devlin, 2013. "One-to-one versus group setting for conducting computer-assisted TTO studies: findings from pilot studies in England and the Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 65-73, July.
    34. Arthur Attema & Yvette Edelaar-Peeters & Matthijs Versteegh & Elly Stolk, 2013. "Time trade-off: one methodology, different methods," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 53-64, July.

  44. Phill O’Neill & Nancy Devlin, 2010. "An Analysis of NICE’s ‘Restricted’ (or ‘Optimized’) Decisions," PharmacoEconomics, Springer, vol. 28(11), pages 987-993, November.

    Cited by:

    1. Fischer, Katharina E. & Rogowski, Wolf H. & Leidl, Reiner & Stollenwerk, Björn, 2013. "Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis," Health Policy, Elsevier, vol. 112(3), pages 187-196.
    2. Fischer, Katharina Elisabeth, 2012. "A systematic review of coverage decision-making on health technologies—Evidence from the real world," Health Policy, Elsevier, vol. 107(2), pages 218-230.

  45. Carl Tilling & Nancy Devlin & Aki Tsuchiya & Ken Buckingham, 2010. "Protocols for Time Tradeoff Valuations of Health States Worse than Dead: A Literature Review," Medical Decision Making, , vol. 30(5), pages 610-619, September.

    Cited by:

    1. Liv Ariane Augestad & Kim Rand-Hendriksen & Ivar Sønbø Kristiansen & Knut Stavem, 2012. "Impact of Transformation of Negative Values and Regression Models on Differences Between the UK and US EQ-5D Time Trade-Off Value Sets," PharmacoEconomics, Springer, vol. 30(12), pages 1203-1214, December.
    2. Federico Augustovski & Lucila Rey-Ares & Vilma Irazola & Mark Oppe & Nancy Devlin, 2013. "Lead versus lag-time trade-off variants: does it make any difference?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 25-31, July.
    3. José Luis Pinto-Prades & Eva Rodríguez-Míguez, 2011. "The Lead Time Trade-Off: The case of health states better than death," Working Papers 1101, Universidade de Vigo, Departamento de Economía Aplicada.
    4. Arthur E. Attema & Matthijs M. Versteegh & Mark Oppe & Werner B. F. Brouwer & Elly A. Stolk, 2013. "Lead Time Tto: Leading To Better Health State Valuations?," Health Economics, John Wiley & Sons, Ltd., vol. 22(4), pages 376-392, April.
    5. Nan Luo & Minghui Li & Elly Stolk & Nancy Devlin, 2013. "The effects of lead time and visual aids in TTO valuation: a study of the EQ-VT framework," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 15-24, July.
    6. Liv Augestad & Kim Rand-Hendriksen & Ivar Kristiansen & Knut Stavem, 2012. "Impact of Transformation of Negative Values and Regression Models on Differences Between the UK and US EQ-5D Time Trade-Off Value Sets," PharmacoEconomics, Springer, vol. 30(12), pages 1203-1214, December.
    7. Matthijs Versteegh & Arthur Attema & Mark Oppe & Nancy Devlin & Elly Stolk, 2013. "Time to tweak the TTO: results from a comparison of alternative specifications of the TTO," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 43-51, July.
    8. Nancy J. Devlin & Aki Tsuchiya & Ken Buckingham & Carl Tilling, 2011. "A uniform time trade off method for states better and worse than dead: feasibility study of the ‘lead time’ approach," Health Economics, John Wiley & Sons, Ltd., vol. 20(3), pages 348-361, March.
    9. Versteegh, MM & Attema, AE & Oppe, M & Devlin, NJ & Stolk, EA, 2012. "Time to tweak the TTO. But how?," MPRA Paper 37989, University Library of Munich, Germany.
    10. Stefan A. Lipman & Arthur E. Attema & Matthijs M. Versteegh, 2022. "Correcting for discounting and loss aversion in composite time trade‐off," Health Economics, John Wiley & Sons, Ltd., vol. 31(8), pages 1633-1648, August.
    11. Bas Janssen & Mark Oppe & Matthijs Versteegh & Elly Stolk, 2013. "Introducing the composite time trade-off: a test of feasibility and face validity," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 5-13, July.
    12. Richard Norman & Paula Cronin & Rosalie Viney, 2012. "Deriving utility weights for the EQ-5D-5L using a discrete choice experiment. CHERE Working Paper 2012/01," Working Papers 2012/01, CHERE, University of Technology, Sydney.
    13. Nicolas A. Menzies & Joshua A. Salomon, 2011. "Non‐monotonicity in the episodic random utility model," Health Economics, John Wiley & Sons, Ltd., vol. 20(12), pages 1523-1531, December.
    14. Rosalie Viney & Richard Norman & John Brazier & Paula Cronin & Madeleine T. King & Julie Ratcliffe & Deborah Street, 2014. "An Australian Discrete Choice Experiment To Value Eq‐5d Health States," Health Economics, John Wiley & Sons, Ltd., vol. 23(6), pages 729-742, June.

  46. Nancy J. Devlin & David Parkin & John Browne, 2010. "Patient‐reported outcome measures in the NHS: new methods for analysing and reporting EQ‐5D data," Health Economics, John Wiley & Sons, Ltd., vol. 19(8), pages 886-905, August.

    Cited by:

    1. McCarthy, Ian M., 2016. "Eliminating composite bias in treatment effects estimates: Applications to quality of life assessment," Journal of Health Economics, Elsevier, vol. 50(C), pages 47-58.
    2. Knott, R. & Lorgelly, P. & Black, N. & Hollingsworth, B., 2016. "Differential item functioning in the EQ-5D: An exploratory analysis using anchoring vignettes," Health, Econometrics and Data Group (HEDG) Working Papers 16/14, HEDG, c/o Department of Economics, University of York.
    3. Hareth Al-Janabi & Andrea Manca & Joanna Coast, 2017. "Predicting carer health effects for use in economic evaluation," PLOS ONE, Public Library of Science, vol. 12(9), pages 1-18, September.
    4. Marta Rodríguez-Hernández & Juan-José Criado-Álvarez & Ana-Isabel Corregidor-Sánchez & José L. Martín-Conty & Alicia Mohedano-Moriano & Begoña Polonio-López, 2021. "Effects of Virtual Reality-Based Therapy on Quality of Life of Patients with Subacute Stroke: A Three-Month Follow-Up Randomized Controlled Trial," IJERPH, MDPI, vol. 18(6), pages 1-11, March.
    5. Nils Gutacker & Andrew Street, 2015. "Multidimensional performance assessment using dominance criteria," Working Papers 115cherp, Centre for Health Economics, University of York.
    6. Shaofan Chen & Bo Burström & Vibeke Sparring & Dongfu Qian & Kristina Burström, 2019. "Differential Impact of an Education-Based Intervention for Patients with Type 2 Diabetes Mellitus in Rural China," IJERPH, MDPI, vol. 16(15), pages 1-12, July.
    7. Nils Gutacker & Andrew Street, 2018. "Multidimensional performance assessment of public sector organisations using dominance criteria," Health Economics, John Wiley & Sons, Ltd., vol. 27(2), pages 13-27, February.
    8. Cristina Gutierrez-Delgado & Rosa-María Galindo-Suárez & Cesar Cruz-Santiago & Koonal Shah & Manny Papadimitropoulos & Yan Feng & Bernarda Zamora & Nancy Devlin, 2021. "EQ-5D-5L Health-State Values for the Mexican Population," Applied Health Economics and Health Policy, Springer, vol. 19(6), pages 905-914, November.
    9. Knott, Rachel J. & Lorgelly, Paula K. & Black, Nicole & Hollingsworth, Bruce, 2017. "Differential item functioning in quality of life measurement: An analysis using anchoring vignettes," Social Science & Medicine, Elsevier, vol. 190(C), pages 247-255.
    10. David Nuttall & David Parkin & Nancy Devlin, 2015. "Inter‐Provider Comparison Of Patient‐Reported Outcomes: Developing An Adjustment To Account For Differences In Patient Case Mix," Health Economics, John Wiley & Sons, Ltd., vol. 24(1), pages 41-54, January.
    11. Ian M. McCarthy, 2015. "Putting the Patient in Patient Reported Outcomes: A Robust Methodology for Health Outcomes Assessment," Health Economics, John Wiley & Sons, Ltd., vol. 24(12), pages 1588-1603, December.

  47. David Parkin & Nigel Rice & Nancy Devlin, 2010. "Statistical Analysis of EQ-5D Profiles: Does the Use of Value Sets Bias Inference?," Medical Decision Making, , vol. 30(5), pages 556-565, September.

    Cited by:

    1. Manuel B. Huber & Julia Felix & Martin Vogelmann & Reiner Leidl, 2017. "Health-Related Quality of Life of the General German Population in 2015: Results from the EQ-5D-5L," IJERPH, MDPI, vol. 14(4), pages 1-12, April.
    2. McCarthy, Ian M., 2016. "Eliminating composite bias in treatment effects estimates: Applications to quality of life assessment," Journal of Health Economics, Elsevier, vol. 50(C), pages 47-58.
    3. Jeff Round & Annie Hawton, 2017. "Statistical Alchemy: Conceptual Validity and Mapping to Generate Health State Utility Values," PharmacoEconomics - Open, Springer, vol. 1(4), pages 233-239, December.
    4. Franz Ombler & Michael Albert & Paul Hansen, 2018. "How Significant Are “High†Correlations Between EQ-5D Value Sets?," Medical Decision Making, , vol. 38(6), pages 635-645, August.
    5. A. Enrique & J. Burke & D. Richards & L. Timulak, 2019. "Quality of Life Outcomes in Internet-Delivered (Space from Depression) Treatment for Depression," Applied Research in Quality of Life, Springer;International Society for Quality-of-Life Studies, vol. 14(5), pages 1301-1313, November.
    6. Tianxin Pan & Brendan Mulhern & Rosalie Viney & Richard Norman & Janel Hanmer & Nancy Devlin, 2022. "A Comparison of PROPr and EQ-5D-5L Value Sets," PharmacoEconomics, Springer, vol. 40(3), pages 297-307, March.
    7. Caitlyn T. Wilke & A. Simon Pickard & Surrey M. Walton & Joern Moock & Thomas Kohlmann & Todd A. Lee, 2010. "Statistical implications of utility weighted and equally weighted HRQL measures: an empirical study," Health Economics, John Wiley & Sons, Ltd., vol. 19(1), pages 101-110, January.
    8. Raymond Oppong & Billingsley Kaambwa & Jacqueline Nuttall & Kerenza Hood & Richard Smith & Joanna Coast, 2013. "The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(2), pages 197-209, April.
    9. Xiaojing Fan & Duolao Wang & Bruce Hellman & Mathieu F. Janssen & Gerben Bakker & Rupert Coghlan & Amelia Hursey & Helen Matthews & Ian Whetstone, 2018. "Assessment of Health-Related Quality of Life between People with Parkinson’s Disease and Non-Parkinson’s: Using Data Drawn from the ‘100 for Parkinson’s’ Smartphone-Based Prospective Study," IJERPH, MDPI, vol. 15(11), pages 1-12, November.

  48. Buckingham, Ken J. & Devlin, Nancy Joy, 2009. "A note on the nature of utility in time and health and implications for cost utility analysis," Social Science & Medicine, Elsevier, vol. 68(2), pages 362-367, January.

    Cited by:

    1. Federico Augustovski & Lucila Rey-Ares & Vilma Irazola & Mark Oppe & Nancy Devlin, 2013. "Lead versus lag-time trade-off variants: does it make any difference?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 25-31, July.
    2. Ariel Beresniak & Antonieta Medina-Lara & Jean Auray & Alain Wever & Jean-Claude Praet & Rosanna Tarricone & Aleksandra Torbica & Danielle Dupont & Michel Lamure & Gerard Duru, 2015. "Validation of the Underlying Assumptions of the Quality-Adjusted Life-Years Outcome: Results from the ECHOUTCOME European Project," PharmacoEconomics, Springer, vol. 33(1), pages 61-69, January.
    3. Papathanasopoulou, Eleni & White, Mathew P. & Hattam, Caroline & Lannin, Aisling & Harvey, Andrea & Spencer, Anne, 2016. "Valuing the health benefits of physical activities in the marine environment and their importance for marine spatial planning," Marine Policy, Elsevier, vol. 63(C), pages 144-152.
    4. Sharma, Rajiv & Stano, Miron, 2010. "Implications of an economic model of health states worse than dead," Journal of Health Economics, Elsevier, vol. 29(4), pages 536-540, July.
    5. Nancy J. Devlin & Aki Tsuchiya & Ken Buckingham & Carl Tilling, 2011. "A uniform time trade off method for states better and worse than dead: feasibility study of the ‘lead time’ approach," Health Economics, John Wiley & Sons, Ltd., vol. 20(3), pages 348-361, March.
    6. Devlin, N. & Tsuchiya, A. & Buckingham, K. & Tilling, C., 2009. "A uniform Time Trade Off method for states better and worse than dead: feasibility study of the ‘lead time’ approach," Working Papers 09/08, Department of Economics, City University London.
    7. Devlin, N. & Tsuchiya, A. & Buckingham, K. & Tilling, C., 2009. "Does the value of quality of life depend on duration?," Working Papers 09/07, Department of Economics, City University London.
    8. Cathrine Elgaard Jensen & Sabrina Storgaard Sørensen & Claire Gudex & Morten Berg Jensen & Kjeld Møller Pedersen & Lars Holger Ehlers, 2021. "The Danish EQ-5D-5L Value Set: A Hybrid Model Using cTTO and DCE Data," Applied Health Economics and Health Policy, Springer, vol. 19(4), pages 579-591, July.

  49. Sofia Dimakou & David Parkin & Nancy Devlin & John Appleby, 2009. "Identifying the impact of government targets on waiting times in the NHS," Health Care Management Science, Springer, vol. 12(1), pages 1-10, March.

    Cited by:

    1. Laudicella, M. & Siciliani, L. & Cookson, R., 2010. "Waiting Times and Socioeconomic Status: Evidence from England," Health, Econometrics and Data Group (HEDG) Working Papers 10/05, HEDG, c/o Department of Economics, University of York.
    2. Meliyanni Johar & Glenn Jones & Michael Keane & Elizabeth Savage & Olena Stavrunova, 2011. "Discrimination in a Universal Health System: Explaining Socioeconomic Waiting Time Gaps," Working Paper Series 165, Finance Discipline Group, UTS Business School, University of Technology, Sydney.
    3. Gutacker, Nils & Siciliani, Luigi & Cookson, Richard, 2016. "Waiting time prioritisation: Evidence from England," Social Science & Medicine, Elsevier, vol. 159(C), pages 140-151.
    4. Johansson, Kjell Arne & Nygaard, Elizabeth & Herlofsen, Berit & Lindemark, Frode, 2017. "Implementation of the 2013 amended Patients’ Rights Act in Norway: Clinical priority guidelines and access to specialised health care," Health Policy, Elsevier, vol. 121(4), pages 346-353.
    5. Sofia Dimakou & Ourania Dimakou & Henrique S. Basso, 2015. "The Asymmetric Effects of Waiting Time Targets in Health Care," BCAM Working Papers 1502, Birkbeck Centre for Applied Macroeconomics.
    6. van de Vijsel, Aart R. & Engelfriet, Peter M. & Westert, Gert P., 2011. "Rendering hospital budgets volume based and open ended to reduce waiting lists: Does it work?," Health Policy, Elsevier, vol. 100(1), pages 60-70, April.
    7. Dixon, Huw & Siciliani, Luigi, 2009. "Waiting-time targets in the healthcare sector: How long are we waiting?," Journal of Health Economics, Elsevier, vol. 28(6), pages 1081-1098, December.
    8. Askildsen, Jan Erik & Holmås, Tor Helge & Kaarbøe, Oddvar, 2009. "Prioritization and patients' rights: Analysing the effect of a reform in the Norwegian Hospital Sector," Working Papers in Economics 07/09, University of Bergen, Department of Economics.
    9. Elsa Marques & Sian Noble & Ashley W. Blom & William Hollingworth, 2014. "Disclosing Total Waiting Times For Joint Replacement: Evidence From The English Nhs Using Linked Hes Data," Health Economics, John Wiley & Sons, Ltd., vol. 23(7), pages 806-820, July.
    10. Silviya Nikolova; & Arthur Sinko; & Matt Sutton;, 2012. "Do maximum waiting times guarantees change clinical priorities? A Conditional Density Estimation approach," Health, Econometrics and Data Group (HEDG) Working Papers 12/07, HEDG, c/o Department of Economics, University of York.
    11. Januleviciute, Jurgita & Askildsen, Jan Erik & Holmås, Tor Helge & Kaarbøe, Oddvar & Sutton, Matt, 2010. "The Impact of Different Prioritisation Policies on Waiting Times: A Comparative Analysis of Norway and Scotland," Working Papers in Economics 07/10, University of Bergen, Department of Economics.
    12. Shimaa Elkomy & Graham Cookson, 2020. "Performance Management Strategy: Waiting Time in the English National Health Services," Public Organization Review, Springer, vol. 20(1), pages 95-112, March.
    13. Dixon, Huw David & Siciliani, Luigi, 2009. "Waiting-time targets in healthcare markets: How long are we waiting?," CEPR Discussion Papers 7261, C.E.P.R. Discussion Papers.
    14. Rossella Verzulli & Rowena Jacobs & Maria Goddard, 2011. "Do hospitals respond to greater autonomy? Evidence from the English NHS," Working Papers 064cherp, Centre for Health Economics, University of York.
    15. McClean, Sally & Gillespie, Jennifer & Garg, Lalit & Barton, Maria & Scotney, Bryan & Kullerton, Ken, 2014. "Using phase-type models to cost stroke patient care across health, social and community services," European Journal of Operational Research, Elsevier, vol. 236(1), pages 190-199.
    16. Siciliani, L., 2016. "Waiting Time Policies in the Health Sector," Seminar Briefing 001724, Office of Health Economics.
    17. Sofia Dimakou & Ourania Dimakou & Henrique Basso, 2015. "Waiting time distribution in public health care: empirics and theory," Health Economics Review, Springer, vol. 5(1), pages 1-27, December.
    18. Stephanie Thomas, 2016. "A Standardized Method for the Evaluation of Adherence to Practice Guidelines," Department of Economics Working Papers 2016-14, McMaster University.
    19. Nikolova, Silviya & Sinko, Arthur & Sutton, Matt, 2015. "Do maximum waiting times guarantees change clinical priorities for elective treatment? Evidence from Scotland," Journal of Health Economics, Elsevier, vol. 41(C), pages 72-88.
    20. Roll, Kathrin & Stargardt, Tom & Schreyögg, Jonas, 2011. "Effect of type of insurance and income on waiting time for outpatient care," hche Research Papers 2011/03, University of Hamburg, Hamburg Center for Health Economics (hche).
    21. Meliyanni Johar & Glenn Stewart Jones & Elizabeth Savage, 2013. "Emergency Admissions And Elective Surgery Waiting Times," Health Economics, John Wiley & Sons, Ltd., vol. 22(6), pages 749-756, June.
    22. Kedai Cheng & Derek S. Young, 2020. "Tolerance intervals for autoregressive models, with an application to hospital waiting lists," Applied Stochastic Models in Business and Industry, John Wiley & Sons, vol. 36(2), pages 268-282, March.
    23. Rossella Verzulli & Rowena Jacobs & Maria Goddard, 2018. "Autonomy and performance in the public sector: the experience of English NHS hospitals," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 607-626, May.
    24. Jan Erik Askildsen & Tor Helge Holmås & Oddvar Kaarboe, 2011. "Monitoring prioritisation in the public health‐care sector by use of medical guidelines. The case of Norway," Health Economics, John Wiley & Sons, Ltd., vol. 20(8), pages 958-970, August.
    25. World Bank, 2015. "Bulgaria Health Financing," World Bank Publications - Reports 22964, The World Bank Group.
    26. Januleviciute, Jurgita & Askildsen, Jan Erik & Kaarboe, Oddvar & Holmås, Tor Helge & Sutton, Matt, 2013. "The impact of different prioritisation policies on waiting times: Case studies of Norway and Scotland," Social Science & Medicine, Elsevier, vol. 97(C), pages 1-6.

  50. Appleby, John & Devlin, Nancy & Parkin, David & Buxton, Martin & Chalkidou, Kalipso, 2009. "Searching for cost effectiveness thresholds in the NHS," Health Policy, Elsevier, vol. 91(3), pages 239-245, August.

    Cited by:

    1. Aidan Hollis, 2016. "Sustainable Financing of Innovative Therapies: A Review of Approaches," PharmacoEconomics, Springer, vol. 34(10), pages 971-980, October.
    2. Levaggi, Rosella, 2014. "Pricing schemes for new drugs: A welfare analysis," Social Science & Medicine, Elsevier, vol. 102(C), pages 69-73.
    3. Mara Airoldi & Alec Morton & Jenifer A. E. Smith & Gwyn Bevan, 2014. "STAR—People-Powered Prioritization," Medical Decision Making, , vol. 34(8), pages 965-975, November.
    4. Laura Levaggi & Rosella Levaggi, 2011. "Welfare properties of restrictions to health care based on cost effectiveness," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 101-110, January.
    5. E. Wetering & E. Stolk & N. Exel & W. Brouwer, 2013. "Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 107-115, February.
    6. Perry-duxbury, Megan & Lomas, James & Asaria, Miqdad & Van Baal, Pieter, 2022. "The relevance of including future healthcare costs in cost-effectiveness threshold calculations for the UK NHS," LSE Research Online Documents on Economics 112503, London School of Economics and Political Science, LSE Library.
    7. Siverskog, Jonathan & Henriksson, Martin, 2022. "The health cost of reducing hospital bed capacity," Social Science & Medicine, Elsevier, vol. 313(C).
    8. Kristian Bolin & Lars Forsgren, 2012. "The Cost Effectiveness of Newer Epilepsy Treatments," PharmacoEconomics, Springer, vol. 30(10), pages 903-923, October.
    9. James Lomas & Jessica Ochalek & Rita Faria, 2022. "Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment," Applied Health Economics and Health Policy, Springer, vol. 20(1), pages 13-18, January.
    10. Helen Dakin & Nancy Devlin & Yan Feng & Nigel Rice & Phill O’Neill & David Parkin, 2013. "The influence of cost-effectiveness and other factors on NICE decisions," Working Papers 093cherp, Centre for Health Economics, University of York.
    11. Levaggi, Laura & Levaggi, Rosella, 2024. "Competition, value-based prices and incentives to research personalised drugs," Socio-Economic Planning Sciences, Elsevier, vol. 93(C).
    12. Laura Catherine Edney & Hossein Haji Ali Afzali & Terence Chai Cheng & Jonathan Karnon, 2018. "Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System," PharmacoEconomics, Springer, vol. 36(2), pages 239-252, February.
    13. Jonathan Karnon & Andrew Partington & Hossein Afzali, 2022. "Strategies for Avoiding Neglect of Opportunity Costs by Decision-Makers," Applied Health Economics and Health Policy, Springer, vol. 20(1), pages 9-11, January.
    14. Martina Garau & Grace Hampson & Nancy Devlin & Nicola Amedeo Mazzanti & Antonio Profico, 2018. "Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)," PharmacoEconomics - Open, Springer, vol. 2(2), pages 153-163, June.
    15. Adrian Towse;Paul Barnsley;Sarah Karlsberg-Schaffer;Jon Sussex, 2013. "Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold," Occasional Paper 000106, Office of Health Economics.
    16. Magnus Johannesson;Bengt Jonsson;Linus Jonsson;Gisela Kobelt;Niklas Zethraeus, 2009. "Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective?," Briefing 000228, Office of Health Economics.
    17. Chris Schilling & Duncan Mortimer & Kim Dalziel, 2017. "Using CART to Identify Thresholds and Hierarchies in the Determinants of Funding Decisions," Medical Decision Making, , vol. 37(2), pages 173-182, February.
    18. Karl Claxton & Simon Walker & Steven Palmer & Mark Sculpher, 2010. "Appropriate Perspectives for Health Care Decisions," Working Papers 054cherp, Centre for Health Economics, University of York.
    19. James F. O’Mahony & Mike Paulden & Chris McCabe, 2021. "NICE’s Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests," PharmacoEconomics, Springer, vol. 39(2), pages 139-146, February.
    20. Chris Sampson & Bernarda Zamora & Sam Watson & John Cairns & Kalipso Chalkidou & Patricia Cubi-Molla & Nancy Devlin & Borja García-Lorenzo & Dyfrig A. Hughes & Ashley A. Leech & Adrian Towse, 2022. "Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy," Applied Health Economics and Health Policy, Springer, vol. 20(5), pages 651-667, September.
    21. Laura Levaggi & Rosella Levaggi, 2017. "Rationing in health care provision: a welfare approach," International Journal of Health Economics and Management, Springer, vol. 17(2), pages 235-249, June.
    22. Jessica Ochalek & Karl Claxton & Paul Revill & Mark Sculpher & Alexandra Rollinger, 2016. "Supporting the development of an essential health package: principles and initial assessment for Malawi," Working Papers 136cherp, Centre for Health Economics, University of York.
    23. Stephen Martin & Nigel Rice & Peter C. Smith, 2012. "Comparing costs and outcomes across programmes of health care," Health Economics, John Wiley & Sons, Ltd., vol. 21(3), pages 316-337, March.
    24. Karlsberg Schaffer, Sarah & Sussex, Jon & Devlin, Nancy & Walker, Andrew, 2015. "Local health care expenditure plans and their opportunity costs," Health Policy, Elsevier, vol. 119(9), pages 1237-1244.
    25. Stefano Capri & Rosella Levaggi, 2011. "Shifting the risk in pricing and reimbursement schemes? A model of risk-sharing agreements for innovative drugs," DEP - series of economic working papers 2/2011, University of Genoa, Research Doctorate in Public Economics.
    26. Jonathan Siverskog & Martin Henriksson, 2020. "Mutually Exclusive Interventions in the Cost-Effectiveness Bookshelf," Medical Decision Making, , vol. 40(3), pages 399-403, April.
    27. Laura Levaggi & Rosella Levaggi, 2016. "Welfare analysis of rationing in health care provision," Working papers 39, Società Italiana di Economia Pubblica.
    28. John McKie & Bradley Shrimpton & Jeff Richardson & Rosalind Hurworth, 2011. "The monetary value of a life year: evidence from a qualitative study of treatment costs," Health Economics, John Wiley & Sons, Ltd., vol. 20(8), pages 945-957, August.
    29. Vincent T Janmaat & Marco J Bruno & Suzanne Polinder & Sylvie Lorenzen & Florian Lordick & Maikel P Peppelenbosch & Manon C W Spaander, 2016. "Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma," PLOS ONE, Public Library of Science, vol. 11(4), pages 1-10, April.

  51. Dakin, Helen Angela & Devlin, Nancy J. & Odeyemi, Isaac A.O., 2006. ""Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making," Health Policy, Elsevier, vol. 77(3), pages 352-367, August.

    Cited by:

    1. E. Wetering & E. Stolk & N. Exel & W. Brouwer, 2013. "Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 107-115, February.
    2. Phill O’Neill & Nancy Devlin, 2010. "An Analysis of NICE’s ‘Restricted’ (or ‘Optimized’) Decisions," PharmacoEconomics, Springer, vol. 28(11), pages 987-993, November.
    3. Colin Green & Karen Gerard, 2009. "Exploring the social value of health‐care interventions: a stated preference discrete choice experiment," Health Economics, John Wiley & Sons, Ltd., vol. 18(8), pages 951-976, August.
    4. Kisser, Agnes & Tüchler, Heinz & Erdös, Judit & Wild, Claudia, 2016. "Factors influencing coverage decisions on medical devices: A retrospective analysis of 78 medical device appraisals for the Austrian hospital benefit catalogue 2008–2015," Health Policy, Elsevier, vol. 120(8), pages 903-912.
    5. Helen Dakin & Nancy Devlin & Yan Feng & Nigel Rice & Phill O’Neill & David Parkin, 2013. "The influence of cost-effectiveness and other factors on NICE decisions," Working Papers 093cherp, Centre for Health Economics, University of York.
    6. Fischer, Katharina E. & Leidl, Reiner & Rogowski, Wolf H., 2011. "A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention," Health Policy, Elsevier, vol. 101(3), pages 290-299, August.
    7. Leonie Segal & Kim Dalziel & Duncan Mortimer, 2010. "Fixing the game: are between‐silo differences in funding arrangements handicapping some interventions and giving others a head‐start?," Health Economics, John Wiley & Sons, Ltd., vol. 19(4), pages 449-465, April.
    8. Eun-Young Bae & Hui Jeong Kim & Hye-Jae Lee & Junho Jang & Seung Min Lee & Yunkyung Jung & Nari Yoon & Tae Kyung Kim & Kookhee Kim & Bong-Min Yang, 2018. "Role of economic evidence in coverage decision-making in South Korea," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-12, October.
    9. Karin Cerri & Martin Knapp & Jose-Luis Fernandez, 2014. "Public funding of pharmaceuticals in the Netherlands: investigating the effect of evidence, process and context on CVZ decision-making," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(7), pages 681-695, September.

  52. Ken Buckingham & Nancy Devlin, 2006. "A theoretical framework for TTO valuations of health," Health Economics, John Wiley & Sons, Ltd., vol. 15(10), pages 1149-1154, October.

    Cited by:

    1. Buckingham, Ken J. & Devlin, Nancy Joy, 2009. "A note on the nature of utility in time and health and implications for cost utility analysis," Social Science & Medicine, Elsevier, vol. 68(2), pages 362-367, January.
    2. David Parkin & Nancy Devlin, 2006. "Is there a case for using visual analogue scale valuations in cost‐utility analysis?," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 653-664, July.
    3. Bansback, Nick & Brazier, John & Tsuchiya, Aki & Anis, Aslam, 2010. "Using a discrete choice experiment to estimate societal health state utility values," MPRA Paper 29933, University Library of Munich, Germany.
    4. Buckingham, K. & Devlin, N., 2008. "A note on the nature of utility in time and health and implications for cost utility analysis," Working Papers 08/02, Department of Economics, City University London.
    5. Jing Guo & R. Tamara Konetzka & Elizabeth Magett & William Dale, 2015. "Quantifying Long-Term Care Preferences," Medical Decision Making, , vol. 35(1), pages 106-113, January.
    6. Nancy J. Devlin & Koonal K. Shah & Brendan J. Mulhern & Krystallia Pantiri & Ben van Hout, 2019. "A new method for valuing health: directly eliciting personal utility functions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(2), pages 257-270, March.
    7. Nicolas A. Menzies & Joshua A. Salomon, 2011. "Non‐monotonicity in the episodic random utility model," Health Economics, John Wiley & Sons, Ltd., vol. 20(12), pages 1523-1531, December.
    8. Daniel M. Hausman, 2010. "Valuing health: a new proposal," Health Economics, John Wiley & Sons, Ltd., vol. 19(3), pages 280-296, March.
    9. Cathrine Elgaard Jensen & Sabrina Storgaard Sørensen & Claire Gudex & Morten Berg Jensen & Kjeld Møller Pedersen & Lars Holger Ehlers, 2021. "The Danish EQ-5D-5L Value Set: A Hybrid Model Using cTTO and DCE Data," Applied Health Economics and Health Policy, Springer, vol. 19(4), pages 579-591, July.

  53. David Parkin & Nancy Devlin, 2006. "Is there a case for using visual analogue scale valuations in cost‐utility analysis?," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 653-664, July.

    Cited by:

    1. Buckingham, Ken J. & Devlin, Nancy Joy, 2009. "A note on the nature of utility in time and health and implications for cost utility analysis," Social Science & Medicine, Elsevier, vol. 68(2), pages 362-367, January.
    2. Hildegard Seidl & Matthias Hunger & Reiner Leidl & Christa Meisinger & Rupert Wende & Bernhard Kuch & Rolf Holle, 2015. "Cost-effectiveness of nurse-based case management versus usual care for elderly patients with myocardial infarction: results from the KORINNA study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(6), pages 671-681, July.
    3. Mara Airoldi & Alec Morton & Jenifer A. E. Smith & Gwyn Bevan, 2014. "STAR—People-Powered Prioritization," Medical Decision Making, , vol. 34(8), pages 965-975, November.
    4. Donna Rowen & Oliver Rivero-Arias & Nancy Devlin & Julie Ratcliffe, 2020. "Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in Child and Adolescent Populations: Where are We Now and Where are We Going?," PharmacoEconomics, Springer, vol. 38(4), pages 325-340, April.
    5. Arthur E. Attema & Werner B.F. Brouwer, 2014. "Deriving Time Discounting Correction Factors For Tto Tariffs," Health Economics, John Wiley & Sons, Ltd., vol. 23(4), pages 410-425, April.
    6. J. Shannon Swan & Chung Yin Kong & Janie M. Lee & Omosalewa Itauma & Elkan F. Halpern & Pablo A. Lee & Sergey Vavinskiy & Olubunmi Williams & Emilie S. Zoltick & Karen Donelan, 2013. "Patient and Societal Value Functions for the Testing Morbidities Index," Medical Decision Making, , vol. 33(6), pages 819-838, August.
    7. Keith Tolley & Catherine Goad & Yunni Yi & Penny Maroudas & Amin Haiderali & Gwilym Thompson, 2013. "Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(5), pages 749-759, October.
    8. Zsombor Zrubka & Zoltán Hermann & László Gulácsi & Valentin Brodszky & Fanni Rencz & Márta Péntek, 2019. "Determinants of the acceptability of health problems in different ages: exploring a new application of the EQ VAS," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 31-41, June.
    9. Christine McDonough & Anna Tosteson, 2007. "Measuring Preferences for Cost-Utility Analysis," PharmacoEconomics, Springer, vol. 25(2), pages 93-106, February.
    10. Buckingham, K. & Devlin, N. & Tabberer, M., 2004. "A theoretical framework for TTO valuations and a taxonomy of TTO approaches: results from a pilot study," Working Papers 04/07, Department of Economics, City University London.
    11. George L. Wehby & Hodad Naderi & James M. Robbins & Timothy N. Ansley & Peter C. Damiano, 2014. "Comparing the Visual Analogue Scale and the Pediatric Quality of Life Inventory for Measuring Health-Related Quality of Life in Children with Oral Clefts," IJERPH, MDPI, vol. 11(4), pages 1-12, April.
    12. Mimmi Åström & Ola Rolfson & Kristina Burström, 2022. "Exploring EQ-5D-Y-3L Experience-Based VAS Values Derived Among Adolescents," Applied Health Economics and Health Policy, Springer, vol. 20(3), pages 383-393, May.
    13. Nancy Devlin & Paul Hansen & Peter Herbison & Susan Macran, 2005. "A ‘new and improved’ EQ-5D valuation questionnaire?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(1), pages 73-82, March.
    14. Ryan, Mandy & Kinghorn, Philip & Entwistle, Vikki A. & Francis, Jill J., 2014. "Valuing patients' experiences of healthcare processes: Towards broader applications of existing methods," Social Science & Medicine, Elsevier, vol. 106(C), pages 194-203.
    15. Dirk Müller & Marion Danner & Kerstin Rhiem & Björn Stollenwerk & Christoph Engel & Linda Rasche & Lisa Borsi & Rita Schmutzler & Stephanie Stock, 2018. "Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(3), pages 341-353, April.
    16. Hirsch Ruchlin & Ralph Insinga, 2008. "A Review of Health-Utility Data for Osteoarthritis," PharmacoEconomics, Springer, vol. 26(11), pages 925-935, November.
    17. Irvine, Alastair & van der Pol, Marjon & Phimister, Euan, 2019. "A comparison of professional and private time preferences of General Practitioners," Social Science & Medicine, Elsevier, vol. 222(C), pages 256-264.
    18. Huynh, Elisabeth & Coast, Joanna & Rose, John & Kinghorn, Philip & Flynn, Terry, 2017. "Values for the ICECAP-Supportive Care Measure (ICECAP-SCM) for use in economic evaluation at end of life," Social Science & Medicine, Elsevier, vol. 189(C), pages 114-128.
    19. Bobinac, Ana & van Exel, N. Job A. & Rutten, Frans F.H. & Brouwer, Werner B.F., 2012. "GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation," Journal of Health Economics, Elsevier, vol. 31(1), pages 158-168.
    20. Koonal K. Shah & Juan Manuel Ramos-Goñi & Simone Kreimeier & Nancy J. Devlin, 2020. "An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(7), pages 1091-1103, September.
    21. Shaofan Chen & Bo Burström & Vibeke Sparring & Dongfu Qian & Kristina Burström, 2019. "Differential Impact of an Education-Based Intervention for Patients with Type 2 Diabetes Mellitus in Rural China," IJERPH, MDPI, vol. 16(15), pages 1-12, July.
    22. Arthur E. Attema & Marieke Krol & Job Exel & Werner B. F. Brouwer, 2018. "New findings from the time trade-off for income approach to elicit willingness to pay for a quality adjusted life year," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(2), pages 277-291, March.
    23. Nancy J. Devlin & Koonal K. Shah & Brendan J. Mulhern & Krystallia Pantiri & Ben van Hout, 2019. "A new method for valuing health: directly eliciting personal utility functions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(2), pages 257-270, March.
    24. Edward J. D. Webb & John O’Dwyer & David Meads & Paul Kind & Penny Wright, 2020. "Transforming discrete choice experiment latent scale values for EQ-5D-3L using the visual analogue scale," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(5), pages 787-800, July.
    25. Khadka, Jyoti & Kwon, Joseph & Petrou, Stavros & Lancsar, Emily & Ratcliffe, Julie, 2019. "Mind the (inter-rater) gap. An investigation of self-reported versus proxy-reported assessments in the derivation of childhood utility values for economic evaluation: A systematic review," Social Science & Medicine, Elsevier, vol. 240(C).
    26. Stavros Petrou & Joseph Kwon & Jason Madan, 2018. "A Practical Guide to Conducting a Systematic Review and Meta-analysis of Health State Utility Values," PharmacoEconomics, Springer, vol. 36(9), pages 1043-1061, September.
    27. Nord, Erik, 2012. "Measuring concerns for severity: Re-examination of a health scale with purported equal interval properties," Health Policy, Elsevier, vol. 105(2), pages 312-316.
    28. Joseph Kwon & Sung Wook Kim & Wendy J. Ungar & Kate Tsiplova & Jason Madan & Stavros Petrou, 2018. "A Systematic Review and Meta-analysis of Childhood Health Utilities," Medical Decision Making, , vol. 38(3), pages 277-305, April.
    29. van den Berg, Bernard & Van Dommelen, Paula & Stam, Piet & Laske-Aldershof, Trea & Buchmueller, Tom & Schut, Frederik T., 2008. "Preferences and choices for care and health insurance," Social Science & Medicine, Elsevier, vol. 66(12), pages 2448-2459, June.
    30. Daniel M. Hausman, 2010. "Valuing health: a new proposal," Health Economics, John Wiley & Sons, Ltd., vol. 19(3), pages 280-296, March.
    31. Kyra Kneis & Afschin Gandjour, 2009. "Economic evaluation of Sinfrontal®in the treatment of acute maxillary sinusitis in adults," Applied Health Economics and Health Policy, Springer, vol. 7(3), pages 181-191, September.
    32. Jeff Richardson & Angelo Iezzi & Kompal Sinha & Munir A. Khan & John Mckie, 2014. "An Instrument For Measuring The Social Willingness To Pay For Health State Improvement," Health Economics, John Wiley & Sons, Ltd., vol. 23(7), pages 792-805, July.

  54. Ashton, Toni & Mays, Nicholas & Devlin, Nancy, 2005. "Continuity through change: The rhetoric and reality of health reform in New Zealand," Social Science & Medicine, Elsevier, vol. 61(2), pages 253-262, July.

    Cited by:

    1. Cookson, Richard & Laudicella, Mauro & Donni, Paolo Li, 2013. "Does hospital competition harm equity? Evidence from the English National Health Service," Journal of Health Economics, Elsevier, vol. 32(2), pages 410-422.
    2. Bevan, Gwyn & Evans, Alice & Nuti, Sabina, 2018. "Reputations count: why benchmarking performance is improving health care across the world," LSE Research Online Documents on Economics 86469, London School of Economics and Political Science, LSE Library.
    3. Ellen A. Stewart & Scott L. Greer & Iain Wilson & Peter D. Donnelly, 2016. "Power to the people? An international review of the democratizing effects of direct elections to healthcare organizations," International Journal of Health Planning and Management, Wiley Blackwell, vol. 31(2), pages 69-85, April.
    4. Came, H. & Doole, C. & McKenna, B. & McCreanor, T., 2018. "Institutional racism in public health contracting: Findings of a nationwide survey from New Zealand," Social Science & Medicine, Elsevier, vol. 199(C), pages 132-139.
    5. Gauld, Robin, 2012. "New Zealand's post-2008 health system reforms: Toward re-centralization of organizational arrangements," Health Policy, Elsevier, vol. 106(2), pages 110-113.
    6. Toth, Federico, 2010. "Healthcare policies over the last 20 years: Reforms and counter-reforms," Health Policy, Elsevier, vol. 95(1), pages 82-89, April.
    7. Margaret Brunton, 2017. "Risking the Sustainability of the Public Health System: Ethical Conundrums and Ideologically Embedded Reform," Journal of Business Ethics, Springer, vol. 142(4), pages 719-734, June.
    8. Petsoulas, Christina & Allen, Pauline & Hughes, David & Vincent-Jones, Peter & Roberts, Jennifer, 2011. "The use of standard contracts in the English National Health Service: A case study analysis," Social Science & Medicine, Elsevier, vol. 73(2), pages 185-192, July.
    9. Elizabeth Craig & Nick Baker & Jo Baxter & Catherine Jackson, 2016. "Creating a Child and Youth Health Monitoring Framework to Inform Health Sector Prioritisation and Planning: Reflections on Ten Years Experience in New Zealand," Child Indicators Research, Springer;The International Society of Child Indicators (ISCI), vol. 9(4), pages 1139-1159, December.

  55. Nancy Devlin & Paul Hansen & Peter Herbison & Susan Macran, 2005. "A ‘new and improved’ EQ-5D valuation questionnaire?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(1), pages 73-82, March.

    Cited by:

    1. David Parkin & Nancy Devlin, 2006. "Is there a case for using visual analogue scale valuations in cost‐utility analysis?," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 653-664, July.
    2. Sharma, Rajiv & Stano, Miron, 2010. "Implications of an economic model of health states worse than dead," Journal of Health Economics, Elsevier, vol. 29(4), pages 536-540, July.

  56. Nancy Devlin & David Parkin, 2004. "Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 437-452, May.

    Cited by:

    1. Elisa F Long & Roshni Mandalia & Sundhiya Mandalia & Sabina S Alistar & Eduard J Beck & Margaret L Brandeau, 2014. "Expanded HIV Testing in Low-Prevalence, High-Income Countries: A Cost-Effectiveness Analysis for the United Kingdom," PLOS ONE, Public Library of Science, vol. 9(4), pages 1-12, April.
    2. Martin Buxton, 2005. "How much are health-care systems prepared to pay to produce a QALY?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(4), pages 285-287, December.
    3. Lakdawalla, Darius N. & Sun, Eric C. & Jena, Anupam B. & Reyes, Carolina M. & Goldman, Dana P. & Philipson, Tomas J., 2010. "An economic evaluation of the war on cancer," Journal of Health Economics, Elsevier, vol. 29(3), pages 333-346, May.
    4. Chris Skedgel & Dominika Wranik & Min Hu, 2018. "The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian On," PharmacoEconomics, Springer, vol. 36(4), pages 467-475, April.
    5. Georgia Kourlaba & Vassilis Fragoulakis & Nikos Maniadakis, 2012. "Economic Evaluation of Clopidogrel in Acute Coronary Syndrome Patients without ST-Segment Elevation in Greece," Applied Health Economics and Health Policy, Springer, vol. 10(4), pages 261-271, July.
    6. J. Raftery, 2014. "NICE’s Cost-Effectiveness Range: Should it be Lowered?," PharmacoEconomics, Springer, vol. 32(7), pages 613-615, July.
    7. Wei Yang & Heather Gage & Daniel Jackson & Monique Raats, 2018. "The effectiveness and cost-effectiveness of plant sterol or stanol-enriched functional foods as a primary prevention strategy for people with cardiovascular disease risk in England: a modeling study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(7), pages 909-922, September.
    8. Andrew M. Jones (ed.), 2012. "The Elgar Companion to Health Economics, Second Edition," Books, Edward Elgar Publishing, number 14021.
    9. Fischer, Katharina Elisabeth & Heisser, Thomas & Stargardt, Tom, 2016. "Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia," Health Policy, Elsevier, vol. 120(10), pages 1115-1122.
    10. Naiyana Praditsitthikorn & Yot Teerawattananon & Sripen Tantivess & Supon Limwattananon & Arthorn Riewpaiboon & Saibua Chichareon & Nantakan Ieumwananonthachai & Viroj Tangcharoensathien, 2011. "Economic Evaluation of Policy Options for Prevention and Control of Cervical Cancer in Thailand," PharmacoEconomics, Springer, vol. 29(9), pages 781-806, September.
    11. Laura Levaggi & Rosella Levaggi, 2011. "Welfare properties of restrictions to health care based on cost effectiveness," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 101-110, January.
    12. Mikael Svensson & Fredrik Nilsson & Karl Arnberg, 2015. "Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness," PharmacoEconomics, Springer, vol. 33(11), pages 1229-1236, November.
    13. Michał Jakubczyk & Bogumił Kamiński, 2017. "Fuzzy approach to decision analysis with multiple criteria and uncertainty in health technology assessment," Annals of Operations Research, Springer, vol. 251(1), pages 301-324, April.
    14. E. Wetering & E. Stolk & N. Exel & W. Brouwer, 2013. "Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 107-115, February.
    15. Colette Mankowski & Sachin Patel & David Trueman & Anthony Bentley & Chris Poole, 2016. "Cost-Effectiveness of Capsaicin 8% Patch Compared with Pregabalin for the Treatment of Patients with Peripheral Neuropathic Pain in Scotland," PLOS ONE, Public Library of Science, vol. 11(3), pages 1-16, March.
    16. Stavros Petrou & Ngianga-Bakwin Kandala & Angela Robinson & Rachel Baker, 2013. "A Person Trade-Off Study to Estimate Age-Related Weights for Health Gains in Economic Evaluation," PharmacoEconomics, Springer, vol. 31(10), pages 893-907, October.
    17. Christian R. C. Kouakou & Thomas G. Poder, 2022. "Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(2), pages 277-299, March.
    18. Phill O’Neill & Nancy Devlin, 2010. "An Analysis of NICE’s ‘Restricted’ (or ‘Optimized’) Decisions," PharmacoEconomics, Springer, vol. 28(11), pages 987-993, November.
    19. Praveen Thokala & Jessica Ochalek & Ashley A. Leech & Thaison Tong, 2018. "Cost-Effectiveness Thresholds: the Past, the Present and the Future," PharmacoEconomics, Springer, vol. 36(5), pages 509-522, May.
    20. Colin Green & Karen Gerard, 2009. "Exploring the social value of health‐care interventions: a stated preference discrete choice experiment," Health Economics, John Wiley & Sons, Ltd., vol. 18(8), pages 951-976, August.
    21. Maynou, Laia & Cairns, John, 2019. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," Health Policy, Elsevier, vol. 123(2), pages 130-139.
    22. Julien Forder, 2009. "Long‐term care and hospital utilisation by older people: an analysis of substitution rates," Health Economics, John Wiley & Sons, Ltd., vol. 18(11), pages 1322-1338, November.
    23. Hodgetts, Katherine & Elshaug, Adam G. & Hiller, Janet E., 2012. "What counts and how to count it: Physicians’ constructions of evidence in a disinvestment context," Social Science & Medicine, Elsevier, vol. 75(12), pages 2191-2199.
    24. John Vernon & Robert Goldberg & Joseph Golec, 2009. "Economic Evaluation and Cost-Effectiveness Thresholds," PharmacoEconomics, Springer, vol. 27(10), pages 797-806, October.
    25. Kisser, Agnes & Tüchler, Heinz & Erdös, Judit & Wild, Claudia, 2016. "Factors influencing coverage decisions on medical devices: A retrospective analysis of 78 medical device appraisals for the Austrian hospital benefit catalogue 2008–2015," Health Policy, Elsevier, vol. 120(8), pages 903-912.
    26. Aris Angelis & Ansgar Lange & Panos Kanavos, 2018. "Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(1), pages 123-152, January.
    27. Fischer, Katharina E. & Rogowski, Wolf H. & Leidl, Reiner & Stollenwerk, Björn, 2013. "Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis," Health Policy, Elsevier, vol. 112(3), pages 187-196.
    28. Maynou, Laia & Cairns, John, 2018. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," LSE Research Online Documents on Economics 90877, London School of Economics and Political Science, LSE Library.
    29. Andrews, Brendon P., 2023. "Economic Evaluation under Ambiguity and Structural Uncertainties," Working Papers 2023-9, University of Alberta, Department of Economics, revised 05 Apr 2024.
    30. David Canning, 2013. "Axiomatic Foundations For Cost‐Effectiveness Analysis," Health Economics, John Wiley & Sons, Ltd., vol. 22(12), pages 1405-1416, December.
    31. Michael Drummond, 2012. "Twenty Years of Using Economic Evaluations for Reimbursement Decisions. What Have We Achieved?," Working Papers 075cherp, Centre for Health Economics, University of York.
    32. Reckers-Droog, V.T. & van Exel, N.J.A. & Brouwer, W.B.F., 2018. "Looking back and moving forward: On the application of proportional shortfall in healthcare priority setting in the Netherlands," Health Policy, Elsevier, vol. 122(6), pages 621-629.
    33. Christine McDonough & Anna Tosteson, 2007. "Measuring Preferences for Cost-Utility Analysis," PharmacoEconomics, Springer, vol. 25(2), pages 93-106, February.
    34. Michael Drummond, 2012. "Economic Evaluation and Decision-makers," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 54, Edward Elgar Publishing.
    35. Daniel Grima & Lisa Bernard & Elizabeth Dunn & Philip McFarlane & David Mendelssohn, 2012. "Cost-Effectiveness Analysis of Therapies for Chronic Kidney Disease Patients on Dialysis," PharmacoEconomics, Springer, vol. 30(11), pages 981-989, November.
    36. Pedram Sendi, 2008. "Bridging the gap between health and non-health investments: moving from cost-effectiveness analysis to a return on investment approach across sectors of economy," International Journal of Health Economics and Management, Springer, vol. 8(2), pages 113-121, June.
    37. Culyer, Anthony J., 2016. "Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use," Health Economics, Policy and Law, Cambridge University Press, vol. 11(4), pages 415-432, October.
    38. Javad Moradpour & Aidan Hollis, 2021. "The economic theory of cost‐effectiveness thresholds in health: Domestic and international implications," Health Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 1139-1151, May.
    39. Hughes, David & Doheny, Shane, 2011. "Deliberating Tarceva: A case study of how British NHS managers decide whether to purchase a high-cost drug in the shadow of NICE guidance," Social Science & Medicine, Elsevier, vol. 73(10), pages 1460-1468.
    40. Helen Dakin & Nancy Devlin & Yan Feng & Nigel Rice & Phill O’Neill & David Parkin, 2013. "The influence of cost-effectiveness and other factors on NICE decisions," Working Papers 093cherp, Centre for Health Economics, University of York.
    41. Gre[ss], Stefan & Niebuhr, Dea & Rothgang, Heinz & Wasem, Jurgen, 2005. "Criteria and procedures for determining benefit packages in health care: A comparative perspective," Health Policy, Elsevier, vol. 73(1), pages 78-91, July.
    42. Georgia Kourlaba & Vassilis Fragoulakis & Nikos Maniadakis, 2012. "Clopidogrel versus Aspirin in Patients with Atherothrombosis," Applied Health Economics and Health Policy, Springer, vol. 10(5), pages 331-342, September.
    43. Girard, Dorota Zdanowska, 2005. "The cost of epidemiological transition: A study of a decrease in pertussis vaccination coverage," Health Policy, Elsevier, vol. 74(3), pages 287-303, November.
    44. Mark Nuijten & Wolfgang Wittenberg & Maximilian Lebmeier, 2007. "Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children," PharmacoEconomics, Springer, vol. 25(1), pages 55-71, January.
    45. Cairns, John, 2006. "Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence compared," Health Policy, Elsevier, vol. 76(2), pages 134-143, April.
    46. Diane Dawson & Hugh Gravelle & Mary O'Mahony & Andrew Street & Martin Weale & Adriana Castelli & Rowena Jacobs & Paul Kind & Pete Loveridge & Stephen Martin & Philip Stevens & Lucy Stokes, 2005. "Developing new approaches to measuring NHS outputs and productivity," Working Papers 006cherp, Centre for Health Economics, University of York, revised Dec 2005.
    47. Jennifer Whitty & Paul Scuffham & Sharyn Rundle-Thielee, 2011. "Public and decision maker stated preferences for pharmaceutical subsidy decisions," Applied Health Economics and Health Policy, Springer, vol. 9(2), pages 73-79, March.
    48. Henry Glick, 2011. "Sample Size and Power for Cost-Effectiveness Analysis (Part 1)," PharmacoEconomics, Springer, vol. 29(3), pages 189-198, March.
    49. John Henderson & Katharina Janke & Carol Propper, 2007. "Are current levels of air pollution in England too high? The impact of pollution on population mortality," CASE Papers case128, Centre for Analysis of Social Exclusion, LSE.
    50. Dakin, Helen Angela & Devlin, Nancy J. & Odeyemi, Isaac A.O., 2006. ""Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making," Health Policy, Elsevier, vol. 77(3), pages 352-367, August.
    51. Malinowski, Krzysztof Piotr & Kawalec, Paweł & Trąbka, Wojciech, 2016. "Impact of patient outcomes and cost aspects on reimbursement recommendations in Poland in 2012–2014," Health Policy, Elsevier, vol. 120(11), pages 1249-1255.
    52. Tania Stafinski & Devidas Menon & Deborah Marshall & Timothy Caulfield, 2011. "Societal Values in the Allocation of Healthcare Resources," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 4(4), pages 207-225, December.
    53. Helen Campbell & Sue Tait & Linda Sharples & Noreen Caine & Timothy Gray & Peter Schofield & Martin Buxton, 2005. "Trial-based cost-utility comparison of percutaneous myocardial laser revascularisation and continued medical therapy for treatment of refractory angina pectoris," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(4), pages 288-297, December.
    54. Andrew Foy & Christopher Sciamanna & Mark Kozak & Edward J. Filippone, 2014. "The Medical Care Cost Ratchet," Cato Journal, Cato Journal, Cato Institute, vol. 34(1), pages 83-98, Winter.
    55. Sonja Sorensen & Siyang Peng & Brigitta Monz & Carole Bradley-Kennedy & Anuraag Kansal, 2013. "A Comparative Analysis of Models Used to Evaluate the Cost-Effectiveness of Dabigatran Versus Warfarin for the Prevention of Stroke in Atrial Fibrillation," PharmacoEconomics, Springer, vol. 31(7), pages 589-604, July.
    56. Kasper M. Johannesen & Karl Claxton & Mark J. Sculpher & Allan J. Wailoo, 2018. "How to design the cost‐effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework," Health Economics, John Wiley & Sons, Ltd., vol. 27(2), pages 41-54, February.
    57. Svensson, Mikael & Hultkrantz, Lars, 2012. "The Willingness to Pay for a QALY - Results based on value of statistical life estimates in Sweden," Karlstad University Working Papers in Economics 2, Karlstad University, Department of Economics.
    58. Qi Gui & Xinghuo Zhang & Liang Liu & Feng Zhao & Wenhao Cheng & Yakui Zhang, 2019. "Cost-utility analysis of total knee arthroplasty for osteoarthritis in a regional medical center in China," Health Economics Review, Springer, vol. 9(1), pages 1-8, December.
    59. Richard Norman & Gisselle Gallego, 2008. "Equity weights for economic evaluation: An Australian Discrete Choice Experiment, CHERE Working Paper 2008/5," Working Papers 2008/5, CHERE, University of Technology, Sydney.
    60. Fischer, Katharina E. & Leidl, Reiner & Rogowski, Wolf H., 2011. "A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention," Health Policy, Elsevier, vol. 101(3), pages 290-299, August.
    61. Chris Schilling & Duncan Mortimer & Kim Dalziel, 2017. "Using CART to Identify Thresholds and Hierarchies in the Determinants of Funding Decisions," Medical Decision Making, , vol. 37(2), pages 173-182, February.
    62. Gregory S. Zaric, 2008. "Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression," Health Economics, John Wiley & Sons, Ltd., vol. 17(11), pages 1277-1294, November.
    63. Howley, P., 2016. "Valuing the benefits from health care interventions using life satisfaction data," Health, Econometrics and Data Group (HEDG) Working Papers 16/01, HEDG, c/o Department of Economics, University of York.
    64. Mattias Ekman & Peter Lindgren & Carolin Miltenburger & Genevieve Meier & Julie Locklear & Mary Chatterton, 2012. "Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode," PharmacoEconomics, Springer, vol. 30(6), pages 513-530, June.
    65. Samuel Shillcutt & Damian Walker & Catherine Goodman & Anne Mills, 2009. "Cost Effectiveness in Low- and Middle-Income Countries," PharmacoEconomics, Springer, vol. 27(11), pages 903-917, November.
    66. Neal Hockley, 2014. "Cost–Benefit Analysis: A Decision-Support Tool or a Venue for Contesting Ecosystem Knowledge?," Environment and Planning C, , vol. 32(2), pages 283-300, April.
    67. Katharina Fischer & Reiner Leidl, 2014. "Analysing coverage decision-making: opening Pandora’s box?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 899-906, December.
    68. Katharina E. Fischer & Björn Stollenwerk & Wolf H. Rogowski, 2013. "Link between Process and Appraisal in Coverage Decisions," Medical Decision Making, , vol. 33(8), pages 1009-1025, November.
    69. Dana Goldman & Darius Lakdawalla & Tomas J. Philipson & Wesley Yin, 2010. "Valuing health technologies at nice: recommendations for improved incorporation of treatment value in HTA," Health Economics, John Wiley & Sons, Ltd., vol. 19(10), pages 1109-1116, October.
    70. Grupo de Economía de la Salud & Jairo Humberto Restrepo, 2012. "Economía de las enfermedades crónicas no transmisibles: Implicaciones para Colombia," Observatorio Seguridad Social 15579, Grupo de Economía de la Salud.
    71. Katharina Janke & Carol Propper & John Henderson, 2009. "Do current levels of air pollution kill? The impact of air pollution on population mortality in England," Health Economics, John Wiley & Sons, Ltd., vol. 18(9), pages 1031-1055, September.
    72. Thornton Snider Julia & Romley John A. & Vogt William B. & Philipson Tomas J., 2012. "The Option Value of Innovation," Forum for Health Economics & Policy, De Gruyter, vol. 15(1), pages 1-19, April.
    73. Marta Osca-Guadalajara & Javier Díaz-Carnicero & Silvia González-de-Julián & David Vivas-Consuelo, 2021. "Markov Models for Economic Evaluation in Osteoporosis Treatment," Mathematics, MDPI, vol. 9(18), pages 1-20, September.
    74. Margreet Franken & Fredrik Nilsson & Frank Sandmann & Anthonius Boer & Marc Koopmanschap, 2013. "Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making," PharmacoEconomics, Springer, vol. 31(9), pages 781-797, September.
    75. Susanne Schmitz & Laura McCullagh & Roisin Adams & Michael Barry & Cathal Walsh, 2016. "Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland," PharmacoEconomics, Springer, vol. 34(9), pages 925-937, September.
    76. Joseph P. Cook & Joseph Golec, 2017. "How excluding some benefits from value assessment of new drugs impacts innovation," Health Economics, John Wiley & Sons, Ltd., vol. 26(12), pages 1813-1825, December.
    77. Warren Linley & Dyfrig Hughes, 2013. "Decision-Makers’ Preferences for Approving New Medicines in Wales: A Discrete-Choice Experiment with Assessment of External Validity," PharmacoEconomics, Springer, vol. 31(4), pages 345-355, April.
    78. Leonie Segal & Kim Dalziel & Duncan Mortimer, 2010. "Fixing the game: are between‐silo differences in funding arrangements handicapping some interventions and giving others a head‐start?," Health Economics, John Wiley & Sons, Ltd., vol. 19(4), pages 449-465, April.
    79. Anthony Harris & Jing Jing Li & Karen Yong, 2016. "What Can We Expect from Value-Based Funding of Medicines? A Retrospective Study," PharmacoEconomics, Springer, vol. 34(4), pages 393-402, April.
    80. Jessica Ochalek & James Lomas & Karl Claxton, 2015. "Cost per DALY averted thresholds for low- and middle-income countries: evidence from cross country data," Working Papers 122cherp, Centre for Health Economics, University of York.
    81. Simon Eckermann, 2015. "Kinky Thresholds Revisited: Opportunity Costs Differ in the NE and SW Quadrants," Applied Health Economics and Health Policy, Springer, vol. 13(1), pages 7-13, February.
    82. Gu, Yuanyuan & Lancsar, Emily & Ghijben, Peter & Butler, James RG & Donaldson, Cam, 2015. "Attributes and weights in health care priority setting: A systematic review of what counts and to what extent," Social Science & Medicine, Elsevier, vol. 146(C), pages 41-52.
    83. Kanavos, Panos & Visintin, Erica & Gentilini, Arianna, 2023. "Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries," Social Science & Medicine, Elsevier, vol. 331(C).
    84. Chris Sampson & Bernarda Zamora & Sam Watson & John Cairns & Kalipso Chalkidou & Patricia Cubi-Molla & Nancy Devlin & Borja García-Lorenzo & Dyfrig A. Hughes & Ashley A. Leech & Adrian Towse, 2022. "Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy," Applied Health Economics and Health Policy, Springer, vol. 20(5), pages 651-667, September.
    85. Hugh Gravelle & Stephen Morris & Matt Sutton, 2006. "Are General Practitioners Good for Endogenous Supply and Health," Working Papers 020cherp, Centre for Health Economics, University of York.
    86. Kate A Halton & David Cook & David L Paterson & Nasia Safdar & Nicholas Graves, 2010. "Cost-Effectiveness of a Central Venous Catheter Care Bundle," PLOS ONE, Public Library of Science, vol. 5(9), pages 1-11, September.
    87. Jennifer A Whitty & Ruth Walker & Xanthe Golenko & Julie Ratcliffe, 2014. "A Think Aloud Study Comparing the Validity and Acceptability of Discrete Choice and Best Worst Scaling Methods," PLOS ONE, Public Library of Science, vol. 9(4), pages 1-9, April.
    88. Mauskopf, Josephine & Chirila, Costel & Birt, Julie & Boye, Kristina S. & Bowman, Lee, 2013. "Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: Have they impacted the National Health Service budget?," Health Policy, Elsevier, vol. 110(1), pages 49-59.
    89. James O’Mahony & Diarmuid Coughlan, 2016. "The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland’s Health System?," PharmacoEconomics, Springer, vol. 34(1), pages 5-11, January.
    90. Appleby, John & Devlin, Nancy & Parkin, David & Buxton, Martin & Chalkidou, Kalipso, 2009. "Searching for cost effectiveness thresholds in the NHS," Health Policy, Elsevier, vol. 91(3), pages 239-245, August.
    91. Joanne Lord & George Laking & Alastair Fischer, 2006. "Non‐linearity in the cost‐effectiveness frontier," Health Economics, John Wiley & Sons, Ltd., vol. 15(6), pages 565-577, June.
    92. E. Stolk & M. Poley, 2005. "Criteria for determining a basic health services package," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(1), pages 2-7, March.
    93. P. Beutels & W. J. Edmunds & R. D. Smith, 2008. "Partially wrong? Partial equilibrium and the economic analysis of public health emergencies of international concern," Health Economics, John Wiley & Sons, Ltd., vol. 17(11), pages 1317-1322, November.
    94. Warren Linley & Dyfrig Hughes, 2012. "Reimbursement Decisions of the All Wales Medicines Strategy Group," PharmacoEconomics, Springer, vol. 30(9), pages 779-794, September.
    95. Eric Deconinck & Houda Miadi-Fargier & Claude Pen & Pauline Brice, 2010. "Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma," PharmacoEconomics, Springer, vol. 28(1), pages 35-46, January.
    96. Tappenden, P & Brazier, J & Ratcliffe, J, 2006. "Does the National Institute for Health and Clinical Excellence take account of factors such as uncertainty and equity as well as incremental cost-effectiveness in commissioning health care services? A," MPRA Paper 29772, University Library of Munich, Germany.
    97. Peter Ghijben & Yuanyuan Gu & Emily Lancsar & Silva Zavarsek, 2018. "Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review," PharmacoEconomics, Springer, vol. 36(3), pages 323-340, March.
    98. Pieter van Baal & David Meltzer & Werner Brouwer, 2016. "Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost‐Effectiveness Analysis," Health Economics, John Wiley & Sons, Ltd., vol. 25(2), pages 237-248, February.
    99. Eun-Young Bae & Hui Jeong Kim & Hye-Jae Lee & Junho Jang & Seung Min Lee & Yunkyung Jung & Nari Yoon & Tae Kyung Kim & Kookhee Kim & Bong-Min Yang, 2018. "Role of economic evidence in coverage decision-making in South Korea," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-12, October.
    100. Frans Rutten & Werner Brouwer & Louis Niessen, 2005. "Practice guidelines based on clinical and economic evidence," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(2), pages 91-93, June.
    101. Takeru Shiroiwa & Yoon‐Kyoung Sung & Takashi Fukuda & Hui‐Chu Lang & Sang‐Cheol Bae & Kiichiro Tsutani, 2010. "International survey on willingness‐to‐pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?," Health Economics, John Wiley & Sons, Ltd., vol. 19(4), pages 422-437, April.
    102. James F. O’Mahony & Diarmuid Coughlan, 2016. "The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland’s Health System?," PharmacoEconomics, Springer, vol. 34(1), pages 5-11, January.
    103. Williams, Iestyn & Bryan, Stirling, 2007. "Understanding the limited impact of economic evaluation in health care resource allocation: A conceptual framework," Health Policy, Elsevier, vol. 80(1), pages 135-143, January.
    104. Fischer, Katharina Elisabeth, 2012. "A systematic review of coverage decision-making on health technologies—Evidence from the real world," Health Policy, Elsevier, vol. 107(2), pages 218-230.
    105. Vuorenkoski, Lauri & Toiviainen, Hanna & Hemminki, Elina, 2008. "Decision-making in priority setting for medicines--A review of empirical studies," Health Policy, Elsevier, vol. 86(1), pages 1-9, April.
    106. Henry Glick, 2011. "Sample Size and Power for Cost-Effectiveness Analysis (Part 2)," PharmacoEconomics, Springer, vol. 29(4), pages 287-296, April.
    107. Stein, K & Dyer, M & Crabb, T & Milne, R & Round, A & Ratcliffe, J & Brazier, J, 2006. "An Internet “Value of Health” panel: recruitment, participation and compliance," MPRA Paper 29770, University Library of Munich, Germany.
    108. John McKie & Bradley Shrimpton & Jeff Richardson & Rosalind Hurworth, 2011. "The monetary value of a life year: evidence from a qualitative study of treatment costs," Health Economics, John Wiley & Sons, Ltd., vol. 20(8), pages 945-957, August.

  57. Nancy J. Devlin & Paul Hansen & Paul Kind & Alan Williams, 2003. "Logical inconsistencies in survey respondents' health state valuations ‐ a methodological challenge for estimating social tariffs," Health Economics, John Wiley & Sons, Ltd., vol. 12(7), pages 529-544, July.

    Cited by:

    1. Leida M. Lamers & Peep F. M. Stalmeier & Paul F. M. Krabbe & Jan J. V. Busschbach, 2006. "Inconsistencies in TTO and VAS Values for EQ-5D Health States," Medical Decision Making, , vol. 26(2), pages 173-181, March.
    2. David Parkin & Nancy Devlin, 2006. "Is there a case for using visual analogue scale valuations in cost‐utility analysis?," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 653-664, July.
    3. Feng Xie & Kathryn Gaebel & Kuhan Perampaladas & Brett Doble & Eleanor Pullenayegum, 2014. "Comparing EQ-5D Valuation Studies," Medical Decision Making, , vol. 34(1), pages 8-20, January.
    4. Bansback, Nick & Brazier, John & Tsuchiya, Aki & Anis, Aslam, 2012. "Using a discrete choice experiment to estimate health state utility values," Journal of Health Economics, Elsevier, vol. 31(1), pages 306-318.
    5. Richard Norman & Paula Cronin & Rosalie Viney & Madeleine King & Deborah Street & John Brazier & Julie Ratcliffe, 2007. "Valuing EQ-5D health states: A review and analysis, CHERE Working Paper 2007/9," Working Papers 2007/9, CHERE, University of Technology, Sydney.
    6. Franz Ombler & Michael Albert & Paul Hansen, 2018. "How Significant Are “High†Correlations Between EQ-5D Value Sets?," Medical Decision Making, , vol. 38(6), pages 635-645, August.
    7. Rodríguez-Míguez, E. & Abellán-Perpiñán, J.M. & Alvarez, X.C. & González, X.M. & Sampayo, A.R., 2016. "The DEP-6D, a new preference-based measure to assess health states of dependency," Social Science & Medicine, Elsevier, vol. 153(C), pages 210-219.
    8. Paul F. M. Krabbe, 2006. "Valuation Structures of Health States Revealed with Singular Value Decomposition," Medical Decision Making, , vol. 26(1), pages 30-37, January.
    9. Yan Feng & Nancy J. Devlin & Koonal K. Shah & Brendan Mulhern & Ben van Hout, 2018. "New methods for modelling EQ‐5D‐5L value sets: An application to English data," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 23-38, January.
    10. Bansback, Nick & Brazier, John & Tsuchiya, Aki & Anis, Aslam, 2010. "Using a discrete choice experiment to estimate societal health state utility values," MPRA Paper 29933, University Library of Munich, Germany.
    11. Lidia Engel & Nick Bansback & Stirling Bryan & Mary M. Doyle-Waters & David G. T. Whitehurst, 2016. "Exclusion Criteria in National Health State Valuation Studies," Medical Decision Making, , vol. 36(7), pages 798-810, October.
    12. Zhihao Yang & Jan van Busschbach & Reinier Timman & M F Janssen & Nan Luo, 2017. "Logical inconsistencies in time trade-off valuation of EQ-5D-5L health states: Whose fault is it?," PLOS ONE, Public Library of Science, vol. 12(9), pages 1-10, September.
    13. Ernest H. Law & Annika L. Pickard & Anika Kaczynski & A. Simon Pickard, 2017. "Choice Blindness and Health-State Choices among Adolescents and Adults," Medical Decision Making, , vol. 37(6), pages 680-687, August.
    14. Franz Ombler & Michael Albert & Paul Hansen, 2017. "The true significance of ‘high’ correlations between EQ-5D value sets," Working Papers 1704, University of Otago, Department of Economics, revised Mar 2017.
    15. Irina Cleemput, 2010. "A social preference valuations set for EQ-5D health states in Flanders, Belgium," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(2), pages 205-213, April.
    16. Julie Chevalier & Gérard Pouvourville, 2013. "Valuing EQ-5D using Time Trade-Off in France," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 57-66, February.
    17. Nancy J. Devlin & Koonal K. Shah & Brendan J. Mulhern & Krystallia Pantiri & Ben van Hout, 2019. "A new method for valuing health: directly eliciting personal utility functions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(2), pages 257-270, March.
    18. Barry Dewitt & Baruch Fischhoff & Alexander L. Davis & Stephen B. Broomell & Mark S. Roberts & Janel Hanmer, 2019. "Exclusion Criteria as Measurements I: Identifying Invalid Responses," Medical Decision Making, , vol. 39(6), pages 693-703, August.
    19. Versteegh, MM & Attema, AE & Oppe, M & Devlin, NJ & Stolk, EA, 2012. "Time to tweak the TTO. But how?," MPRA Paper 37989, University Library of Munich, Germany.
    20. Barry Dewitt & Baruch Fischhoff & Alexander L. Davis & Stephen B. Broomell & Mark S. Roberts & Janel Hanmer, 2019. "Exclusion Criteria as Measurements II: Effects on Utility Functions," Medical Decision Making, , vol. 39(6), pages 704-716, August.
    21. Mônica Viegas Andrade & Kenya Noronha & Paul Kind & Carla de Barros Reis & Lucas Resende de Carvalho, 2016. "Logical Inconsistencies in 3 Preference Elicitation Methods for EQ-5D Health States," Medical Decision Making, , vol. 36(2), pages 242-252, February.
    22. Sullivan, Trudy & Hansen, Paul & Ombler, Franz & Derrett, Sarah & Devlin, Nancy, 2020. "A new tool for creating personal and social EQ-5D-5L value sets, including valuing ‘dead’," Social Science & Medicine, Elsevier, vol. 246(C).
    23. Markian Pahuta & Aaron Frombach & Emile Hashem & Stewart Spence & Christina Sun & Eugene K. Wai & Joel Werier & Carl Walraven & Doug Coyle, 2019. "The Psychometric Properties of a Self-Administered, Open-Source Module for Valuing Metastatic Epidural Spinal Cord Compression Utilities," PharmacoEconomics - Open, Springer, vol. 3(2), pages 197-204, June.
    24. Aidan Coville & Victor Orozco & Arndt Reichert, 2019. "Paying Attention to Technology Innovations," World Bank Publications - Reports 34339, The World Bank Group.

  58. Nancy Devlin & Paul Hansen, 2001. "Health care spending and economic output: Granger causality," Applied Economics Letters, Taylor & Francis Journals, vol. 8(8), pages 561-564.

    Cited by:

    1. Jochen Hartwig, 2006. "What Drives Health Care Expenditure? Baumol's Model of "Unbalanced Growth" Revisited," KOF Working papers 06-133, KOF Swiss Economic Institute, ETH Zurich.
    2. Philip O. Alege & Oluwasogo S. Adediran & Adeyemi A. Ogundipe, 2016. "Pollutant Emissions, Energy Consumption and Economic Growth in Nigeria," International Journal of Energy Economics and Policy, Econjournals, vol. 6(2), pages 202-207.
    3. Aurangzeb, 2003. "Relationship between Health Expenditure and GDP in an Augmented Solow Growth Model for Pakistan: An Application of Co-integration and Error-Correction Modeling," Lahore Journal of Economics, Department of Economics, The Lahore School of Economics, vol. 8(2), pages 1-16, Jul-Dec.
    4. Nadide Sevil Halıcı-Tülüce & İbrahim Doğan & Cüneyt Dumrul, 2016. "Is income relevant for health expenditure and economic growth nexus?," International Journal of Health Economics and Management, Springer, vol. 16(1), pages 23-49, March.
    5. Narayan Sethi & Saileja Mohanty & Aurolipsa Das & Malayaranjan Sahoo, 2024. "Health Expenditure and Economic Growth Nexus: Empirical Evidence from South Asian Countries," Global Business Review, International Management Institute, vol. 25(2_suppl), pages 229-243, April.
    6. Erkan Erdil & I. Hakan Yetkiner, 2009. "The Granger-causality between health care expenditure and output: a panel data approach," Applied Economics, Taylor & Francis Journals, vol. 41(4), pages 511-518.
    7. Jochen Hartwig, 2008. "Has Health Capital Formation Cured 'Baumol's Disease'? - Panel Granger Causality Evidence for OECD Countries," KOF Working papers 08-206, KOF Swiss Economic Institute, ETH Zurich.
    8. Costa-Font, J & Gemmill M & Rubert G, 2009. "Re-visiting the Health Care Luxury Good Hypothesis: Aggregation, Precision, and Publication Biases?," Health, Econometrics and Data Group (HEDG) Working Papers 09/02, HEDG, c/o Department of Economics, University of York.
    9. Ali Akbar Fazaeli & Hossein Ghaderi & Masoud Salehi & Ali Reza Fazaeli, 2016. "Health Care Expenditure and GDP in Oil Exporting Countries: Evidence From OPEC Data, 1995-2012," Global Journal of Health Science, Canadian Center of Science and Education, vol. 8(2), pages 1-93, February.
    10. Cristian C. Popescu & Laura Diaconu (Maxim), 2021. "Government Spending and Economic Growth: A Cointegration Analysis on Romania," Sustainability, MDPI, vol. 13(12), pages 1-16, June.
    11. Biswajit Maitra, 2018. "Investment in Physical, Human Capital, Economic Growth and Life Expectancy in Bangladesh," South Asia Economic Journal, Institute of Policy Studies of Sri Lanka, vol. 19(2), pages 251-269, September.
    12. Hartwig, Jochen, 2010. "Is health capital formation good for long-term economic growth? - Panel Granger-causality evidence for OECD countries," Journal of Macroeconomics, Elsevier, vol. 32(1), pages 314-325, March.
    13. Muhammad Usman & Zhiqiang Ma & Muhammad Wasif Zafar & Abdul Haseeb & Rana Umair Ashraf, 2019. "Are Air Pollution, Economic and Non-Economic Factors Associated with Per Capita Health Expenditures? Evidence from Emerging Economies," IJERPH, MDPI, vol. 16(11), pages 1-22, June.
    14. Yuan, Mingqing, 2023. "The nexus between economic growth, healthcare expenditure, and CO2 emissions in Asia-Pacific countries: Evidence from a PVAR approach," MPRA Paper 119994, University Library of Munich, Germany.
    15. Arshia Amiri & Ulf-g Gerdtham & Bruno Ventelou, 2012. "HIV/AIDS-GDP Nexus? Evidence from panel-data for African countries," Economics Bulletin, AccessEcon, vol. 32(1), pages 1060-1067.
    16. Henryk Gurgul & Łukasz Lach & Roland Mestel, 2012. "The relationship between budgetary expenditure and economic growth in Poland," Central European Journal of Operations Research, Springer;Slovak Society for Operations Research;Hungarian Operational Research Society;Czech Society for Operations Research;Österr. Gesellschaft für Operations Research (ÖGOR);Slovenian Society Informatika - Section for Operational Research;Croatian Operational Research Society, vol. 20(1), pages 161-182, March.
    17. Tang, Chor Foon, 2010. "The determinants of health expenditure in Malaysia: A time series analysis," MPRA Paper 24356, University Library of Munich, Germany.
    18. Joan Costa Font & Jordi Pons Novell, 2005. "Public Health Expenditure and Spatial Interactions in a Decentralized National Health System," Working Papers in Economics 139, Universitat de Barcelona. Espai de Recerca en Economia.
    19. Alfredo M. Pereira & Rui M. Pereira & Pedro G. Rodrigues, 2019. "Health care investments and economic performance in Portugal: an industry level analysis," Journal of Economic Studies, Emerald Group Publishing Limited, vol. 46(6), pages 1174-1200, October.
    20. Francesco Ricci & Marios Zachariadis, 2006. "Determinants of Public Health Outcomes: A Macroeconomic Perspective," Computing in Economics and Finance 2006 107, Society for Computational Economics.
    21. Ayhan Kuloglu & Ebru Topcu, 2016. "The Relationship Between Health And Growth In Eurasian Economic Union," Eurasian Journal of Economics and Finance, Eurasian Publications, vol. 4(4), pages 42-48.
    22. Weichun Chen & Judith A. Clarke & Nilanjana Roy, 2014. "Health and wealth: Short panel Granger causality tests for developing countries," The Journal of International Trade & Economic Development, Taylor & Francis Journals, vol. 23(6), pages 755-784, September.
    23. Odhiambo, Nicholas M, 2021. "Health expenditure and economic growth in Sub-Saharan Africa: An empirical investigation," Working Papers 28863, University of South Africa, Department of Economics.
    24. Gurgul, Henryk & Lach, Łukasz, 2011. "Causality analysis between public expenditure and economic growth of Polish economy in last decade," MPRA Paper 52281, University Library of Munich, Germany.
    25. Sasa Obradovic & Nemanja Lojanica, 2018. "Is Health Care Necessity or Luxury Good? Panel Data Analysis on the Example of the SEEHN Countries," Managing Global Transitions, University of Primorska, Faculty of Management Koper, vol. 16(3 (Fall)), pages 195-214.
    26. Kamil Dybczak & Bartosz Przywara, 2010. "The role of technology in health care expenditure in the EU," European Economy - Economic Papers 2008 - 2015 400, Directorate General Economic and Financial Affairs (DG ECFIN), European Commission.
    27. Roel van Elk & Esther Mot & P.H. Franses, 2009. "Modelling health care expenditures; overview of the literature and evidence from a panel time series model," CPB Discussion Paper 121, CPB Netherlands Bureau for Economic Policy Analysis.
    28. N.M. Odhiambo, 2021. "Health Expenditure and Economic Growth in Sub-Saharan Africa: An Empirical Investigation," Working Papers AESRI-2021-05, African Economic and Social Research Institute (AESRI), revised Jan 2021.
    29. Arshia Amiri & Ulf-G Gerdtham & Bruno Ventelou, 2012. "A new approach for estimation of long-run relationships in economic analysis using Engle-Granger and artificial intelligence methods," Working Papers halshs-00606048, HAL.
    30. Biswajit Maitra & C.K. Mukhopadhyay, 2012. "Public spending on education, health care and economic growth in selected countries of Asia and the Pacific," Asia-Pacific Development Journal, United Nations Economic and Social Commission for Asia and the Pacific (ESCAP), vol. 19(2), pages 19-48, December.
    31. Erkan Erdil & I. Hakan Yetkiner, 2004. "A Panel Data Approach for Income-Health Causality," Working Papers FNU-47, Research unit Sustainability and Global Change, Hamburg University, revised Apr 2004.
    32. Tang, Chor Foon, 2011. "Multivariate Granger Causality and the Dynamic Relationship between Health Care Spending, Income and Relative Price of Health Care in Malaysia," Hitotsubashi Journal of Economics, Hitotsubashi University, vol. 52(2), pages 199-214, December.
    33. Aylar Jalili & Hossein Panahi & Sakineh Sojoodi, 2022. "Investigating the causal relationship between woman's health and economic growth in groups D8 and G7 countries," Quality & Quantity: International Journal of Methodology, Springer, vol. 56(1), pages 359-374, February.
    34. Oded Galor & David Mayer-Foulkes, 2004. "Food for Thought: Basic Needs and Persistent Educational Inequality," GE, Growth, Math methods 0410002, University Library of Munich, Germany.
    35. Driouchi, Ahmed & Harkat, Tahar, 2017. "Granger Causality and the Factors underlying the Role of Younger Generations in Economic, Social and Political Changes in Arab Countries," MPRA Paper 77218, University Library of Munich, Germany.
    36. Hsin-Pei Hsueh & Chien-Ming Wang & Cheng-Feng Wu & Fangjhy Li, 2019. "Investigation of the Co-Movement Relationship between Medical Expenditure and GDP in Taiwan-Based on Wavelet Analysis," IJERPH, MDPI, vol. 16(24), pages 1-9, December.
    37. V. Chandran Govindaraju & Ramesh Rao & Sajid Anwar, 2011. "Economic growth and government spending in Malaysia: a re-examination of Wagner and Keynesian views," Economic Change and Restructuring, Springer, vol. 44(3), pages 203-219, August.
    38. David Prieto & Santiago Lago-Peñas, 2012. "Decomposing the determinants of health care expenditure: the case of Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(1), pages 19-27, February.
    39. Declan French, 2012. "Causation between health and income: a need to panic," Empirical Economics, Springer, vol. 42(2), pages 583-601, April.
    40. Ärshiya Ämiri & Mikael Linden, 2016. "Income and total expenditure on health in OECD countries: Evidence from panel data and Hsiao's version of Granger non-causality tests," Economics and Business Letters, Oviedo University Press, vol. 5(1), pages 1-9.
    41. Adeel Saleem & Ghulam Sarwar & Jahanzaib Sultan & Zulfiqar Ali, 2022. "Determinants of Public Healthcare Investment: Cointegration and Causality Evidence from Pakistan," Journal of Economic Impact, Science Impact Publishers, vol. 4(2), pages 01-13.
    42. Shu-Chen Chang & Teng-Yu Chang, 2012. "Threshold Effects of Economic Growth on Air Pollution under Regimes of Corruption," Economics Bulletin, AccessEcon, vol. 32(1), pages 1046-1059.
    43. Yilmaz Bayar & Marius Dan Gavriletea & Mirela Oana Pintea & Ioana Cristina Sechel, 2021. "Impact of Environment, Life Expectancy and Real GDP per Capita on Health Expenditures: Evidence from the EU Member States," IJERPH, MDPI, vol. 18(24), pages 1-14, December.
    44. Sidan Li & Shibing You & Duochenxi Liu & Yukun Wang, 2023. "National Quality and Sustainable Development: An Empirical Analysis Based on China’s Provincial Panel Data," Sustainability, MDPI, vol. 15(6), pages 1-22, March.
    45. Suren Basov, 2002. "Heterogenous Human Capital: Life Cycle Investment in Health and Education," Department of Economics - Working Papers Series 838, The University of Melbourne.
    46. João A. S. ANDRADE & Adelaide P. S. DUARTE & Marta C. N. SIMÕES, 2018. "Education and health: welfare state composition and growth across country groups," Eastern Journal of European Studies, Centre for European Studies, Alexandru Ioan Cuza University, vol. 9, pages 111-144, December.
    47. João Sousa Andrade & Marta Simões & Adelaide Duarte, 2013. "Despesa Pública em Educação e Saúde e Crescimento Económico: Um Contributo para o Debate sobre as Funções Sociais do Estado," GEMF Working Papers 2013-18, GEMF, Faculty of Economics, University of Coimbra.

  59. Scuffham, P. & Devlin, N. & Eberhart-Phillips, J. & Wilson-Salt, R., 1999. "The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule," Social Science & Medicine, Elsevier, vol. 49(6), pages 763-779, September.

    Cited by:

    1. Nancy Thiry & Philippe Beutels & Pierre Damme & Eddy Doorslaer, 2003. "Economic Evaluations of Varicella Vaccination Programmes," PharmacoEconomics, Springer, vol. 21(1), pages 13-38, January.
    2. M. Brisson & W. J. Edmunds, 2006. "Impact of Model, Methodological, and Parameter Uncertainty in the Economic Analysis of Vaccination Programs," Medical Decision Making, , vol. 26(5), pages 434-446, September.
    3. Jane Hall & Patricia Kenny & Madeleine King & Jordan Louviere & Rosalie Viney & Angela Yeoh, 2002. "Using stated preference discrete choice modelling to evaluate the introduction of varicella vaccination," Health Economics, John Wiley & Sons, Ltd., vol. 11(5), pages 457-465, July.

  60. Szeto, Kam Leong & Devlin, Nancy J., 1996. "The cost-effectiveness of mammography screening: evidence from a microsimulation model for New Zealand," Health Policy, Elsevier, vol. 38(2), pages 101-115, November.

    Cited by:

    1. Natasha Stout & Amy Knudsen & Chung Kong & Pamela McMahon & G. Gazelle, 2009. "Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines," PharmacoEconomics, Springer, vol. 27(7), pages 533-545, July.
    2. Irmgard C. Schiller-Frühwirth & Beate Jahn & Marjan Arvandi & Uwe Siebert, 2017. "Cost-Effectiveness Models in Breast Cancer Screening in the General Population: A Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 333-351, June.
    3. Israel Vieira & Valter Senna & Paul Harper & Arjan Shahani, 2011. "Tumour doubling times and the length bias in breast cancer screening programmes," Health Care Management Science, Springer, vol. 14(2), pages 203-211, June.
    4. Anell, Anders & Norinder, Anna, 2000. "Health outcome measures used in cost-effectiveness studies: a review of original articles published between 1986 and 1996," Health Policy, Elsevier, vol. 51(2), pages 87-99, March.
    5. Lisa M. Maillart & Julie Simmons Ivy & Scott Ransom & Kathleen Diehl, 2008. "Assessing Dynamic Breast Cancer Screening Policies," Operations Research, INFORMS, vol. 56(6), pages 1411-1427, December.
    6. Bech, Mickael & Gyrd-Hansen, Dorte, 2000. "Cost implications of routine mammography screening of women 50-69 years in the County of Funen, Denmark," Health Policy, Elsevier, vol. 54(2), pages 125-141, November.
    7. Brailsford, S.C. & Harper, P.R. & Sykes, J., 2012. "Incorporating human behaviour in simulation models of screening for breast cancer," European Journal of Operational Research, Elsevier, vol. 219(3), pages 491-507.

Books

  1. Nancy Devlin;Jon Sussex, 2011. "Incorporating Multiple Criteria in HTA: Methods and Processes," Monograph 000189, Office of Health Economics.

    Cited by:

    1. Henk Broekhuizen & Catharina Groothuis-Oudshoorn & Janine Til & J. Hummel & Maarten IJzerman, 2015. "A Review and Classification of Approaches for Dealing with Uncertainty in Multi-Criteria Decision Analysis for Healthcare Decisions," PharmacoEconomics, Springer, vol. 33(5), pages 445-455, May.
    2. Praveen Thokala & Jessica Ochalek & Ashley A. Leech & Thaison Tong, 2018. "Cost-Effectiveness Thresholds: the Past, the Present and the Future," PharmacoEconomics, Springer, vol. 36(5), pages 509-522, May.
    3. Axel C. Mühlbacher & Anika Kaczynski, 2016. "Making Good Decisions in Healthcare with Multi-Criteria Decision Analysis: The Use, Current Research and Future Development of MCDA," Applied Health Economics and Health Policy, Springer, vol. 14(1), pages 29-40, February.
    4. Aris Angelis & Panos Kanavos, 2016. "Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment," PharmacoEconomics, Springer, vol. 34(5), pages 435-446, May.
    5. López-Bastida, J. & Ramos-Goñi, J.M. & Aranda-Reneo, I. & Trapero-Bertran, M. & Kanavos, P. & Rodriguez Martin, B., 2019. "Using a stated preference discrete choice experiment to assess societal value from the perspective of decision-makers in Europe. Does it work for rare diseases?," Health Policy, Elsevier, vol. 123(2), pages 152-158.
    6. Cleemput, Irina & Devriese, Stephan & Kohn, Laurence & Westhovens, René, 2018. "A multi-criteria decision approach for ranking unmet needs in healthcare," Health Policy, Elsevier, vol. 122(8), pages 878-884.
    7. Scheil-Adlung, Xenia., 2015. "Global evidence on inequities in rural health protection : new data on rural deficits in health coverage for 174 countries," ILO Working Papers 994876213402676, International Labour Organization.
    8. Jennifer Whitty & Emily Lancsar & Kylie Rixon & Xanthe Golenko & Julie Ratcliffe, 2014. "A Systematic Review of Stated Preference Studies Reporting Public Preferences for Healthcare Priority Setting," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 7(4), pages 365-386, December.
    9. Helen Dakin & Nancy Devlin & Yan Feng & Nigel Rice & Phill O’Neill & David Parkin, 2013. "The influence of cost-effectiveness and other factors on NICE decisions," Working Papers 093cherp, Centre for Health Economics, University of York.
    10. Kevin Marsh & J. Jaime Caro & Alaa Hamed & Erica Zaiser, 2017. "Amplifying Each Patient’s Voice: A Systematic Review of Multi-criteria Decision Analyses Involving Patients," Applied Health Economics and Health Policy, Springer, vol. 15(2), pages 155-162, April.
    11. Martina Garau & Grace Hampson & Nancy Devlin & Nicola Amedeo Mazzanti & Antonio Profico, 2018. "Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)," PharmacoEconomics - Open, Springer, vol. 2(2), pages 153-163, June.
    12. Nils Gutacker & Andrew Street, 2015. "Multidimensional performance assessment using dominance criteria," Working Papers 115cherp, Centre for Health Economics, University of York.
    13. Angelis, A. & Linch, M. & Montibeller, G. & Molina-Lopez, T. & Zawada, A. & Orzel, K. & Arickx, F. & Espin, J. & Kanavos, P., 2020. "Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework," Social Science & Medicine, Elsevier, vol. 246(C).
    14. Nils Gutacker & Andrew Street, 2018. "Multidimensional performance assessment of public sector organisations using dominance criteria," Health Economics, John Wiley & Sons, Ltd., vol. 27(2), pages 13-27, February.
    15. Mónica D. Oliveira & Inês Mataloto & Panos Kanavos, 2019. "Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(6), pages 891-918, August.
    16. Kevin Marsh & Tereza Lanitis & David Neasham & Panagiotis Orfanos & Jaime Caro, 2014. "Assessing the Value of Healthcare Interventions Using Multi-Criteria Decision Analysis: A Review of the Literature," PharmacoEconomics, Springer, vol. 32(4), pages 345-365, April.
    17. Joey Au & Andrew Coleman & Trudy Sullivan, 2015. "A Practical Approach to Well-being Based Policy Development: What Do New Zealanders Want from Their Retirement Income Policies?," Treasury Working Paper Series 15/14, New Zealand Treasury.
    18. James Buchanan & Sarah Wordsworth, 2019. "Evaluating the Outcomes Associated with Genomic Sequencing: A Roadmap for Future Research," PharmacoEconomics - Open, Springer, vol. 3(2), pages 129-132, June.
    19. Jon Sussex & Adrian Towse & Nancy Devlin, 2013. "Operationalizing Value-Based Pricing of Medicines," PharmacoEconomics, Springer, vol. 31(1), pages 1-10, January.
    20. Amanda Cole;Grace Hampson;Nancy Devlin;David Grainger;Eui-Kyung Lee;Wija Oortwijn, 2016. "“New Age” Decision Making in HTA: Is It Applicable in Asia?," Briefing 001741, Office of Health Economics.
    21. Powdthavee, Nattavudh & van den Berg, Bernard, 2011. "Putting different price tags on the same health condition: Re-evaluating the well-being valuation approach," Journal of Health Economics, Elsevier, vol. 30(5), pages 1032-1043.
    22. Morton, Alec, 2014. "Aversion to health inequalities in healthcare prioritisation: A multicriteria optimisation perspective," Journal of Health Economics, Elsevier, vol. 36(C), pages 164-173.
    23. Andrew Briggs, 2016. "A View from the Bridge: Health Economic Evaluation — A Value‐Based Framework?," Health Economics, John Wiley & Sons, Ltd., vol. 25(12), pages 1499-1502, December.
    24. Livio Garattini & Anna Padula, 2018. "Multiple Criteria Decision Analysis in Health Technology Assessment for Drugs: Just Another Illusion?," Applied Health Economics and Health Policy, Springer, vol. 16(1), pages 1-4, February.

  2. Nancy Devlin;John Appleby, 2010. "Getting the Most out of PROMs: Putting Health Outcomes at the Heart of NHS Decision-Making," Monograph 000220, Office of Health Economics.

    Cited by:

    1. Bischof, Anja & Salvi, Irene & Kuklinski, David & Vogel, Justus & Geissler, Alexander, 2023. "Design Principles of Clinical Dashboards Incorporating PROMs: Crafting and Elaborating the Potential of Clinical Dashboards Incorporating PROMs," Working Paper Series in Health Economics, Management and Policy 2023-05, University of St.Gallen, School of Medicine, Chair of Health Economics, Policy and Management.
    2. Madhavan, Naveen & White, Gareth R.T. & Jones, Paul, 2023. "Identifying the value of a clinical information system during the COVID-19 pandemic," Technovation, Elsevier, vol. 120(C).
    3. Anabela Coelho & Candan Kendir & Eliana Barrenho & Niek Klazinga & Cláudia Paiva & Joaquim Abreu de Sousa & Salomé Gonçalves-Monteiro & Patrícia Redondo & Ana Bastos & Armanda Nogueira & Fábio Botelho, 2023. "Patient-Reported Outcomes and Experiences Assessment in Women with Breast Cancer: Portuguese Case Study," IJERPH, MDPI, vol. 20(4), pages 1-11, February.
    4. Zoe Moula & Nicola Walshe & Elsa Lee, 2021. "Making Nature Explicit in Children’s Drawings of Wellbeing and Happy Spaces," Child Indicators Research, Springer;The International Society of Child Indicators (ISCI), vol. 14(4), pages 1653-1675, August.
    5. Stirling Bryan & Craig Mitton & Cam Donaldson, 2014. "Breaking The Addiction To Technology Adoption," Health Economics, John Wiley & Sons, Ltd., vol. 23(4), pages 379-383, April.
    6. Max W de Graaf & Inge H F Reininga & Erik Heineman & Mostafa El Moumni, 2019. "The development and internal validation of a model to predict functional recovery after trauma," PLOS ONE, Public Library of Science, vol. 14(3), pages 1-16, March.
    7. Moula, Zoe & Aithal, Supritha & Karkou, Vicky & Powell, Joanne, 2020. "A systematic review of child-focused outcomes and assessments of arts therapies delivered in primary mainstream schools," Children and Youth Services Review, Elsevier, vol. 112(C).
    8. Elizabeth Lumley & Patrick Phillips & Ahmed Aber & Helen Buckley‐Woods & Georgina L. Jones & Jonathan A. Michaels, 2019. "Experiences of living with varicose veins: A systematic review of qualitative research," Journal of Clinical Nursing, John Wiley & Sons, vol. 28(7-8), pages 1085-1099, April.
    9. Ole Marten & Wolfgang Greiner, 2022. "Feasibility properties of the EQ-5D-3L and 5L in the general population: evidence from the GP Patient Survey on the impact of age," Health Economics Review, Springer, vol. 12(1), pages 1-10, December.
    10. Sarah Derrett & Mike Herdman & Lucky G. Ngwira & Elizabeth Yohe Moore & Jennifer Jelsma, 2021. "A New Approach to Assessing Children’s Interpretation of Severity Qualifiers in a Multi-Attribute Utility Instrument–The EQ-5D-Y-5L: Development and Testing," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 14(5), pages 591-600, September.
    11. Nancy J. Devlin & Koonal K. Shah & Yan Feng & Brendan Mulhern & Ben van Hout, 2018. "Valuing health‐related quality of life: An EQ‐5D‐5L value set for England," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 7-22, January.
    12. Minvielle, E. & Fierobe, A. & Fourcade, A. & Ferrua, M. & di Palma, M. & Scotté, F. & Mir, O., 2023. "The use of patient-reported outcome and experience measures for health policy purposes: A scoping review in oncology," Health Policy, Elsevier, vol. 129(C).
    13. Paul F M Krabbe, 2013. "A Generalized Measurement Model to Quantify Health: The Multi-Attribute Preference Response Model," PLOS ONE, Public Library of Science, vol. 8(11), pages 1-12, November.
    14. Milena Vainieri & Guido Noto & Francesca Ferre & Laura C. Rosella, 2020. "A Performance Management System in Healthcare for All Seasons?," IJERPH, MDPI, vol. 17(15), pages 1-10, August.
    15. Matthew Skellern, 2017. "The hospital as a multi-product firm: the effect of hospital competition on value-added indicators of clinical quality," CEP Discussion Papers dp1484, Centre for Economic Performance, LSE.
    16. K. Klose & S. Kreimeier & U. Tangermann & I. Aumann & K. Damm, 2016. "Patient- and person-reports on healthcare: preferences, outcomes, experiences, and satisfaction – an essay," Health Economics Review, Springer, vol. 6(1), pages 1-11, December.
    17. Laika Köse Tamer & Gülten Sucu Dağ, 2020. "The Assessment of Pain and the Quality of Postoperative Pain Management in Surgical Patients," SAGE Open, , vol. 10(2), pages 21582440209, May.
    18. Michela Luciana Luisa Zini & Giuseppe Banfi, 2021. "A Narrative Literature Review of Bias in Collecting Patient Reported Outcomes Measures (PROMs)," IJERPH, MDPI, vol. 18(23), pages 1-12, November.
    19. Wei-Han Cheng & Haridarshan Patel & Wan-Ju Lee & Fang-Ju Lin & A. Pickard, 2015. "Positive Outcomes of Varicose Vein Surgery: The Patient Perspective," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 8(4), pages 329-337, August.
    20. Leah Couzner & Maria Crotty & Richard Norman & Julie Ratcliffe, 2013. "A Comparison of the EQ-5D-3L and ICECAP-O in an Older Post-Acute Patient Population Relative to the General Population," Applied Health Economics and Health Policy, Springer, vol. 11(4), pages 415-425, August.
    21. Deepa Jahagirdar & Thilo Kroll & Karen Ritchie & Sally Wyke, 2013. "Patient-Reported Outcome Measures for Chronic Obstructive Pulmonary Disease," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 6(1), pages 11-21, March.
    22. Kirstie L. Haywood & Roger Wilson & Sophie Staniszewska & Sam Salek, 2016. "Using PROMs in Healthcare: Who Should Be in the Driving Seat—Policy Makers, Health Professionals, Methodologists or Patients?," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 9(6), pages 495-498, December.
    23. David Nuttall & David Parkin & Nancy Devlin, 2015. "Inter‐Provider Comparison Of Patient‐Reported Outcomes: Developing An Adjustment To Account For Differences In Patient Case Mix," Health Economics, John Wiley & Sons, Ltd., vol. 24(1), pages 41-54, January.
    24. Nancy J. Devlin & David Parkin & John Browne, 2010. "Patient‐reported outcome measures in the NHS: new methods for analysing and reporting EQ‐5D data," Health Economics, John Wiley & Sons, Ltd., vol. 19(8), pages 886-905, August.

  3. John Appleby;Nancy Devlin;Diane Dawson, 2004. "How Much Should We Spend on the NHS?," Monograph 000490, Office of Health Economics.

    Cited by:

    1. Sue Llewellyn, 2005. "Performance, Productivity and Innovation in Health Care Organisations: Comparing England and Scotland," Australian Accounting Review, CPA Australia, vol. 15(37), pages 15-24, November.
    2. Adam Oliver, 2005. "The English National Health Service: 1979‐2005," Health Economics, John Wiley & Sons, Ltd., vol. 14(S1), pages 75-99, September.

  4. Clive Pritchard;Nancy Devlin;Adrian Towse, 2002. "Cost-Effectiveness Thresholds: Economic and ethical issues," Monograph 000473, Office of Health Economics.

    Cited by:

    1. Martin Buxton, 2005. "How much are health-care systems prepared to pay to produce a QALY?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(4), pages 285-287, December.
    2. Pieroni, Luca & Chiavarini, Manuela & Minelli, Liliana & Salmasi, Luca, 2012. "The role of anti-smoking legislation on cigarette and alcohol consumption habits in Italy," MPRA Paper 42480, University Library of Munich, Germany.
    3. Emma Beard & Robert West & Fabiana Lorencatto & Ben Gardner & Susan Michie & Lesley Owens & Lion Shahab, 2019. "What do cost-effective health behaviour-change interventions contain? A comparison of six domains," PLOS ONE, Public Library of Science, vol. 14(4), pages 1-24, April.
    4. Peter J. Neumann, 2009. "American Exceptionalism and American Health Care: Implications for the US Debate on Cost-Effectiveness Analysis," Briefing 000232, Office of Health Economics.
    5. Shah, Koonal K. & Tsuchiya, Aki & Wailoo, Allan J., 2015. "Valuing health at the end of life: A stated preference discrete choice experiment," Social Science & Medicine, Elsevier, vol. 124(C), pages 48-56.
    6. Kamran Bagheri Lankarani & Sulmaz Ghahramani & Najmeh Moradi & Hadi Raeisi Shahraki & Farhad Lotfi & Behnam Honarvar, 2018. "Willingness-to-Pay for One Quality-Adjusted Life-Year: A Population-Based Study from Iran," Applied Health Economics and Health Policy, Springer, vol. 16(6), pages 837-846, December.
    7. Devlin, N., 2003. "Does NICE have a cost effectiveness threshold and what other factors influence its decisions? A discrete choice analysis," Working Papers 03/01, Department of Economics, City University London.
    8. Odejar, Maria & Baker, Rachel & Ryan, Mandy & Donalson, Cam & Bateman, Ian J. & Jones-Lee, M & Lancsar, Emily & Mason, Helen & Pinto Paredes, JL & Robinson, A & Shackley, P & Smith, R & Sugdem, R & Wi, 2010. "Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the Social Value of a QALY Project," MPRA Paper 108869, University Library of Munich, Germany.
    9. Girard, Dorota Zdanowska, 2005. "The cost of epidemiological transition: A study of a decrease in pertussis vaccination coverage," Health Policy, Elsevier, vol. 74(3), pages 287-303, November.
    10. Anthony H. Harris & Suzanne R. Hill & Geoffrey Chin & Jing Jing Li & Emily Walkom, 2008. "The Role of Value for Money in Public Insurance Coverage Decisions for Drugs in Australia: A Retrospective Analysis 1994-2004," Medical Decision Making, , vol. 28(5), pages 713-722, September.
    11. McCabe, C & Claxton, K & Culyer, AJ, 2008. "The NICE Cost-Effectiveness Threshold: What it is and What that Means," MPRA Paper 26466, University Library of Munich, Germany.
    12. Coast, Joanna & Smith, Richard D. & Lorgelly, Paula, 2008. "Welfarism, extra-welfarism and capability: The spread of ideas in health economics," Social Science & Medicine, Elsevier, vol. 67(7), pages 1190-1198, October.
    13. Smith, Richard D. & Richardson, Jeff, 2005. "Can we estimate the `social' value of a QALY?: Four core issues to resolve," Health Policy, Elsevier, vol. 74(1), pages 77-84, September.
    14. Richard Cookson, 2003. "Willingness to pay methods in health care: a sceptical view," Health Economics, John Wiley & Sons, Ltd., vol. 12(11), pages 891-894, November.
    15. Hugh Gravelle & Stephen Morris & Matt Sutton, 2006. "Are General Practitioners Good for Endogenous Supply and Health," Working Papers 020cherp, Centre for Health Economics, University of York.
    16. Joanne Lord & George Laking & Alastair Fischer, 2006. "Non‐linearity in the cost‐effectiveness frontier," Health Economics, John Wiley & Sons, Ltd., vol. 15(6), pages 565-577, June.
    17. B. Brüggenjürgen & P. Lindgren & B. Ehlken & H.-J. Rupprecht & S. Willich, 2007. "Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(1), pages 51-57, March.
    18. Adam Oliver, 2005. "The English National Health Service: 1979‐2005," Health Economics, John Wiley & Sons, Ltd., vol. 14(S1), pages 75-99, September.
    19. E. Remák & J. Hutton & M. Price & K. Peeters & I. Adriaenssen, 2003. "A Markov model of treatment of newly diagnosed epilepsy in the UK," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 4(4), pages 271-278, December.
    20. Nancy Devlin & David Parkin, 2004. "Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 437-452, May.
    21. Rutger P. Daems & Edith L. Maes & Christoph Glaetzer, 2012. "Pharmaceutical Pricing in a Globalized World: Crossing the income divide and ability to pay," Working Papers 2012/24, Maastricht School of Management.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.